var title_f35_33_36368="Mammo benign calcification";
var content_f35_33_36368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mammographic calcifications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique mammogram demonstrates a classic benign, partially calcified fibroadenoma with typical coarse, popcorn-like calcifications. These findings are not suspicious and do not require biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa Esserman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36368=[""].join("\n");
var outline_f35_33_36368=null;
var title_f35_33_36369="Sciatic nerve block";
var content_f35_33_36369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Sciatic nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posterior approach of Labat places the patient in the lateral decubitus position with the extremity flexed at the hip and knee (Sims' position). Anatomic landmarks include the posterior superior iliac spine (PSIS), greater trochanter, and sacral hiatus. A line is drawn between the PSIS and greater trochanter and bisected with a line measuring 3 to 5 cm drawn toward the buttock. The needle is inserted at the intersection of the bisected line and a line drawn from the greater trochanter to the sacral hiatus. The needle is inserted perpendicular to the skin and local anesthetic is injected after observing the appropriate muscular response to stimulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36369=[""].join("\n");
var outline_f35_33_36369=null;
var title_f35_33_36370="Patient information: Vulvar pain (The Basics)";
var content_f35_33_36370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83971\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/10/160\">",
"         Adult female external genitalia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/2/13346\">",
"         Patient information: Atrophic vaginitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/11/20658\">",
"         Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/60/43970\">",
"         Patient information: Dyspareunia (painful sex) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/1/14354\">",
"         Patient information: Vaginal yeast infection (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/48/31490\">",
"         Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/23/7537\">",
"         Patient information: Vaginal dryness (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/53/2899\">",
"         Patient information: Vaginal yeast infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vulvar pain (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H74855068\">",
"      <span class=\"h1\">",
"       What is vulvar pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vulvar pain is pain in the area around the opening of the vagina (",
"      <a class=\"graphic graphic_figure graphicRef53704 \" href=\"mobipreview.htm?0/10/160\">",
"       figure 1",
"      </a>",
"      ). Vulvar pain can feel different to different women. Symptoms of vulvar pain can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Burning or stabbing pain",
"       </li>",
"       <li>",
"        Irritation in the vulva &ndash; Some women also have itching.",
"       </li>",
"       <li>",
"        Feeling like something rough is rubbing the area",
"       </li>",
"       <li>",
"        Swelling &ndash; Some women feel like they are sitting on a hard ball or knot.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Vulvar pain can be in a specific area or all over. Some women have pain all the time. Others have pain only when something touches the vulva. For example, some women feel pain when they wash the area or a sex partner touches it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H74855083\">",
"      <span class=\"h1\">",
"       What causes vulvar pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vulvar pain has many different causes. Some common causes include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An infection of the vagina or vulva",
"       </li>",
"       <li>",
"        A reaction to a soap, lotion, or other product that was on the vulva or in the vagina",
"       </li>",
"       <li>",
"        Hormone changes after a woman has a baby &nbsp;",
"       </li>",
"       <li>",
"        A tear in the vulva from having a baby &ndash; A woman can have pain while the tear is healing.",
"       </li>",
"       <li>",
"        Menopause &ndash; This is the time when a woman stops getting her monthly period.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some cases of vulvar pain do not have a cause that doctors can find.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H74855098\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have vulvar pain, see a doctor or nurse so that he or she can figure out the cause. Your doctor or nurse will talk with you and do an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H74855113\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do tests to look for the cause of your vulvar pain.",
"     </p>",
"     <p>",
"      The most common tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tests on a sample of fluid from the vagina",
"       </li>",
"       <li>",
"        Blood and urine tests &ndash; These can look for infections.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might also have a test called a &ldquo;biopsy.&rdquo; In this test, a doctor takes a small sample of skin from the vulva. Another doctor looks at the sample under a microscope. You might have this test if other tests do not show the cause of your vulvar pain, but most women with vulvar pain do not need it. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H74855128\">",
"      <span class=\"h1\">",
"       How is vulvar pain treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on the cause. If the pain is from another medical condition such as an infection, treating the condition usually gets rid of the pain. &nbsp;",
"     </p>",
"     <p>",
"      Other treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Using medicines to relieve pain &ndash; These can be a cream you put on your skin or a pill you take by mouth. &nbsp;",
"       </li>",
"       <li>",
"        Talking to a counselor &ndash; Sex or relationship problems can cause vulvar pain. Or having vulvar pain can cause sex problems later on. Counseling can help with these problems. &nbsp;",
"       </li>",
"       <li>",
"        Changing your diet &ndash; Some foods and drinks irritate the bladder and cause vulvar pain. Your doctor might tell you to avoid:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Certain foods, such as tomatoes, alcohol, oranges, and grapefruit",
"       </li>",
"       <li>",
"        Chocolate",
"       </li>",
"       <li>",
"        Coffee, tea, or sodas with caffeine",
"       </li>",
"       <li>",
"        Sugar-free foods or drinks",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Putting a cold pack on the vulva &ndash; Such as a frozen gel pack or bag of frozen food wrapped in a soft cloth.",
"       </li>",
"       <li>",
"        Taking a sitz bath - Soaking for 5 to 10 minutes in 2 or 3 inches of warm water is called a &ldquo;sitz bath.&rdquo; Do not add soap, bubble bath, or anything else to the water.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your vulvar pain is caused by certain types of infections, your sex partner will also need to see a doctor for treatment.",
"     </p>",
"     <p>",
"      If sex hurts, stop having it until you get treatment. Having painful sex can create sex and relationship problems in the future.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H74855143\">",
"      <span class=\"h1\">",
"       Can vulvar pain be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can prevent vulvar pain from some causes by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Using warm water and unscented non-soap cleanser to wash your vulva",
"       </li>",
"       <li>",
"        Taking baths in plain warm water, and not using scented bath products",
"       </li>",
"       <li>",
"        Wearing cotton underwear, and not wearing underwear or pants that are too tight",
"       </li>",
"       <li>",
"        Not using sprays or powders on your vagina",
"       </li>",
"       <li>",
"        Not douching (douching is when a woman puts a liquid inside her vagina to rinse it out)",
"       </li>",
"       <li>",
"        Not wiping with baby wipes or scented toilet paper after you use the toilet",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have vulvar pain, your doctor might tell you to avoid certain activities, such as bike riding or horseback riding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H74855158\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/2/13346?source=see_link\">",
"       Patient information: Atrophic vaginitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/11/20658?source=see_link\">",
"       Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/60/43970?source=see_link\">",
"       Patient information: Dyspareunia (painful sex) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/1/14354?source=see_link\">",
"       Patient information: Vaginal yeast infection (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=see_link\">",
"       Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"       Patient information: Vaginal dryness (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/53/2899?source=see_link\">",
"       Patient information: Vaginal yeast infection (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/33/36370?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83971 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36370=[""].join("\n");
var outline_f35_33_36370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74855068\">",
"      What is vulvar pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74855083\">",
"      What causes vulvar pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74855098\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74855113\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74855128\">",
"      How is vulvar pain treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74855143\">",
"      Can vulvar pain be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74855158\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/10/160\">",
"      Adult female external genitalia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/2/13346?source=related_link\">",
"      Patient information: Atrophic vaginitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/11/20658?source=related_link\">",
"      Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=related_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/60/43970?source=related_link\">",
"      Patient information: Dyspareunia (painful sex) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/53/2899?source=related_link\">",
"      Patient information: Vaginal yeast infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/1/14354?source=related_link\">",
"      Patient information: Vaginal yeast infection (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_33_36371="Clindamycin and benzoyl peroxide: Drug information";
var content_f35_33_36371=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin and benzoyl peroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/6/20580?source=see_link\">",
"    see \"Clindamycin and benzoyl peroxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/11/28851?source=see_link\">",
"    see \"Clindamycin and benzoyl peroxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acanya&reg;;",
"     </li>",
"     <li>",
"      BenzaClin&reg;;",
"     </li>",
"     <li>",
"      Duac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BenzaClin&reg;;",
"     </li>",
"     <li>",
"      Clindoxyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Topical Skin Product;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply to affected areas after skin has been cleansed and dried:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acanya&reg;:",
"     </i>",
"     Apply pea-sized amount once daily; use &gt;12 weeks has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      BenzaClin&reg;:",
"     </i>",
"     Apply twice daily (morning and evening).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammatory acne:",
"     </b>",
"     Topical:",
"     <i>",
"      Duac&reg;:",
"     </i>",
"     Apply once daily in the evening.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F152786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/11/28851?source=see_link\">",
"      see \"Clindamycin and benzoyl peroxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, topical: Clindamycin phosphate 1% and benzoyl peroxide 5% (50 g); Clindamycin phosphate 1.2% and benzoyl peroxide 5% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acanya&reg;: Clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BenzaClin&reg;: Clindamycin phosphate 1% and benzoyl peroxide 5% (25 g, 35 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duac&reg;: Clindamycin phosphate 1.2% and benzoyl peroxide 5% (45 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin should be clean and dry before applying. For external use only; avoid applying to inside nose, mouth, eyes, and mucous membranes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of acne vulgaris",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Erythema (&le;26%), scaling (&le;18%), peeling (2% to 17%), dry skin (&le;15%), itching (&le;15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Burning (&le;8%), stinging (&le;6%), pruritus (2%), sunburn (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Application site reaction (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, anaphylaxis,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), colitis, diarrhea, exfoliation, irritation, pain at application site, pseudomembranous colitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzoyl peroxide, clindamycin, lincomycin, or any component of the formulation; history of regional enteritis, ulcerative colitis, pseudomembranous colitis or antibiotic-associated colitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleaching effects: May bleach hair or colored fabric.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Erythromycin: Concomitant use with erythromycin-containing products is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical acne products: Use concomitant topical acne therapy with caution; cumulative irritancy may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with mucous membranes and eyes. Inform patients to use skin protection and minimize prolonged exposure to sun and avoid tanning beds.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F152768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clindamycin is excreted in breast milk following oral and parenteral administration; the extent of excretion, if any, following topical use, in this combination is not known.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F152766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Acanya External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2-2.5% (50 g): $337.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (BenzaClin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-5% (25 g): $256.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (BenzaClin with Pump External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-5% (35 g): $359.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Clindamycin Phos-Benzoyl Perox External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-5% (50 g): $269.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2-5% (45 g): $203.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Duac External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2-5% (45 g): $248.65",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F854893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benzaclin (MX);",
"     </li>",
"     <li>",
"      Benzalin (IL);",
"     </li>",
"     <li>",
"      Benzolac-CL (HK, ID);",
"     </li>",
"     <li>",
"      Clidan B (AR);",
"     </li>",
"     <li>",
"      Clindacur (AR);",
"     </li>",
"     <li>",
"      Clindapack (MX);",
"     </li>",
"     <li>",
"      Clindoxyl (AR);",
"     </li>",
"     <li>",
"      Clindoxyl Gel (AT, DK, FI);",
"     </li>",
"     <li>",
"      Clindoxyl Once Daily (SG);",
"     </li>",
"     <li>",
"      DUAC (CH, CZ, DE, EE, ES, GB, IE, IL, MY, NL, NZ, PH, PL, PT, SE, TH);",
"     </li>",
"     <li>",
"      Duac Once Daily (AU, HK, TW);",
"     </li>",
"     <li>",
"      Indoxyl Gel (CN, CO, CR, DO, GR, GT, HN, MX, NI, PA, PE, PY, SV);",
"     </li>",
"     <li>",
"      Klina (CN);",
"     </li>",
"     <li>",
"      Sinac (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clindamycin and benzoyl peroxide have activity against",
"     <i>",
"      Propionibacterium acnes",
"     </i>",
"     <i>",
"      in vitro",
"     </i>",
"     . This organism has been associated with acne vulgaris. Benzoyl peroxide releases free-radical oxygen which oxidizes bacterial proteins in the sebaceous follicles decreasing the number of anaerobic bacteria and decreasing irritating-type free fatty acids. Clindamycin reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8950 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36371=[""].join("\n");
var outline_f35_33_36371=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152776\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854892\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152791\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152779\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152786\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152780\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152760\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152748\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152762\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152761\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152789\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152765\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152752\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299059\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152755\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152757\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152767\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152781\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152768\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152766\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854893\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152751\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152764\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/6/20580?source=related_link\">",
"      Clindamycin and benzoyl peroxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/11/28851?source=related_link\">",
"      Clindamycin and benzoyl peroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_33_36372="Dutasteride: Drug information";
var content_f35_33_36372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dutasteride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/28/6596?source=see_link\">",
"    see \"Dutasteride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avodart&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avodart&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      5 Alpha-Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Males:",
"     <b>",
"      Benign prostatic hyperplasia (BPH):",
"     </b>",
"     Oral: 0.5 mg once daily alone or in combination with tamsulosin",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F163875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; no specific adjustments recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avodart&reg;: 0.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F163848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Capsule should be swallowed whole; do not chew or open; contact with opened capsule can cause oropharyngeal irritation. Should not be touched or handled by women who are pregnant or are of childbearing age.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic benign prostatic hyperplasia (BPH) as monotherapy or combination therapy with tamsulosin",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F163883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of male pattern baldness",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Endocrine &amp; metabolic: Impotence (1% to 5%), libido decreased (&le;3%), ejaculation disorders (&le;1%), gynecomastia (including breast tenderness, breast enlargement; &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, cardiac failure, depressed mood, dizziness, edema (localized), hypersensitivity, prostate cancer (high-grade), pruritus, rash, skin reactions (serious), TSH increased, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency of adverse events (except gynecomastia) tends to decrease with continued use (&gt;6 months).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dutasteride, other 5&alpha;-reductase inhibitors (eg, finasteride), or any component of the formulation; children; women of childbearing potential; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for dutasteride therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been shown to reduce the overall incidence of prostate cancer, although an increase in the incidence of high-grade prostate cancers has been observed; 5-ARIs are not approved in the U.S. or Canada for the prevention of prostate cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Use with caution with concurrent use of potent, chronic CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women/pregnancy: Active ingredient can be absorbed through the skin; women should always use caution whenever handling. Pregnant women or women trying to conceive should not handle the product; if contact with a leaking capsule occurs, wash area immediately with soap and water; dutasteride may negatively impact fetal development.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Other urological diseases, including prostate cancer, should be ruled out before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donation: Avoid donating blood during or for 6 months following treatment cessation due to risk of administration to a pregnant female transfusion recipient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PSA monitoring: Reduces prostate specific antigen (PSA) by ~50% within 3-6 months of use. If following serial PSAs, re-establish a new baseline &ge;3 months after treatment initiation; monitor PSA periodically thereafter. If interpreting an isolated PSA value in a patient treated for &ge;3 months, then double the PSA value for comparison to a normal PSA value in an untreated man. Failure to demonstrate a meaningful PSA decrease (&lt;50%) or a PSA increase while on this medication may be associated with an increased risk for prostate cancer (NCCN Prostate Cancer Early Detection Guidelines, v.1.2011). Patients on a 5-ARI with any increase in PSA levels, even if within normal limits, should be evaluated; may indicate presence of prostate cancer.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F163865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: No effect or interaction noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Maximum serum concentrations reduced by 10% to 15% when taken with food; not clinically significant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease dutasteride levels. Avoid saw palmetto (concurrent use has not been adequately studied).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preclinical data (animal studies) suggests that the suppression of circulating levels of dihydrotestosterone may inhibit the development of the external genital organs and lead to feminization of a male fetus carried by a woman exposed to dutasteride. Pregnant woman and those who may become pregnant should not handle the capsules because dutasteride is absorbed through the skin. It is distributed into the semen.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated in women of childbearing potential",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F163854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F163852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Avodart Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (30): $151.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F163844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Objective and subjective signs of relief of benign prostatic hyperplasia, including improvement in urinary flow, reduction in symptoms of urgency, and relief of difficulty in micturition; for serial PSA monitoring, establish a new baseline PSA level after 3 months of therapy and monitor PSA periodically thereafter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F163855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avidart (ES);",
"     </li>",
"     <li>",
"      Avodart (AR, AT, AU, BB, BE, BG, BM, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, KP, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, RU, SE, SG, SR, SV, TH, TR, TT, TW);",
"     </li>",
"     <li>",
"      Duprost (IN);",
"     </li>",
"     <li>",
"      Prostasil (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dutasteride is a 4-azo analog of testosterone and is a competitive, selective inhibitor of both reproductive tissues (type 2) and skin and hepatic (type 1) 5&alpha;-reductase. This results in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Absorbed via skin when handling capsules",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 300-500 L, ~12% of serum concentrations partitioned into semen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99% to albumin; ~97% to &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein; &gt;96% to semen protein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 isoenzyme; forms metabolites: 6-hydroxydutasteride has activity similar to parent compound, 4&prime;-hydroxydutasteride and 1,2-dihydrodutasteride are much less potent than parent",
"     <i>",
"      in vitro",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~60% (range: 40% to 94%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~5 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (40% as metabolites, ~5% as unchanged drug); urine (&lt;1% as unchanged drug); ~55% of dose unaccounted for",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andriole G, Bostwick D, Brawley O, et al, &ldquo;Chemoprevention of Prostate Cancer in Men at High Risk: Rationale and Design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2004, 172(4 Pt 1):1314-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36372/abstract-text/15371831/pubmed\" id=\"15371831\" target=\"_blank\">",
"        15371831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andriole G, Bostwick DG, Brawley OW, et al, &ldquo;Effect of Dutasteride on the Risk of Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(13):1192-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36372/abstract-text/20357281/pubmed\" id=\"20357281\" target=\"_blank\">",
"        20357281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andriole G, Roehrborn C, Schulman C, et al, &ldquo;Effect of Dutasteride on the Detection of Prostate Cancer in Men With Benign Prostatic Hyperplasia,&rdquo;",
"      <i>",
"       Urology,",
"      </i>",
"      2004, 64(3):537-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36372/abstract-text/15351586/pubmed\" id=\"15351586\" target=\"_blank\">",
"        15351586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kramer BS, Hagerty KL, Justman S, et al, &ldquo;Use of 5-&alpha;-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1502-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36372/abstract-text/19252137/pubmed\" id=\"19252137\" target=\"_blank\">",
"        19252137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prostate Cancer Early Detection,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8672 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36372=[""].join("\n");
var outline_f35_33_36372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163870\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854889\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163887\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163872\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163873\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163874\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163875\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163846\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163832\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163848\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163847\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163883\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163885\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163851\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163835\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163881\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163839\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163865\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163842\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163853\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163877\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163854\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163852\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163844\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163855\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163834\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163850\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/28/6596?source=related_link\">",
"      Dutasteride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_33_36373="Micrograph neurothekeoma";
var content_f35_33_36373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micrograph neurothekeoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) This photomicrograph shows a neurothekeoma of the pretibial region. Neurothekeomas are variably myxoid, moderately cellular neoplasms lacking either Schwann or perineurial cell differentiation. They are distinguished from nerve sheath myxomas by virtue of their increased cellularity and reduced myxoid background. H&amp;E, x100. B) This is a higher power photomicrograph demonstrating a cluster of tumor cells, which are variably spindle-shaped or epithelioid in appearance. H&amp;E, x400.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John E Donahue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36373=[""].join("\n");
var outline_f35_33_36373=null;
var title_f35_33_36374="Cholestyramine resin: Drug information";
var content_f35_33_36374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cholestyramine resin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/6/34917?source=see_link\">",
"    see \"Cholestyramine resin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/27/1462?source=see_link\">",
"    see \"Cholestyramine resin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prevalite&reg;;",
"     </li>",
"     <li>",
"      Questran&reg;;",
"     </li>",
"     <li>",
"      Questran&reg; Light",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Cholamine;",
"     </li>",
"     <li>",
"      Novo-Cholamine Light;",
"     </li>",
"     <li>",
"      Olestyr;",
"     </li>",
"     <li>",
"      PMS-Cholestyramine;",
"     </li>",
"     <li>",
"      Questran&reg;;",
"     </li>",
"     <li>",
"      Questran&reg; Light Sugar Free;",
"     </li>",
"     <li>",
"      ZYM-Cholestyramine-Light;",
"     </li>",
"     <li>",
"      ZYM-Cholestyramine-Regular",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Bile Acid Sequestrant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosages are expressed in terms of anhydrous resin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dyslipidemia:",
"     </b>",
"     Oral: Initial: 4 g 1-2 times/day; increase gradually over &ge;1-month intervals; maintenance: 8-16 g/day divided in 2 doses; maximum: 24 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/27/1462?source=see_link\">",
"      see \"Cholestyramine resin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosages are expressed in terms of anhydrous resin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dyslipidemia (unlabeled use):",
"     </b>",
"     Oral: 240 mg/kg/day in 2-3 divided doses; titrate dose to response and tolerance; maximum: 8 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F150875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; however, use with caution in renal impairment; may cause hyperchloremic acidosis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13389155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary; not absorbed from the gastrointestinal tract.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: Cholestyramine resin 4 g/5 g of powder (210 g); Cholestyramine resin 4 g/5.7 g of powder (239.4 g); Cholestyramine resin 4 g/9 g of powder (378 g); Cholestyramine resin 4 g/5 g packet (60s); Cholestyramine resin 4 g/5.7 g packet (60s); Cholestyramine resin 4 g/9 g packet (60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevalite&reg;: Cholestyramine resin 4 g/5.5 g of powder (231 g); Cholestyramine resin 4 g/5.5 g packet (42s, 60s) [contains phenylalanine 14.1 mg/5.5 g; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Questran&reg;: Cholestyramine resin 4 g/9 g of powder (378 g); Cholestyramine resin 4 g/9 g packet (60s) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Questran&reg; Light: Cholestyramine resin 4 g/5 g of powder (210 g); Cholestyramine resin 4 g/5 g packet (60s) [contains phenylalanine 14 mg/5 g; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F150853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer prepared suspension orally. Not to be taken in dry form. Suspension should not be sipped or held in mouth for prolonged periods (may cause tooth discoloration or enamel decay). Administration at mealtime is recommended. Twice-daily dosing is recommended, but may be administered in 1-6 doses daily.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in the management of primary hypercholesterolemia; pruritus associated with elevated levels of bile acids; regression of arteriolosclerosis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13389137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diarrhea associated with excess fecal bile acids (Westergaard, 2007); may be used to enhance elimination of digoxin when non-life-threatening toxicity occurs (Henderson, 1988)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, drowsiness, eructation, fatigue, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, rash, skin irritation, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperchloremic acidosis (children), libido increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, biliary colic, black stools, constipation, dental bleeding, dental caries, dental erosion, diarrhea, diverticulitis, duodenal ulcer bleeding, dysphagia, eructation, flatulence, gallbladder calcification, GI hemorrhage, intestinal obstruction (rare), hemorrhoidal bleeding, nausea, pancreatitis, perianal irritation, rectal bleeding, rectal pain, steatorrhea, taste disturbance, tongue irritation, tooth discoloration, ulcer, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hypothrombinemia, liver function abnormalities, prothrombin time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis, backache, joint/muscle/nerve pain, osteoporosis, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Night blindness (rare), uveitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis, dysuria, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hiccups, swollen glands",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bile acid sequestering resins or any component of the formulation; complete biliary obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Chronic use may be associated with bleeding problems (especially in high doses); may be prevented with use of oral vitamin K therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation: May produce or exacerbate constipation problems; initiate therapy at a reduced dose in patients with a history of constipation. Hemorrhoids may be worsened.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased absorption (orally administered drugs): Not to be taken simultaneously with many other medicines (decreased absorption).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients susceptible to fat-soluble vitamin deficiencies: Use with caution in patients susceptible to fat-soluble vitamin deficiencies. Absorption of fat soluble vitamins A, D, E, and K and folic acid may be decreased; patients should take vitamins &ge;4 hours before cholestyramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Cholestyramine Resin may decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens).  Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins).  Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: Cholestyramine Resin may decrease the serum concentration of Fluvastatin.  Management: Administer fluvastatin at least 1 hour or greater (particularly with extended-release form) before, or at least 4 hours after cholestyramine to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: Cholestyramine Resin may decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Cholestyramine Resin may decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Cholestyramine Resin may decrease the serum concentration of PHENobarbital.  Management: Administer phenobarbital at least 1 hour before or 4-6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Bile Acid Sequestrants may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Bile Acid Sequestrants may diminish the therapeutic effect of Vancomycin.  Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of folic acid, calcium, and iron.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of fat-soluble vitamins (vitamins A, D, E, and K).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F150846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F150859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholestyramine is not absorbed systemically, but may interfere with vitamin absorption; therefore, regular prenatal supplementation may not be adequate. There are no studies in pregnant women; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F150879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not enter breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13389138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to lack of systemic absorption cholestyramine is not expected to be excreted into breast milk; however, the tendency of cholestyramine to interfere with vitamin absorption may have an effect on the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F150860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplementation of vitamins A, D, E, and K, folic acid, and iron may be required with high-dose, long-term therapy. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F150858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Cholestyramine Light Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (60): $127.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Cholestyramine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (60): $127.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Prevalite Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (42): $115.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Questran Light Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (60): $306.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Questran Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (60): $304.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Cholestyramine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g/dose (378 g): $55.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Prevalite Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g/dose (231 g): $72.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Questran Light Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g/dose (210 g): $134.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Questran Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g/dose (378 g): $133.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13389168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum cholesterol and triglyceride levels before initiating treatment and periodically throughout treatment (in accordance with NCEP guidelines)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F150861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Choles (TW);",
"     </li>",
"     <li>",
"      Colestiramina (CN, CO);",
"     </li>",
"     <li>",
"      Colestrol (IT);",
"     </li>",
"     <li>",
"      Kolestran (TR);",
"     </li>",
"     <li>",
"      Lipocol-Merz (DE);",
"     </li>",
"     <li>",
"      Quantalan (CH, PT);",
"     </li>",
"     <li>",
"      Quantalan Zuckerfrei (AT);",
"     </li>",
"     <li>",
"      Questran (BE, BG, DK, EC, EG, FI, FR, GB, GR, HK, HN, IE, IT, KP, MX, NL, NO, NZ, SE);",
"     </li>",
"     <li>",
"      Questran Light (AR, BR, CZ, MY);",
"     </li>",
"     <li>",
"      Questran Lite (AU, NZ, PH, ZA);",
"     </li>",
"     <li>",
"      Questran Loc (DK, SE);",
"     </li>",
"     <li>",
"      Resincolestiramina (SG, UY);",
"     </li>",
"     <li>",
"      Semide (TW);",
"     </li>",
"     <li>",
"      Sequest (ID);",
"     </li>",
"     <li>",
"      Vasosan (PL);",
"     </li>",
"     <li>",
"      Vasosan P-Granulat (DE);",
"     </li>",
"     <li>",
"      Vasosan S-Granulat (DE, FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F150837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Forms a nonabsorbable complex with bile acids in the intestine, releasing chloride ions in the process; inhibits enterohepatic reuptake of intestinal bile salts and thereby increases the fecal loss of bile salt-bound low density lipoprotein cholesterol",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (as insoluble complex with bile acids)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36374/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36374/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henderson RP and Solomon CP, &ldquo;Use of Cholestyramine in the Treatment of Digoxin Intoxication,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1988,148(3):745-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36374/abstract-text/3341874/pubmed\" id=\"3341874\" target=\"_blank\">",
"        3341874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36374/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36374/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westergaard H, &ldquo;Bile Acid Malabsorption,&rdquo;",
"      <i>",
"       Curr Treat Options Gastroenterol",
"      </i>",
"      , 2007, 10(1):28-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/33/36374/abstract-text/17298762/pubmed\" id=\"17298762\" target=\"_blank\">",
"        17298762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9258 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36374=[""].join("\n");
var outline_f35_33_36374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150870\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150871\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150889\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150873\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150884\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150874\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150875\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389155\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150849\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150834\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150853\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150852\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389137\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150887\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150856\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150838\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299034\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150843\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150866\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150846\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150859\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150879\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389138\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150860\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150858\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389168\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150861\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150837\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150855\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9258|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/6/34917?source=related_link\">",
"      Cholestyramine resin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/27/1462?source=related_link\">",
"      Cholestyramine resin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_33_36375="Bones of the foot";
var content_f35_33_36375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Bones of the foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 582px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The foot has 28 bones, including 14 phalanges, seven tarsal bones (talus, calcaneus, cuboid, navicular, and three cuneiforms), five metatarsals, and two sesamoids. The hindfoot connects to the midfoot at the midtarsal (Chopart) joint. The midfoot connects to the forefoot at the Lisfranc joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36375=[""].join("\n");
var outline_f35_33_36375=null;
var title_f35_33_36376="Overview of ankle fractures in adults";
var content_f35_33_36376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of ankle fractures in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36376/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36376/contributors\">",
"     Scott M Koehler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36376/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36376/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36376/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36376/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/33/36376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankle fractures are increasingly common injuries that necessitate a careful approach for proper management. Over five million ankle injuries occur each year in the United States alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of ankle fractures that result from minor trauma (ie, indirect or low energy fractures), including a basic approach to their evaluation and management. Fibular fractures above the lateral malleolus, tibial fractures, and ankle injuries other than fractures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26726?source=see_link\">",
"     \"Fibular fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26358?source=see_link\">",
"     \"Overview of tibial fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1030?source=see_link\">",
"     \"Posterior and medial ankle tendinopathies not involving the Achilles tendon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ankle fractures is approximately 187 fractures per 100,000 people each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/1\">",
"     1",
"    </a>",
"    ]. Since the mid-1900s, this rate has increased significantly in many industrialized countries, most likely due to growth in the number of people involved in athletics and in the size of the elderly population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of ankle fractures are malleolar fractures: 60 to 70 percent occur as unimalleolar fractures, 15 to 20 percent as bimalleolar fractures, and 7 to 12 percent as trimalleolar fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. There are similar fracture rates overall between women and men, but men have a higher rate as young adults, while women have higher rates in the 50 to 70-year age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cigarette smoking and a high body mass index have been associated with ankle fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In contrast to fractures of the radius and other fractures common among perimenopausal and postmenopausal women, bone density does not appear to be a major risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bony anatomy of the ankle consists of the articulation of the distal tibia and fibula with the talus. These bones are held together by the ligaments of the ankle to form a mortise. The weight-bearing portion of the mortise consists of the tibial plafond and the talar dome. The mortise gains its stability from the bony relationships of the ankle and from surrounding structures.",
"   </p>",
"   <p>",
"    The lateral ligament complex consists of the anterior talofibular ligament, the calcaneofibular ligament, and the posterior talofibular ligament (",
"    <a class=\"graphic graphic_figure graphicRef72462 \" href=\"mobipreview.htm?0/9/159\">",
"     figure 1",
"    </a>",
"    ). The medial ankle complex consists of the deep and superficial fibers of the deltoid ligament (",
"    <a class=\"graphic graphic_figure graphicRef51952 \" href=\"mobipreview.htm?34/57/35728\">",
"     figure 2",
"    </a>",
"    ). The peroneal tendons, anterior and posterior tibialis tendons, Achilles tendon, and joint capsule provide additional support.",
"   </p>",
"   <p>",
"    The syndesmosis of the ankle refers to the articulation of the distal tibia and fibula. Support is provided by the anterior tibiofibular ligament, the posterior tibiofibular ligament, the transverse tibiofibular ligament (posteriorly), and the interosseous membrane, which extends from the ankle proximally. These structures strengthen the mortise and prevent the distal tibia and fibula from separating. Abnormal forces that rotate the talus within the mortise push the tibia and fibula apart and may cause an injury to the syndesmotic ligaments or a fracture.",
"   </p>",
"   <p>",
"    The motion of the ankle is complex. Although the joint moves primarily in the sagittal plane to enable dorsiflexion and plantarflexion of the foot, motion occurs in several planes. Inversion and eversion of the foot occur mainly at the subtalar joint.",
"   </p>",
"   <p>",
"    The talar dome is narrower posteriorly. It therefore fits more tightly into the mortise, creating greater joint stability, when the ankle is dorsiflexed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The position of the talus in the mortise depends more on the medial supporting structures, which are stronger, than the lateral structures. Therefore, the ankle is better able to withstand forces that stress the medial side of the joint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The posterior tibial artery and tibial nerve run together just posterior and lateral to the medial malleolus. The anterior tibial artery (dorsalis pedis in the foot) and deep peroneal nerve run together and cross the ankle joint anteriorly, approximately in the midline, just lateral to the extensor hallucis longus and below the extensor retinaculum.",
"   </p>",
"   <p>",
"    There is no single, widely accepted definition of the anatomic margins of the lateral malleolus. For the purpose of this review, the lateral malleolus refers to the distal part of the fibula that articulates with the talus and distal tibia. Lateral malleolar fractures are those that lie between the distal tip of the fibula and the most proximal portion of the fibula, which lies directly adjacent to the tibia in the tibial groove (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75649 \" href=\"mobipreview.htm?8/20/8527\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lateral malleolus provides stability against excessive eversion of the ankle and foot. The medial malleolus is the most distal part of the tibia and articulates with the medial aspect of the talar dome. The posterior aspect of the distal tibia is commonly referred to as the posterior malleolus. It primarily includes the portion of the tibia where the posterior tibiofibular ligament attaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankle injuries that result from bending forces are commonly described as inversion or eversion injuries. Technically, inversion and eversion are motions of the subtalar joint and become supination and pronation when combined with ankle and midfoot motion. Internal and external rotation of the ankle refers to the rotation of the talus within the joint.",
"   </p>",
"   <p>",
"    Supination (inversion) injuries typically cause distraction of the lateral ankle structures and compression of the medial structures. Pronation (eversion) injuries cause medial distraction and lateral compression. Structures being distracted (or stretched) generally fracture or tear before structures being compressed. As an example, injuries that occur while the ankle is supinated will result in damage to the distal fibula and its associated ligaments, which are being stretched, before any damage occurs to the distal tibia and its deltoid ligament complex.",
"   </p>",
"   <p>",
"    In addition to bending forces, rotational forces often contribute to ankle injuries by placing further stress on supporting structures and forcing the malleoli apart.",
"   </p>",
"   <p>",
"    Orthopedists commonly classify the mechanism of injury using two descriptors. The first describes the position of the ankle at the time of injury; the second refers to the force applied to the ankle that causes the injury. As an example, a",
"    <span class=\"nowrap\">",
"     \"supination/external",
"    </span>",
"    rotation\" injury refers to the ankle in a supinated position with an external rotation force applied to it. These descriptors predict the sequence in which structures are injured and provide the basis for the Lauge-Hansen system of ankle fracture classification used to guide orthopedic decision making. The amount of force sustained during the injury is a third factor, in addition to ankle position and force direction, which determines the type and extent of injury.",
"   </p>",
"   <p>",
"    Several studies question the accuracy of the Lauge-Hansen scheme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A complete discussion of classification systems is beyond the scope of this review and can be found elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/3,9,12\">",
"     3,9,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One classification scheme deserves further mention because of its simplicity and clinical relevance. In this approach, the ankle is conceived as a ring of supporting structures surrounding the talus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/8\">",
"     8",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef55837 \" href=\"mobipreview.htm?21/41/22164\">",
"     figure 3",
"    </a>",
"    ). Supporting structures may be ligaments or bones. If the ring is broken at one site, the injury is stable and can be managed nonoperatively; if the ring is broken at two or more sites, the injury is unstable and is managed operatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Malleolar fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated malleolar fractures tend to be stable if they are nondisplaced (ie, there is no contralateral or syndesmotic injury). However, care must be taken with fractures of the medial malleolus. Disruption of lateral or posterior structures often occurs in association with these fractures, though they may initially appear to be isolated injuries.",
"   </p>",
"   <p>",
"    Posterior malleolar fractures occur either from the impact of the talus on the posterior aspect of the tibia (often as part of a pilon fracture) or from an external rotation or pronation (eversion) force. They occur in association with disruption of the posterior tibiofibular ligament. Posterior malleolar fractures rarely occur in isolation. They are more commonly associated with fibular fractures and additional ligament damage, and they are generally unstable injuries.",
"   </p>",
"   <p>",
"    Fractures of both the lateral and medial malleoli are called bimalleolar. These fractures often occur as a result of a pronation (eversion) force and are unstable.",
"   </p>",
"   <p>",
"    A bimalleolar fracture with a fracture of the posterior malleolus is referred to as a trimalleolar fracture. Trimalleolar fractures are unstable and typically occur with injuries of greater force. They have a higher risk of complication than bimalleolar fractures and require surgical stabilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent conditions, such as an open fracture, neurovascular compromise, or fracture dislocation, must be treated immediately. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Initial treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to the mechanism of injury, the physician's history should ascertain the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Site of the most significant pain",
"     </li>",
"     <li>",
"      Other injured areas (eg, lumbar spine, hip, knee)",
"     </li>",
"     <li>",
"      Length of time from injury to presentation",
"     </li>",
"     <li>",
"      Neurovascular symptoms",
"     </li>",
"     <li>",
"      Ability to bear weight",
"     </li>",
"     <li>",
"      History of any previous injury or surgery",
"     </li>",
"     <li>",
"      Related comorbidities (eg, diabetes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ankle fracture, particularly one sustained in a fall, may mask other injuries such as a lumbar compression fracture.",
"   </p>",
"   <p>",
"    Clinicians should inspect the injured ankle for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Swelling",
"     </li>",
"     <li>",
"      Deformity",
"     </li>",
"     <li>",
"      Skin abnormalities, such as lacerations (possible open fracture), tenting, or blistering (caused by rapid stretching of the skin)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The amount of swelling is not a reliable guide to the presence of a fracture.",
"   </p>",
"   <p>",
"    Clinicians should palpate the ankle looking for the point of maximal tenderness and other tender areas. The examiner should palpate the tibia and fibula, especially the fibular neck, to evaluate for possible associated fractures. Testing for ligamentous laxity can be deferred until after radiographs are obtained; it is often not tolerated in the setting of an acute fracture.",
"   </p>",
"   <p>",
"    Pulses of the dorsalis pedis and posterior tibialis arteries and distal capillary refill should be checked. Sensation and motor function should be assessed. A detailed discussion of the physical examination of the ankle is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once emergent conditions have been ruled out, the first priority in the evaluation of ankle fractures is to determine whether the fracture is stable, and can be managed nonoperatively, or unstable, and must be referred. Typically, an ankle fracture is stable if it meets the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is isolated to the lateral, medial, or posterior malleolus.",
"     </li>",
"     <li>",
"      It is nondisplaced.",
"     </li>",
"     <li>",
"      It is not associated with a ligamentous injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ankle fracture is unstable if two or more sites of significant injury are present, such as a lateral malleolar fracture with deltoid ligament disruption or a bimalleolar fracture. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ottawa ankle rules have been shown to help the examiner in determining if radiographs of the ankle or foot are needed in the evaluation of an acute ankle injury (",
"    <a class=\"graphic graphic_figure graphicRef69818 \" href=\"mobipreview.htm?32/53/33618\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who do not meet the Ottawa criteria are unlikely to have a fracture, and radiographs are typically not needed in the acute setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/13\">",
"     13",
"    </a>",
"    ]. A full discussion of the Ottawa rules is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34296?source=see_link&amp;anchor=H19#H19\">",
"     \"Ankle sprain\", section on 'Ottawa ankle rules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ankle fractures are typically evaluated using plain radiographs. Anterior-posterior (AP), oblique, and lateral views are standard. The oblique radiograph, also called the mortise view, should be obtained as an AP projection with a 10 to 20 degree lateral angle to help visualize injuries of the syndesmosis and talus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66441 \" href=\"mobipreview.htm?7/61/8159\">",
"     image 2",
"    </a>",
"    ). On the mortise view, the relationship of the medial and lateral malleoli can be measured with respect to the talus. Normally, the distances between the talus and the lateral malleolus, the talus and the medial malleolus, and the talus and the tibial plafond are uniform throughout the mortise.",
"   </p>",
"   <p>",
"    Isolated lateral and medial malleolar fractures are best seen on the AP view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53671 \" href=\"mobipreview.htm?20/59/21427\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74497 \" href=\"mobipreview.htm?1/58/1952\">",
"     image 4",
"    </a>",
"    ). Posterior malleolar fractures are best seen on the lateral view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64402 \" href=\"mobipreview.htm?23/19/23856\">",
"     image 5",
"    </a>",
"    ). On the mortise view, discrepancies in the relationship between the talus and the medial and lateral malleoli can help identify an unstable fracture or soft tissue injury (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74130 \" href=\"mobipreview.htm?31/18/32033\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78751 \" href=\"mobipreview.htm?21/29/21968\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The presence of medial injury determines the stability of lateral malleolar fractures. Stress radiographs are needed to determine the stability of the joint in cases of a lateral malleolar fracture with deltoid ligament tenderness but no widening of the joint on initial radiographs. Deltoid ligament injury is assumed if a distance greater than 4 mm is measured between the talus and the medial malleolus on either a standard mortise or stress radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78751 \" href=\"mobipreview.htm?21/29/21968\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. Adequate external rotation of the foot is necessary for obtaining accurate stress radiographs. Clinicians should avoid inflicting undue pain when obtaining such studies by providing adequate analgesia and limiting the force applied when this causes excessive discomfort.",
"   </p>",
"   <p>",
"    The gravity stress mortise radiograph has been shown to be as sensitive and specific as a manual stress mortise radiograph (",
"    <a class=\"graphic graphic_picture graphicRef85927 \" href=\"mobipreview.htm?13/16/13574\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/14\">",
"     14",
"    </a>",
"    ]. A decision about surgical intervention should not be based on stress radiographs alone. The integrity of the deltoid ligament can be further assessed with magnetic resonance imaging (MRI) if necessary.",
"   </p>",
"   <p>",
"    Isolated medial malleolar and isolated posterior malleolar fractures are considered stable if no associated injury is present, fracture displacement is equal to 2 mm or less, and joint surface involvement is less than 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/9,12\">",
"     9,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a fracture of the talus is suspected, or if significant comminution is present, a CT scan will further delineate the extent of the injury and identify fracture displacement. If plain films are negative and clinical suspicion is high for specific soft tissue or cartilage injuries, MRI is more useful (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55291 \" href=\"mobipreview.htm?30/19/31027\">",
"     image 8",
"    </a>",
"    ). Both MRI and triple-phase bone scintigraphy (bone scan) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67194 \" href=\"mobipreview.htm?2/26/2465\">",
"     image 9",
"    </a>",
"    ) are helpful in diagnosing a stress fracture in the ankle region, especially if plain radiographs are normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open fractures and any injury with associated neurologic or vascular deficits require immediate surgical referral.",
"   </p>",
"   <p>",
"    The two major indications for operative fixation of an ankle fracture are loss of joint congruency or loss of joint stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/3,9,12\">",
"     3,9,12",
"    </a>",
"    ]. Loss of joint congruency, such as occurs with severe posterior malleolar fractures and pilon fractures, occurs in the setting of more severe trauma (pilon fractures occur when relatively strong axial forces drive the tibial plafond into the talar dome). Fractures that create joint instability as a result of minor trauma are more common.",
"   </p>",
"   <p>",
"    Typically, an ankle fracture is unstable and will need surgical stabilization if two sites of significant injury are present. All trimalleolar, bimalleolar, and isolated malleolar fractures with an opposing ligament rupture (eg, a lateral malleolar fracture with deltoid ligament disruption) are unstable and require orthopedic referral. If there is any uncertainty about the stability of the ankle, the patient should be referred.",
"   </p>",
"   <p>",
"    Injuries that lead to a distal fibular fracture above the tibiotalar joint line are almost always associated with a syndesmotic disruption and should be referred to an orthopedist (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69461 \" href=\"mobipreview.htm?9/63/10239\">",
"     image 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82310 \" href=\"mobipreview.htm?38/32/39439\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58275 \" href=\"mobipreview.htm?17/54/18287\">",
"     image 12",
"    </a>",
"    ). Posterior malleolar fractures that result in loss of joint congruency should also be referred.",
"   </p>",
"   <p>",
"    Unstable fractures often require open reduction with internal fixation. Whether operative or nonoperative management is used, the goal of treatment is anatomic alignment to maximize function and minimize the risk of post-traumatic osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent conditions, such as an open fracture or neurovascular impairment, require immediate surgical consultation and treatment. Fracture dislocations must be reduced immediately to prevent severe complications, such as avascular necrosis.",
"   </p>",
"   <p>",
"    Once emergent conditions are excluded, clinicians should evaluate the fracture more closely, focusing on any malalignment or instability, to determine proper management and follow-up. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above.) The ankle should be splinted at 90 degrees (ie, neutral position) to provide support and control pain. Usually, a short-leg posterior splint is sufficient. A sugar-tong (ie, coaptation) splint can be added for additional mediolateral support. If significant swelling or deformity is present, adequate padding should be placed prior to application of the splint to allow for further swelling, while maintaining stability.",
"   </p>",
"   <p>",
"    Clinicians should instruct the patient to call immediately for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain that is severe or increasing",
"     </li>",
"     <li>",
"      Numbness that is new or worsening",
"     </li>",
"     <li>",
"      Skin discoloration (eg, dusky toes) distal to the splint",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complaints may represent vascular compromise or some other serious complication and should be investigated immediately. Any patient complaint of skin irritation, a splint which has become excessively tight or loose, or a splint which has gotten wet should also be assessed. An examination and repeat radiographs to check for acceptable alignment are generally performed during the first follow-up visit.",
"   </p>",
"   <p>",
"    For stable, nondisplaced, isolated malleolar fractures, the patient should rest, elevate the involved ankle above the level of the heart, and apply ice, while keeping the splint dry. If the injured leg is placed in a prefabricated splint able to withstand ambulation, the patient may bear weight as tolerated.",
"   </p>",
"   <p>",
"    Patients awaiting orthopedic consultation or surgery should remain nonweightbearing in a splint (as described above), apply ice while keeping the splint dry, and use pain medication as needed. If surgery is planned in the acute setting, excessive use of narcotic analgesics should be avoided, if possible, until the orthopedic surgeon is able to explain the procedure and obtain informed consent. Management of specific fracture types is discussed immediately below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Management of specific malleolar fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little high quality evidence to determine the best treatment of ankle fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/15\">",
"     15",
"    </a>",
"    ]. Our recommendations below are based upon limited randomized trials, observational data, and clinical experience. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lateral malleolar fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture stability determines treatment. The location of an isolated lateral malleolar fracture in relationship to the joint can help to determine if the fracture is stable. Lateral malleolar fractures below the level of the mortise (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53427 \" href=\"mobipreview.htm?37/18/38190\">",
"     image 13",
"    </a>",
"    ) are typically stable and less likely to be associated with additional ligament injuries. When an ankle injury causes a fracture above the level of the mortise (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69461 \" href=\"mobipreview.htm?9/63/10239\">",
"     image 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82310 \" href=\"mobipreview.htm?38/32/39439\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58275 \" href=\"mobipreview.htm?17/54/18287\">",
"     image 12",
"    </a>",
"    ), it is typically unstable due to the associated syndesmosis injury and must be referred for surgical evaluation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The stability of fractures at the level of the mortise (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53671 \" href=\"mobipreview.htm?20/59/21427\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78751 \" href=\"mobipreview.htm?21/29/21968\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74131 \" href=\"mobipreview.htm?5/25/5520\">",
"     image 14",
"    </a>",
"    ) depends upon the integrity of the medial structures (mainly the deep deltoid ligament and the medial malleolus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/13\">",
"     13",
"    </a>",
"    ]. The presence of a lateral malleolar fracture together with a medial fracture or significant deltoid ligament disruption significantly increases the risk of joint instability, even if alignment is well maintained (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74130 \" href=\"mobipreview.htm?31/18/32033\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instability is demonstrated by 3 mm or more of displacement of the fibular fracture, an associated medial fracture, or a medial ligament disruption, each of which should prompt orthopedic referral (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78751 \" href=\"mobipreview.htm?21/29/21968\">",
"     image 7",
"    </a>",
"    ). Medial swelling, ecchymosis, or tenderness, suggesting the possibility of medial ligament injury, indicates the need for stress radiographs, such as the gravity stress mortise view, to determine the degree of instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/14\">",
"     14",
"    </a>",
"    ]. If medial instability is demonstrated or suspected, orthopedic referral is obtained. If the medial structures are intact and there is minimal fibular displacement, patients do well. Stress radiographs are described above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Radiographic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two Scandinavian studies provided follow-up on patients with isolated lateral malleolar fractures at or below the level of the ankle joint and found that greater than 90 percent of patients had good clinical results regardless of treatment, provided fibular displacement did not exceed 3 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] . Other studies comparing operative with nonoperative treatment of isolated lateral malleolar fractures have shown no significant difference in outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/5-7,9,18\">",
"     5-7,9,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon such studies, treatment for isolated lateral malleolar fractures is primarily nonoperative. If the fracture consists solely of a small, nondisplaced transverse avulsion fragment, the patient may be treated like a patient with a severe ankle sprain, ie, with early motion, bracing, and gradual rehabilitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53427 \" href=\"mobipreview.htm?37/18/38190\">",
"     image 13",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    .) If the fracture is oblique through the lateral malleolus at or below the level of the ankle joint, the patient may be treated in a short-leg walking cast or removable cast boot, in neutral position, for four to six weeks, weight-bearing as tolerated (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74131 \" href=\"mobipreview.htm?5/25/5520\">",
"     image 14",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Radiographs should be repeated 10 to 14 days after the injury to ensure that alignment remains acceptable and again at four to six weeks to assess healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/12\">",
"     12",
"    </a>",
"    ]. An examination of the ankle, including palpation for medial tenderness, should also be performed at these time intervals. In most cases, healing can be assessed clinically. Once healing is evident (ie, nontender over the fracture site with radiographic evidence of adequate callus around the fracture), the patient may begin unsupported weight-bearing and gradual rehabilitation. If healing is insufficient, the ankle should be immobilized or braced for an additional two weeks and then reassessed. Persistent pain and a lack of callus formation should prompt orthopedic referral.",
"   </p>",
"   <p>",
"    Treatment of fractures of the proximal fibula and fibular shaft are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26726?source=see_link\">",
"     \"Fibular fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Isolated medial or posterior malleolar fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care must be taken with these fractures to confirm the absence of associated injuries. Fractures with associated injuries, such as a proximal fibular fracture, are referred. If the fractures are truly nondisplaced, isolated injuries, they can be treated initially in a splint (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74497 \" href=\"mobipreview.htm?1/58/1952\">",
"     image 4",
"    </a>",
"    ). Patients should not bear weight until their initial follow-up visit.",
"   </p>",
"   <p>",
"    Five to seven days following the injury, patients are re-evaluated, including repeat radiographs to confirm alignment. If the isolated nature of the injury is confirmed by x-ray, the patient can be placed in a walking cast or walking boot. The cast or boot should hold the ankle at 90 degrees to prevent a flexion contracture.",
"   </p>",
"   <p>",
"    Patients remain in the cast or boot, weight-bearing as tolerated, for four to six weeks. Radiographs are repeated four weeks after the injury and subsequently every two weeks until the fracture is clinically healed (ie, nontender over the fracture site with radiographic evidence of adequate callus around the fracture). Once clinically healed, patients should begin a gentle rehabilitation program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lateral malleolar fractures with deltoid ligament injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lateral malleolar fracture with disruption of the deltoid ligament is unstable and is managed no differently than a bimalleolar fracture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78751 \" href=\"mobipreview.htm?21/29/21968\">",
"     image 7",
"    </a>",
"    ). The instability associated with these injuries has been confirmed in outcome studies and cadaveric research models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/12\">",
"     12",
"    </a>",
"    ]. Anatomic reduction of the ankle with surgical stabilization leads to better clinical results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with this injury should be splinted with the ankle joint at 90 degrees, remain nonweightbearing, and be referred to an orthopedist within a few days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bimalleolar and trimalleolar fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These fractures are unstable and require operative fixation. Patients should be splinted with the ankle joint at 90 degrees, remain nonweightbearing, and be referred to an orthopedist within a few days (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74130 \" href=\"mobipreview.htm?31/18/32033\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54533 \" href=\"mobipreview.htm?6/39/6783\">",
"     image 15",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     REHABILITATION AFTER ANKLE FRACTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of rehabilitation after an ankle fracture is to restore any loss of motion, strength, or proprioception that may have occurred as a result of the injury or the subsequent immobilization and disuse related to treatment. There is little evidence that any specific rehabilitation program improves clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/9\">",
"     9",
"    </a>",
"    ]. It is possible that individuals may return to their preinjury level of activity more quickly with aggressive rehabilitation. For most ankle fractures, rehabilitation can be carried out with a basic home exercise program of stretching, range of motion, strengthening, and balance exercises.",
"   </p>",
"   <p>",
"    A systematic review of 38 controlled trials related to the rehabilitation of ankle fractures found the evidence to be of limited quality and noted the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early performance of ankle exercises following surgical fixation improved ankle function and mobility, while decreasing pain, but was associated with higher rates of adverse events (eg, surgical wound complications), although most problems were minor. Use of a removable immobilization device was necessary for this approach. For protocols involving early exercise, the authors emphasized the importance of the patient&rsquo;s ability to comply with the regimen safely and precisely.",
"     </li>",
"     <li>",
"      Early ambulation following surgical repair may improve ankle motion, but studies supporting this approach are small and contradictory.",
"     </li>",
"     <li>",
"      Neither stretching nor manual therapy (passive motion exercises performed by a trained professional) appeared to improve function following the immobilization period regardless of whether management was surgical or conservative.",
"     </li>",
"     <li>",
"      Treatment with electrical or thermal stimulation devices or with ultrasound was not supported by high quality evidence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13789930\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankle fractures have a relatively low complication rate when managed appropriately. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for orthopedic consultation or referral'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Acute complications of ankle fractures, such as injuries to peripheral nerves or vascular structures, open fractures, and compartment syndrome, are readily identified in most cases and require emergent surgical consultation. Nerve injury can occur at the time of injury from lacerations caused by fracture fragments, direct contusion, or traction, but may also occur during subsequent treatment from casting or splinting materials that compress the nerve. Injuries to the lateral ankle or pressure on the proximal fibula from a cast or splint may lead to peroneal nerve injury causing weak foot dorsiflexion; injuries to the medial ankle may lead to tibial nerve injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of lower extremity peripheral nerve syndromes\", section on 'Peroneal nerve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of lower extremity peripheral nerve syndromes\", section on 'Posterior tibial nerve'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Lower extremity compartment syndrome is less likely to occur from ankle fractures than from fractures of the diaphysis of the tibia or fibula. Nevertheless, any patient complaining of increasing pain or new numbness and tingling or other symptoms concerning for compartment syndrome during treatment for an ankle injury should be examined without delay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Clinical features and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, skin damage can occur from stretching or abrasions incurred at the time of injury or from subsequent splinting and casting. Blisters and abrasions should be followed closely until they heal because of the risk of cellulitis.",
"   </p>",
"   <p>",
"    Potential chronic complications of ankle fractures include instability, osteoarthritis, and pain. Failure to recognize a syndesmotic injury that accompanies a fibular fracture above the ankle joint may lead to instability and premature osteoarthritis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55206 \" href=\"mobipreview.htm?12/48/13071\">",
"     image 16",
"    </a>",
"    ). In addition, a missed medial ligament injury in the setting of a lateral malleolar fracture can lead to instability, which can progress to joint pain and degeneration of the articular surface. While less than five percent of patients with unimalleolar fractures develop degenerative changes, detectable several years later by radiograph, as many as 20 percent of patients with bimalleolar fractures develop such radiographic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonunion or malunion of ankle fractures is uncommon. Nevertheless, orthopedic referral is generally needed if a fracture does not appear to be healing as expected by eight weeks following the injury. Inadequate healing is suggested by persistent or worsening pain or tenderness at the fracture site, or by signs of inadequate healing on plain radiographs. Orthopedic referral is necessary if the fracture displaces during the course of treatment.",
"   </p>",
"   <p>",
"    If functional deficits (eg, restricted motion) persist despite appropriate management and rehabilitation, reevaluation for associated injuries, such as ligament or tendon disruption, or osteochondral injury, should be performed. Orthopedic consultation or imaging with MRI may be needed in such cases.",
"   </p>",
"   <p>",
"    Complex regional pain syndrome (CRPS) may develop in the days or weeks following an ankle fracture. Pain from CRPS is more severe than that expected from the inciting injury and is often associated with such findings as abnormal skin color, temperature change, diminished motor function, and edema (",
"    <a class=\"graphic graphic_picture graphicRef67994 \" href=\"mobipreview.htm?2/56/2945\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76716 \" href=\"mobipreview.htm?40/26/41376\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic patients have an increased risk of complications after ankle fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/12\">",
"     12",
"    </a>",
"    ]. Skin injury, postoperative infection, and malunion occur more frequently in diabetics. We suggest more frequent clinic visits (every two to three weeks), including careful skin examination and radiographs, for these patients.",
"   </p>",
"   <p>",
"    According to retrospective reviews, elderly patients generally have more complex fracture patterns when compared to those under age 65 and are more prone to postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36376/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, overall functional outcomes among patients above and below 65 years are similar when baseline function and the complexity of the fracture are taken into account. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/25/40338?source=see_link\">",
"       \"Patient information: Ankle fracture (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=see_link\">",
"       \"Patient information: Fractures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ankle fractures are common injuries. The vast majority of ankle fractures are malleolar fractures; 60 to 70 percent are unimalleolar. Supination (inversion) injuries typically cause distraction (stretching) of the lateral ankle structures and compression of the medial structures. Pronation (eversion) injuries cause medial distraction and lateral compression. Structures being distracted generally fracture or tear before structures being compressed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Relevant anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open fractures and any injury with associated neurologic or vascular deficits require immediate surgical referral. Fracture dislocations require rapid reduction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An ankle fracture, particularly one sustained in a fall, may mask other injuries. Particularly with elderly patients and cases involving significant trauma, the clinician should palpate the lumbar spine, the hip, the tibia and fibula, especially the fibular neck, and the foot as part of the evaluation for possible associated injuries. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once emergent conditions have been ruled out, the first priority in the evaluation of ankle fractures is to determine whether the fracture is stable, and can be managed nonoperatively, or unstable, and must be referred. Typically, an ankle fracture is stable if it meets the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is isolated to the lateral, medial, or posterior malleolus.",
"     </li>",
"     <li>",
"      It is nondisplaced.",
"     </li>",
"     <li>",
"      It is not associated with a ligamentous injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ankle fracture is unstable if two or more sites of significant injury are present, such as a lateral malleolar fracture with deltoid ligament disruption or a bimalleolar fracture. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Ottawa ankle rules help to determine whether radiographs of the ankle or foot are needed in the evaluation of an acute ankle injury (",
"      <a class=\"graphic graphic_figure graphicRef69818 \" href=\"mobipreview.htm?32/53/33618\">",
"       figure 4",
"      </a>",
"      ). Anterior-posterior (AP), oblique, and lateral views are the standard views obtained if the patient meets the Ottawa criteria. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of ankle fractures consists of splinting, ice, elevation, and analgesics. The ankle should be splinted at 90 degrees. Usually, a short-leg posterior splint is sufficient. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unstable ankle fractures often require surgical repair. Management of the major types of ankle fractures is discussed in the text. The goal of rehabilitation after an ankle fracture is to restore any loss of motion, strength, or proprioception that may have occurred. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management of specific malleolar fractures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Rehabilitation after ankle fracture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/1\">",
"      Daly PJ, Fitzgerald RH Jr, Melton LJ, Ilstrup DM. Epidemiology of ankle fractures in Rochester, Minnesota. Acta Orthop Scand 1987; 58:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/2\">",
"      Jensen SL, Andresen BK, Mencke S, Nielsen PT. Epidemiology of ankle fractures. A prospective population-based study of 212 cases in Aalborg, Denmark. Acta Orthop Scand 1998; 69:48.",
"     </a>",
"    </li>",
"    <li>",
"     Marsh, JL, Saltzman, CL. Ankle Fractures. In: Rockwood and Green's Fractures in Adults, Bucholz, RW and Heckman, JD (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p.2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/4\">",
"      Court-Brown CM, McBirnie J, Wilson G. Adult ankle fractures--an increasing problem? Acta Orthop Scand 1998; 69:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/5\">",
"      Valtola A, Honkanen R, Kr&ouml;ger H, et al. Lifestyle and other factors predict ankle fractures in perimenopausal women: a population-based prospective cohort study. Bone 2002; 30:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/6\">",
"      Honkanen R, Tuppurainen M, Kr&ouml;ger H, et al. Relationships between risk factors and fractures differ by type of fracture: a population-based study of 12,192 perimenopausal women. Osteoporos Int 1998; 8:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/7\">",
"      Seeley DG, Kelsey J, Jergas M, Nevitt MC. Predictors of ankle and foot fractures in older women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996; 11:1347.",
"     </a>",
"    </li>",
"    <li>",
"     Simon, RR, Koenigsknecht, SJ. Fractures of the Ankle. In: Emergency Orthopedics: The Extremities, McGraw-Hill, New York 2001. p.497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/9\">",
"      Michelson JD. Fractures about the ankle. J Bone Joint Surg Am 1995; 77:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/10\">",
"      Gardner MJ, Demetrakopoulos D, Briggs SM, et al. The ability of the Lauge-Hansen classification to predict ligament injury and mechanism in ankle fractures: an MRI study. J Orthop Trauma 2006; 20:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/11\">",
"      Michelson J, Solocoff D, Waldman B, et al. Ankle fractures. The Lauge-Hansen classification revisited. Clin Orthop Relat Res 1997; :198.",
"     </a>",
"    </li>",
"    <li>",
"     Carr, JB. Malleolar fractures and soft tissue injuries of the ankle. In: Skeletal trauma: Basic science, management and reconstruction, 3rd edition, Browner, BD, Jupiter, JB, Levine, AM, Trafton, PG (Eds), Saunders, Philadelphia 2003. p.2326.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/13\">",
"      Markert RJ, Walley ME, Guttman TG, Mehta R. A pooled analysis of the Ottawa ankle rules used on adults in the ED. Am J Emerg Med 1998; 16:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/14\">",
"      van den Bekerom MP, Mutsaerts EL, van Dijk CN. Evaluation of the integrity of the deltoid ligament in supination external rotation ankle fractures: a systematic review of the literature. Arch Orthop Trauma Surg 2009; 129:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/15\">",
"      Donken CC, Al-Khateeb H, Verhofstad MH, van Laarhoven CJ. Surgical versus conservative interventions for treating ankle fractures in adults. Cochrane Database Syst Rev 2012; 8:CD008470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/16\">",
"      Bauer M, Jonsson K, Nilsson B. Thirty-year follow-up of ankle fractures. Acta Orthop Scand 1985; 56:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/17\">",
"      Kristensen KD, Hansen T. Closed treatment of ankle fractures. Stage II supination-eversion fractures followed for 20 years. Acta Orthop Scand 1985; 56:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/18\">",
"      Pakarinen HJ, Flinkkil TE, Ohtonen PP, Ristiniemi JY. Stability criteria for nonoperative ankle fracture management. Foot Ankle Int 2011; 32:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/19\">",
"      Lin CW, Donkers NA, Refshauge KM, et al. Rehabilitation for ankle fractures in adults. Cochrane Database Syst Rev 2012; 11:CD005595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/20\">",
"      Anderson SA, Li X, Franklin P, Wixted JJ. Ankle fractures in the elderly: initial and long-term outcomes. Foot Ankle Int 2008; 29:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36376/abstract/21\">",
"      Davidovitch RI, Walsh M, Spitzer A, Egol KA. Functional outcome after operatively treated ankle fractures in the elderly. Foot Ankle Int 2009; 30:728.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 227 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36376=[""].join("\n");
var outline_f35_33_36376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Malleolar fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Management of specific malleolar fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lateral malleolar fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Isolated medial or posterior malleolar fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lateral malleolar fractures with deltoid ligament injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bimalleolar and trimalleolar fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      REHABILITATION AFTER ANKLE FRACTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13789930\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/227\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/227|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/20/8527\" title=\"diagnostic image 1\">",
"      Lateral malleolus definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/61/8159\" title=\"diagnostic image 2\">",
"      Ankle mortise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/59/21427\" title=\"diagnostic image 3\">",
"      Oblique uncomplicated fracture of the lateral malleolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/58/1952\" title=\"diagnostic image 4\">",
"      Isolated uncomplicated fracture of the medial malleolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/19/23856\" title=\"diagnostic image 5\">",
"      Oblique fractures of the lateral and posterior malleoli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/18/32033\" title=\"diagnostic image 6\">",
"      Bimalleolar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/29/21968\" title=\"diagnostic image 7\">",
"      Unstable lateral malleolar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/19/31027\" title=\"diagnostic image 8\">",
"      MRI showing osteochondral injury talus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/26/2465\" title=\"diagnostic image 9\">",
"      Bone scan stress fracture distal fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/63/10239\" title=\"diagnostic image 10\">",
"      Fibula fracture above lateral malleolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/32/39439\" title=\"diagnostic image 11\">",
"      Fibula fracture above lateral malleolus lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/54/18287\" title=\"diagnostic image 12\">",
"      Fibula fracture above lateral malleolus Mortise view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/18/38190\" title=\"diagnostic image 13\">",
"      Avulsionfracture of lateral malleolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/25/5520\" title=\"diagnostic image 14\">",
"      Lateral malleolar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/39/6783\" title=\"diagnostic image 15\">",
"      Trimalleolar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/48/13071\" title=\"diagnostic image 16\">",
"      Osteoarthritis following ankle fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/227|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/9/159\" title=\"figure 1\">",
"      Lateral ankle ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/57/35728\" title=\"figure 2\">",
"      Medial ankle ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/41/22164\" title=\"figure 3\">",
"      Ankle fracture ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/53/33618\" title=\"figure 4\">",
"      Ottawa ankle rules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/227|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/16/13574\" title=\"picture 1\">",
"      Gravity stress mortise x-ray of ankle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/56/2945\" title=\"picture 2\">",
"      Ankle fracture complicated by complex regional pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/26/41376\" title=\"picture 3\">",
"      Ankle fracture after resolution of CRPS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34296?source=related_link\">",
"      Ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26726?source=related_link\">",
"      Fibular fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26358?source=related_link\">",
"      Overview of tibial fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/25/40338?source=related_link\">",
"      Patient information: Ankle fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1030?source=related_link\">",
"      Posterior and medial ankle tendinopathies not involving the Achilles tendon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_33_36377="Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)";
var content_f35_33_36377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36377/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36377/contributors\">",
"     Clifford E Kashtan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36377/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36377/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36377/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36377/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/33/36377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary nephritis (or Alport syndrome) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Alport syndrome is a primary basement membrane disorder arising from mutations in genes encoding several members of the type IV collagen protein family.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of Alport syndrome will be reviewed here. The pathogenesis, genetics, and pathology of Alport syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alport syndrome is a genetically heterogeneous disease that results from mutations in genes encoding the alpha-3, alpha-4, and alpha-5 chains of type IV collagen. These alpha IV collagen chains are normally located in various basement membranes of the kidney, cochlea, and eye. Abnormalities in these chains result in defective basement membranes at these sites, leading to the clinical features of this disorder (ie, progressive glomerular disease, sensorineural hearing loss, and ocular abnormalities). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\", section on 'Genetics'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical manifestations and course'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Transmission of Alport syndrome can be X-linked, autosomal recessive, or autosomal dominant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked transmission accounts for approximately 80 percent of affected patients and arises from mutations in the COL4A5 gene on the X chromosome.",
"     </li>",
"     <li>",
"      Autosomal recessive variant accounts for about 15 percent of patients with Alport syndrome and arises from genetic defects in either the COL4A3 or COL4A4 genes.",
"     </li>",
"     <li>",
"      Autosomal dominant disease accounts for 5 percent of patients with Alport syndrome and arises from heterozygous mutations in the COL4A3 or COL4A4 genes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198375925\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alport syndrome has been reported in hundreds of unrelated kindreds that represent all geographic and ethnic groups. Although the overall incidence in the general population is unknown, data from the United States demonstrates Alport syndrome accounts for 3 percent of children with end-stage renal disease (ESRD) and 0.2 percent of adults with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case series of patients undergoing kidney biopsies demonstrate that the difficulty in determining the incidence as the diagnosis of Alport syndrome varies from 1 to 11 percent depending upon the indications for biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gene frequency of Alport syndrome in the United States has been estimated at 1:5000 to 10,000, suggesting there are approximately 30,000 to 60,000 affected individuals in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classical presentation of Alport syndrome is based upon clinical manifestations of affected males with X-linked disease. These features include glomerular disease that progresses to end-stage renal disease (ESRD), ocular abnormalities (eg, anterior lenticonus), sensorineural hearing loss, and a family history of hematuria associated with renal failure and deafness.",
"   </p>",
"   <p>",
"    Clinical presentation and course in patients with autosomal recessive disease are similar to those with X-linked disease. Patients with autosomal dominant disease generally exhibit more gradual loss of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial renal manifestation of Alport syndrome is asymptomatic persistent microscopic hematuria, which is present in early childhood in affected patients. Since screening urinalysis is seldom performed in routine pediatric primary care, microscopic hematuria may not be detected unless the patient is screened because of an affected family member. Recurrent episodes of gross hematuria are not uncommon especially during childhood. Gross hematuria may be the initial presenting finding and often occurs after an upper respiratory infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/11\">",
"     11",
"    </a>",
"    ]. Boys without hematuria by the age of 10 years are unlikely to have Alport syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In early childhood, the serum creatinine and blood pressure are normal. Over time, proteinuria, hypertension, and progressive renal insufficiency develop. ESRD usually occurs between the ages of 16 and 35 years in patients with X-linked or autosomal recessive disease. In some families, the course is more indolent with renal failure being delayed until age 45 to 60, especially in those with autosomal dominant Alport syndrome.",
"   </p>",
"   <p>",
"    In females with X-linked Alport syndrome, recurrent episodes of gross hematuria, proteinuria, hearing loss, and diffuse glomerular basement membrane (GBM) thickening are associated with more severe renal dysfunction and ESRD at an earlier age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Phenotype-genotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tempo of progressive renal dysfunction depends, at least in part, upon the underlying mutation. Patients with large deletions and nonsense mutations have more severe disease (both renal and extrarenal) than those with missense mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/1-4,13\">",
"     1-4,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in the following reviews of families with X-linked Alport syndrome that demonstrated the correlation between ESRD and types of mutation in the COL4A5(IV) gene.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study of 195 European families, the risk of ESRD by 30 years of age for patients with missense mutations, splice site mutations, and large deletion, nonsense, or frameshift mutations was 50, 70, and 90 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/13\">",
"       13",
"      </a>",
"      ]. Large rearrangements of the COL4A5 gene or any mutations that shift the reading frame of the gene were also associated with early onset of hearing loss and a higher incidence of anterior lenticonus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the second study of 175 families from the United States, the average age of onset for ESRD for patients with missense mutations, splice site mutations, and truncating mutations was 37, 28, and 25 years of age, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/14\">",
"       14",
"      </a>",
"      ]. Mutations located closer to the 5' end of the gene were associated with a younger onset of ESRD, and an increased risk of ocular changes and hearing loss than those located closer to the 3' end. Patients with splice or truncating mutations were also more likely to have ocular abnormalities and hearing loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral sensorineural hearing loss is a common feature in patients with Alport syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/15\">",
"     15",
"    </a>",
"    ]. Hearing loss begins in the high frequency range and progresses over time to frequencies in the range of conversational speech. One study of families with X-linked disease reported that audiologic testing detected hearing loss in 85 percent of affected boys and 18 percent of female carriers by 15 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/11\">",
"     11",
"    </a>",
"    ]. In general, the rate of hearing loss is similar to the progression of renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ocular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several ocular defects involving the lens, retina, and cornea have been reported in patients with Alport syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lens &ndash; Anterior lenticonus is a regular conical protrusion on the anterior aspect of the lens due to thinning of the lens capsule. It occurs in 20 to 30 percent of males with X-linked Alport syndrome and is pathognomonic of the disease. Lenticonus can be complicated by the presence of subcapsular cataracts, which may lead to loss of visual acuity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"       \"Cataract in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retina &ndash; Retinal changes are asymptomatic, and when there is anterior lenticonus, they are always present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/18\">",
"       18",
"      </a>",
"      ]. The changes consist of bilateral white or yellow granulations that are superficially located in the retina surrounding the foveal area [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/19\">",
"       19",
"      </a>",
"      ]. These findings are also specific for Alport syndrome.",
"     </li>",
"     <li>",
"      Cornea &ndash; Corneal changes are nonspecific findings in patients with Alport syndrome and include posterior polymorphous dystrophy and recurrent corneal erosion, which can cause severe ocular pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with X-linked Alport syndrome are heterozygous carriers of the disease mutation. They have a range of clinical findings due to lyonization, by which only one X chromosome is active per cell. As a result, approximately one-half of their cells will express the mutant COL4A5 gene and the remaining cells the normal COL4A5 gene, leading to a variable phenotype that is generally less severe than in affected males.",
"   </p>",
"   <p>",
"    This was shown in a study of the natural history of female carriers with proven COL4A5 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/20\">",
"     20",
"    </a>",
"    ]. Among female carriers followed in 195 affected families, the incidence of ESRD before age 40 was only 12 percent, compared with 90 percent in affected males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/13\">",
"     13",
"    </a>",
"    ]. With increasing age, there was an increased risk of progressive renal disease with a 30 percent probability of developing ESRD by age 60 in these female carriers. However, this may be an overestimate, since approximately one-third of the women, most likely less severely affected, were lost to follow-up. There was variation in phenotypes among family members with the same genotype, most likely due to the variability of gene expression due to lyonization.",
"   </p>",
"   <p>",
"    Risk factors for chronic renal insufficiency in female carriers include episodic gross hematuria in childhood, sensorineural deafness, proteinuria, and the presence of the characteristic lamellation of the basement membrane (GBM) associated with Alport syndrome on renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. By comparison, female carriers with only asymptomatic hematuria by the age of 30 to 40 years have a very small risk of developing ESRD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Leiomyomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas are benign tumors characterized by visceral smooth muscle overgrowth within the respiratory, gastrointestinal, and female reproductive tracts. They are found in 2 to 5 percent of patients and carriers of X-linked Alport syndrome who have chromosomal microdeletion at the 5' ends of COL4A, which extend into the adjacent COL4A6 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23922451\">",
"    <span class=\"h2\">",
"     Arterial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysms of the thoracic and abdominal aorta have been reported in relatively young male patients, as well as a single case of intracranial aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23922459\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A contiguous gene syndrome consisting of X-linked Alport syndrome, midface hypoplasia, and mental retardation resulting from chromosomal microdeletion involving the COL4A5 gene and adjacent genes has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis of Alport syndrome is generally suspected from the family history of renal failure and deafness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/29\">",
"     29",
"    </a>",
"    ], the diagnosis is usually confirmed by a skin or renal biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal and skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a renal biopsy specimen, the characteristic finding of longitudinal splitting of the lamina densa of the glomerular basement membrane (GBM) detected by electron microscopy is diagnostic for Alport syndrome (",
"    <a class=\"graphic graphic_picture graphicRef68942 graphicRef79434 \" href=\"mobipreview.htm?36/44/37577\">",
"     picture 1A-B",
"    </a>",
"    ). However, in young patients, this characteristic appearance of a laminated GBM may not be present. In males with X-linked Alport syndrome, for example, the proportion of GBM showing splitting increases from about 30 percent by age 10 to more than 90 percent by age 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link&amp;anchor=H15#H15\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\", section on 'Renal pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If immunostaining of type IV collagen is used and demonstrates absence or an abnormal distribution of the alpha-3, alpha-4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alpha-5(IV) chains of the GBM, the diagnosis can be made in a child with a family history of renal failure and deafness without the ultrastructural finding of a laminated GBM (",
"    <a class=\"graphic graphic_figure graphicRef81373 \" href=\"mobipreview.htm?38/17/39192\">",
"     figure 1",
"    </a>",
"    ). For example, immunostaining demonstrates absence of staining of the alpha-3, alpha-4, and alpha-5 (IV) chains in the glomerular basement membrane in two-thirds of male patients and discontinuous distribution in female carriers. In addition, there is no staining of alpha-5 (IV) chain in the distal tubular membrane of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link&amp;anchor=H8#H8\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\", section on 'Alpha-3, alpha-4, and alpha-5(IV) chain tissue distribution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A less invasive potential method to diagnose a child with suspected X-linked Alport syndrome is a skin biopsy using commercially available monoclonal antibody against the alpha-5(IV) chain (",
"    <a class=\"graphic graphic_picture graphicRef72404 \" href=\"mobipreview.htm?3/37/3668\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/1,31-35\">",
"     1,31-35",
"    </a>",
"    ]. If the protein is clearly absent in a suspected male (or is clearly mosaic in a female), a diagnosis of Alport syndrome (or a genetic carrier) can be made without further testing. If the test demonstrates expression of the alpha-5(IV) chain, then the patient has one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mutation in the COL4A5 gene that permits deposition of a functionally abnormal but antigenically normal alpha-5(IV) chain, which occurs in about 30 percent of male patients with X-linked disease.",
"     </li>",
"     <li>",
"      Autosomal recessive Alport syndrome with abnormalities in either the COL4A3 or COL4A4 gene.",
"     </li>",
"     <li>",
"      Another disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these uncertain cases, the diagnosis of Alport syndrome can subsequently be confirmed or excluded by a renal biopsy with analysis of type IV collagen expression in the kidney. A renal biopsy should also be performed if results of a skin biopsy are equivocal and a diagnosis is required because of signs of possible progressive renal disease, such as hypertension, proteinuria, or an elevated plasma creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link&amp;anchor=H9#H9\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\", section on 'Skin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In up to 15 percent of cases, there is no identified family history of renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/2\">",
"     2",
"    </a>",
"    ] and the diagnosis is made by the presence of the characteristic finding of lamination of the GBM in samples from a renal biopsy. These cases represent new mutations in the COL4A3, COL4A4, or COL4A5 genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Molecular genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular genetic testing may eventually become the diagnostic procedure of choice because it is noninvasive and can be extremely accurate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Since the rate of progression of renal disease may be dependent upon the underlying specific mutation, molecular analysis may eventually provide more prognostic data than either renal or skin biopsy.",
"   </p>",
"   <p>",
"    The large size and high GC content of the COL4A5 gene render direct mutational analysis of genomic DNA technically difficult. In addition, the analysis of genomic DNA may not detect large gene rearrangements or splice site mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, direct mutational analysis of coding sequence (ie, mRNA), rather than genomic DNA, may provide a less laborious and more sensitive method for the detection of splice site mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Since COL4A5 mRNA is expressed in the skin and hair roots, analysis of cells from these sites may allow a relatively noninvasive diagnostic test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/40,44,45\">",
"     40,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate settings in which genetic testing may be beneficial include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal diagnosis.",
"     </li>",
"     <li>",
"      Confirmation or exclusion of the disorder in patients who cannot be unequivocally diagnosed by biopsy.",
"     </li>",
"     <li>",
"      Absolute exclusion of the carrier state in an asymptomatic female.",
"     </li>",
"     <li>",
"      When X-linked and autosomal recessive disease cannot be differentiated by pedigree and immunohistochemical analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current information on molecular testing for Alport syndrome can be obtained at",
"    <a class=\"external\" href=\"file://www.genereviews.org/\">",
"     www.genereviews.org",
"    </a>",
"    . (Accessed March 17, 2008).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alport syndrome is typically differentiated from other major causes of persistent glomerular hematuria by a positive family history of hematuria associated with renal failure and deafness. Other glomerular disorders that present in children with microscopic hematuria include IgA nephropathy, in which the family history is usually negative; and thin basement membrane nephropathy, in which the family history may be positive for hematuria but renal failure and deafness are absent. The diagnosis of Alport syndrome is confirmed by skin or renal biopsy. Alport syndrome is distinguished by the presence of the characteristic finding of lamination of the glomerular basement membrane (GBM) in samples from a renal biopsy or absence of type IV collagen by immunostaining. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/2/17445?source=see_link\">",
"     \"Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Megathrombocytopenia (thrombocytopenia with large or giant platelets) has been described in some families with autosomal dominant hereditary nephritis and sensorineural deafness. This complex has been referred to as Epstein syndrome or Fechtner syndrome when associated with leukocyte cytoplasmic inclusions. These disorders have been mapped to chromosome 22, and result from mutations in the gene encoding nonmuscle myosin heavy chain 9 (MYH9). Mutations in this gene can also cause Sebastian syndrome, another giant platelet disorder, and nonsyndromic hereditary deafness. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25591?source=see_link&amp;anchor=H20#H20\">",
"     \"Causes of thrombocytopenia in children\", section on 'Giant platelet disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, Epstein and Fechtner syndromes represent distinct disorders arising from mutations in noncollagen genes, not variants of autosomal dominant Alport syndrome. In some patients, ultrastructural changes reminiscent of Alport syndrome may be present. However, immunostaining for type IV collagen is normal in patients with Epstein or Fechtner syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who develop end-stage renal disease, transplantation is the preferred modality for renal replacement therapy in our practice.",
"   </p>",
"   <p>",
"    There is no specific treatment for Alport syndrome currently available. The use of angiotensin antagonists or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been described in uncontrolled studies on human patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Angiotensin blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that angiotensin blockade therapy reduces proteinuria and diminishes the rate of glomerulosclerosis and disease progression in patients with Alport syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 12-week clinical trial of 30 children with Alport syndrome,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/19/40247?source=see_link\">",
"       losartan",
"      </a>",
"      (angiotensin receptor blockers) reduced proteinuria to a greater extent than placebo or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/22/36199?source=see_link\">",
"       amlodipine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of patients followed by the European Alport Registry for a mean duration of over 20 years, retrospective analysis found that initiation of angiotensin-converting enzyme inhibitors delayed dialysis in patients with proteinuria and normal renal function compared with those who never received such therapy or who received treatment only when they developed impaired renal function (dialysis initiated at a mean age of 40, 22, and 25 years, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of animal models of Alport syndrome have also demonstrated that animals treated with ACE inhibitors compared with controls had a slower decline in renal function, slower increase in proteinuria, and less renal damage (eg, reduced renal fibrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these results, angiotensin blockade with an ACE inhibitor (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/18/32040?source=see_link\">",
"     enalapril",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/38/15976?source=see_link\">",
"     lisinopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    ) or an angiotensin receptor blocker (ARB; eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/19/40247?source=see_link\">",
"     losartan",
"    </a>",
"    ) is recommended in patients with Alport syndrome and overt proteinuria. It is also reasonable to consider angiotensin blockade therapy in those patients who have microalbuminuria, but who have not yet developed overt proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'ACE inhibitors/ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a canine model of X-linked Alport syndrome,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    treatment failed to diminish proteinuria, but resulted in longer renal survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, uncontrolled studies of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy have produced divergent results. In a Spanish study of eight patients who ranged in age from 15 to 27 years of age at follow-up, serum creatinine values remained stable compared with pretreatment measurements after a mean duration of cyclosporine therapy of 8.4 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, patients had either a lower or equivalent degree of proteinuria compared with baseline values. In contrast, a study of nine French patients reported that cyclosporine therapy suppressed proteinuria, but reduced glomerular filtration rate and possibly accelerated renal fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/55\">",
"     55",
"    </a>",
"    ]. In an uncontrolled study of Italian children with Alport syndrome, cyclosporine therapy transiently reduced proteinuria, but did not prevent subsequent decline in renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As there is the potential for nephrotoxicity, until further data demonstrate benefit from",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy, we do not suggest that this agent be used in patients with Alport syndrome to slow the progression of renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Alport syndrome typically have excellent renal transplant outcomes. Recurrent disease does not occur in the transplanted graft because the donor kidney has a normal glomerular basement membrane (GBM). However, anti-glomerular basement membrane antibody disease (anti-GBM antibody disease) occurs in approximately 3 percent of affected males who receive transplants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anti-GBM antibody disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;De novo anti-GBM antibody disease develops in approximately 3 percent of transplanted males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/2,18,31,57-63\">",
"     2,18,31,57-63",
"    </a>",
"    ]. In males with X-linked disease, antibodies are directed primarily against the alpha-5(IV) chain, but antibodies against the alpha-3(IV) chain are also found in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/4,57,60,63-65\">",
"     4,57,60,63-65",
"    </a>",
"    ]. In patients with autosomal recessive Alport syndrome who develop posttransplant anti-GBM disease, the predominant target of anti-GBM antibodies is the alpha-3(IV) chain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of cases of posttransplant anti-GBM disease in Alport syndrome occur in males. This is consistent with the hypothesis that even a female heterozygote who developed end-stage renal disease would have some cells synthesizing and secreting a normal alpha-5(IV) chain, thus a transplanted kidney would not be expressing a new antigenic epitope to these patients. However, posttransplant anti-GBM disease has been described in females with autosomal recessive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In these patients, the anti-GBM antibodies are directed primarily against the alpha-3(IV) chain.",
"   </p>",
"   <p>",
"    Although anti-GBM antibody disease usually occurs in the first year after transplantation, an interval of several years between transplantation and presentation with anti-GBM disease can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/31\">",
"     31",
"    </a>",
"    ]. Affected patients typically have circulating anti-GBM antibodies and up to three-quarters of patients may develop crescentic glomerulonephritis and loss of the graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/31,58,59\">",
"     31,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key to early diagnosis of posttransplant anti-GBM antibody disease is a low threshold for obtaining an allograft biopsy with indirect immunofluorescence, which demonstrates the characteristic finding of linear deposition of IgG along the glomerular capillaries and occasionally the distal tubules. The clinician should not rely solely on commercial anti-GBM assays because they are optimized for detection of antibodies directed against the Goodpasture antigen rather than antibodies against the alpha5 IV chain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4409?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasmapheresis and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , which are initially used in treating primary anti-GBM disease, appear to be of",
"    <strong>",
"     limited",
"    </strong>",
"    benefit in posttransplant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/31\">",
"     31",
"    </a>",
"    ]. Retransplantation in these patients is associated with a high risk of recurrence (seven of eight in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7432?source=see_link\">",
"     \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the incidence of clinical anti-GBM antibody disease is low, renal transplantation is",
"    <strong>",
"     not",
"    </strong>",
"    contraindicated in patients with Alport syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the optimal management is uncertain in patients who lost their first graft to anti-GBM antibody disease. The recurrence rate is high in subsequent transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/43,64\">",
"     43,64",
"    </a>",
"    ], but isolated cases of successful retransplantation have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear why only some patients develop anti-GBM antibody disease after transplantation. In patients with X-linked disease, the specific type of mutation may be an important factor in developing anti-GBM antibody disease. The risk appears to be greatest in patients with COL4A5 mutations that prevent synthesis of the alpha-5(IV) chain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/59,61,64\">",
"     59,61,64",
"    </a>",
"    ]. This was illustrated in one review of Alport patients with posttransplant anti-GBM disease that reported 54 percent (7 of 13) of patients with anti-GBM disease had large deletions in the COL4A5 gene compared with a deletion frequency of 16 percent in all patients with Alport syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a COL4A5 gene deletion alone does not appear to be sufficient to cause anti-GBM disease following renal transplantation. In one study, only one of seven patients with a COL4A5 deletion and complete absence of the alpha-5(IV) chain developed anti-GBM disease in the renal transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/4\">",
"     4",
"    </a>",
"    ], suggesting that factors other than exposure to a previously unseen antigen must be involved. The complex interplay between the host's underlying gene defect, immune response factors such as antigen presentation, and immunosuppression are all factors that must be considered in the development of posttransplant anti-GBM disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in the ability to activate the cellular arm of the immune system may be another reason why only some patients develop posttransplant anti-GBM disease. One study evaluated the variation in anti-GBM antibody formation in patients with Alport syndrome in whom posttransplant disease had or had not developed (12 and 10 patients, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/41\">",
"     41",
"    </a>",
"    ]. All patients in both groups displayed some combination of antibodies directed against the alpha 3, 4, or 5 chains of type IV collagen, and the pattern of antibody expression did not differ between the two groups. It has also been noted that some Alport patients develop linear IgG staining of the transplant GBM, without concomitant evidence of C3 deposition, glomerulonephritis, or allograft dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/58\">",
"     58",
"    </a>",
"    ]. These data suggest that nonhumoral immune factors contribute to the variation in the frequency of anti-GBM disease posttransplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23922467\">",
"    <span class=\"h3\">",
"     Living-related donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since Alport syndrome is a familial disorder, potential living-related kidney donors for Alport patients must be carefully evaluated. Male relatives who do not have hematuria are suitable candidates. Women who are heterozygous for X-linked Alport syndrome are less desirable candidates, with some exceptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595174595\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our management approach is consistent with the clinical practice recommendations for the treatment of Alport syndrome from the Alport Syndrome Research Collaborative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36377/abstract/72\">",
"     72",
"    </a>",
"    ]. It consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Annual monitoring for microalbuminuria and proteinuria as soon as the diagnosis of Alport syndrome is made or beginning at one year of age for at-risk children.",
"     </li>",
"     <li>",
"      Angiotensin blockade therapy is initiated when patients develop overt proteinuria defined as a urinary protein-creatinine ratio",
"      <span class=\"nowrap\">",
"       (Uprot/Ucr)",
"      </span>",
"      &gt;0.2",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      or urinary protein excretion greater than 4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per hour in a timed collection. The targeted therapeutic goal of urinary protein-creatinine ratio based on expert consensus is reducing proteinuria by a minimum of 50 percent in patients with a",
"      <span class=\"nowrap\">",
"       Uprot/Ucr",
"      </span>",
"      between 0.2 and 1",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      or a ratio less than 0.5",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      for those with a baseline value &gt;2",
"      <span class=\"nowrap\">",
"       mg/mg.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Angiotensin blockade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin blockade therapy is considered in male patients in whom there is a high risk of end-stage renal disease (ESRD) by 30 years of age (ie, those with large deletion, nonsense, or frameshift mutations of the COL4A5 gene) and who have microalbuminuria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link&amp;anchor=H10#H10\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Issues with measuring urine albumin'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5\">",
"       'Phenotype-genotype correlation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive measures are initiated to prevent and treat complications of chronic kidney disease as they develop, which are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link\">",
"       \"Overview of the management of chronic kidney disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal transplantation is the preferred option over dialysis for patients who develop ESRD. However, as noted above, there is a small, but not insignificant risk of developing anti-GBM antibody disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alport syndrome is a genetically heterogeneous disease that results from mutations in genes encoding the alpha-3, alpha-4, and alpha-5(IV) chains of type IV collagen. X-linked, autosomal recessive, and autosomal dominant forms of the disease account for 80, 15, and 5 percent of cases, respectively. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of the alpha-3, alpha-4, or alpha-5(IV) chains of type IV collagen cause basement membrane impairment in the glomerulus, eye, and inner ear resulting in the clinical findings of Alport syndrome.",
"     </li>",
"     <li>",
"      The classical presentation of Alport syndrome is based upon clinical manifestations of affected males with X-linked disease. These features include glomerular disease that progresses to end-stage renal disease (ESRD), ocular abnormalities (eg, anterior lenticonus), sensorineural hearing loss, and a positive family history of renal failure and hearing loss.",
"     </li>",
"     <li>",
"      Patients with autosomal recessive disease have a similar clinical presentation and course as those with X-linked disease, whereas patients with autosomal dominant disease generally have a slower deterioration of renal function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations and course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial renal manifestation of Alport syndrome is usually asymptomatic microscopic hematuria. Gross hematuria may also be a presenting finding, which may occur after an upper respiratory infection. The serum creatinine and blood pressure are normal in early childhood, but progressive renal insufficiency, hypertension, and increasing proteinuria develop with time. End-stage renal disease usually occurs in affected individuals between the ages of 16 and 35, but the course is more indolent in some families. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Renal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with X-linked Alport syndrome are heterozygous carriers of the gene mutation and have a range of clinical findings due to lyonization, in which only one X chromosome is active per cell. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Carriers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Alport syndrome is usually suspected from the family history of renal failure and deafness. Confirmation of the diagnosis is made by either skin or renal biopsy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no specific treatment to correct the underlying defect for Alport syndrome.",
"     </li>",
"     <li>",
"      In patients with Alport disease and overt proteinuria, angiotensin blockade therapy reduces the rate of protein excretion and appears to slow the progression of the disease. As a result, we recommend annual monitoring for proteinuria as soon as Alport syndrome is diagnosed, and treating any patient with Alport disease and overt proteinuria with angiotensin blockade therapy using either an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). It is reasonable to consider angiotensin blockade therapy in patients who have microalbuminuria, but have not yet developed overt proteinuria. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Angiotensin blockade'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of hypertension in children and adolescents\", section on 'ACE inhibitors/ARBs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       not",
"      </strong>",
"      recommend",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy in patients with Alport syndrome (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Cyclosporine has not been shown to reduce the rate of renal disease progression and has significant side effects including cyclosporine renal toxicity. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either dialysis or transplantation can be performed in patients with Alport syndrome who develop end-stage renal disease.",
"     </li>",
"     <li>",
"      The preferred modality of renal replacement therapy is renal transplantation. Recurrent disease does not occur in the transplant (since the donor glomerular basement membrane [GBM] is normal); however, approximately 3 percent of transplanted males develop de novo anti-GBM antibody disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Renal transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Anti-GBM antibody disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/1\">",
"      Kashtan CE. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 1999; 78:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/2\">",
"      Tryggvason K, Zhou J, Hostikka SL, Shows TB. Molecular genetics of Alport syndrome. Kidney Int 1993; 43:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/3\">",
"      Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/4\">",
"      Antignac C, Knebelmann B, Drouot L, et al. Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression. J Clin Invest 1994; 93:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/5\">",
"      Waldherr R. Familial glomerular disease. Contrib Nephrol 1982; 33:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/6\">",
"      Trachtman H, Weiss RA, Bennett B, Greifer I. Isolated hematuria in children: indications for a renal biopsy. Kidney Int 1984; 25:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/7\">",
"      Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Nephrol Dial Transplant 1998; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/8\">",
"      Hasstedt SJ, Atkin CL. X-linked inheritance of Alport syndrome: family P revisited. Am J Hum Genet 1983; 35:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/9\">",
"      Pochet JM, Bobrie G, Landais P, et al. Renal prognosis in Alport's and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant 1989; 4:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/10\">",
"      Marcocci E, Uliana V, Bruttini M, et al. Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant 2009; 24:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/11\">",
"      Gubler M, Levy M, Broyer M, et al. Alport's syndrome. A report of 58 cases and a review of the literature. Am J Med 1981; 70:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/12\">",
"      Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 2008; 4:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/13\">",
"      Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 2000; 11:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/14\">",
"      Bekheirnia MR, Reed B, Gregory MC, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010; 21:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/15\">",
"      Izzedine H, Tankere F, Launay-Vacher V, Deray G. Ear and kidney syndromes: molecular versus clinical approach. Kidney Int 2004; 65:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/16\">",
"      Gr&uuml;nfeld JP. The clinical spectrum of hereditary nephritis. Kidney Int 1985; 27:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/17\">",
"      Shaw EA, Colville D, Wang YY, et al. Characterization of the peripheral retinopathy in X-linked and autosomal recessive Alport syndrome. Nephrol Dial Transplant 2007; 22:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/18\">",
"      Byrne MC, Budisavljevic MN, Fan Z, et al. Renal transplant in patients with Alport's syndrome. Am J Kidney Dis 2002; 39:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/19\">",
"      Perrin D, Jungers P, Gr&uuml;nfeld JP, et al. Perimacular changes in Alport's syndrome. Clin Nephrol 1980; 13:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/20\">",
"      Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \"European Community Alport Syndrome Concerted Action\" study. J Am Soc Nephrol 2003; 14:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/21\">",
"      Gr&uuml;nfeld JP, No&euml;l LH, Hafez S, Droz D. Renal prognosis in women with hereditary nephritis. Clin Nephrol 1985; 23:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/22\">",
"      Kashtan CE. Alport syndrome and the X chromosome: implications of a diagnosis of Alport syndrome in females. Nephrol Dial Transplant 2007; 22:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/23\">",
"      Dahan K, Heidet L, Zhou J, et al. Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females. Kidney Int 1995; 48:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/24\">",
"      Uliana V, Marcocci E, Mucciolo M, et al. Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2. Pediatr Nephrol 2011; 26:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/25\">",
"      Vaicys C, Hunt CD, Heary RF. Ruptured intracranial aneurysm in an adolescent with Alport's syndrome--a new expression of type IV collagenopathy: case report. Surg Neurol 2000; 54:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/26\">",
"      Lyons OT, St John ER, Morales JP, et al. Ruptured thoracoabdominal aortic aneurysm in a renal transplant patient with Alport's syndrome. Ann Vasc Surg 2007; 21:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/27\">",
"      Kashtan CE, Segal Y, Flinter F, et al. Aortic abnormalities in males with Alport syndrome. Nephrol Dial Transplant 2010; 25:3554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/28\">",
"      Vitelli F, Piccini M, Caroli F, et al. Identification and characterization of a highly conserved protein absent in the Alport syndrome (A), mental retardation (M), midface hypoplasia (M), and elliptocytosis (E) contiguous gene deletion syndrome (AMME). Genomics 1999; 55:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/29\">",
"      Pirson Y. Making the diagnosis of Alport's syndrome. Kidney Int 1999; 56:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/30\">",
"      Rumpelt HJ. Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 1980; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/31\">",
"      Kashtan CE, Michael AF. Alport syndrome. Kidney Int 1996; 50:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/32\">",
"      Massella L, Onetti Muda A, Faraggiana T, et al. Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease. Kidney Int 2003; 64:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/33\">",
"      Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/34\">",
"      van der Loop FT, Monnens LA, Schr&ouml;der CH, et al. Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin. Kidney Int 1999; 55:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/35\">",
"      Kashtan CE. Alport syndrome: is diagnosis only skin-deep? Kidney Int 1999; 55:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/36\">",
"      Kitagawa K, Nakanishi K, Iijima K, et al. Mutation in alpha 5(IV) collagen chain gene in nonfamilial hematuria. J Am Soc Nephrol 1995; 6:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/37\">",
"      Martin P, Heiskari N, Zhou J, et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 1998; 9:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/38\">",
"      Inoue Y, Nishio H, Shirakawa T, et al. Detection of mutations in the COL4A5 gene in over 90% of male patients with X-linked Alport's syndrome by RT-PCR and direct sequencing. Am J Kidney Dis 1999; 34:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/39\">",
"      Arrondel C, Desch&ecirc;nes G, Le Meur Y, et al. A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia. Kidney Int 2004; 65:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/40\">",
"      King K, Flinter FA, Green PM. A two-tier approach to mutation detection in the COL4A5 gene for Alport syndrome. Hum Mutat 2006; 27:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/41\">",
"      Kalluri R, Werner MC, Zamborsky ED, et al. Identification of alpha 3, alpha 4, and alpha 5 chains of type IV collagen as the primary target for the alport post-transplant anti-GBM alloantibodies (abstract). J Am Soc Nephrol 1997; 8:498A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/42\">",
"      G&ouml;bel J, Olbricht CJ, Offner G, et al. Kidney transplantation in Alport's syndrome: long-term outcome and allograft anti-GBM nephritis. Clin Nephrol 1992; 38:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/43\">",
"      Browne G, Brown PA, Tomson CR, et al. Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int 2004; 65:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/44\">",
"      King K, Flinter FA, Nihalani V, Green PM. Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet 2002; 111:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/45\">",
"      Taz&oacute;n-Vega B, Ars E, Burset M, et al. Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples. Am J Kidney Dis 2007; 50:257.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/46\">",
"      Cohen EP, Lemann J Jr. In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression. Am J Kidney Dis 1996; 27:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/47\">",
"      Proesmans W, Knockaert H, Trouet D. Enalapril in paediatric patients with Alport syndrome: 2 years' experience. Eur J Pediatr 2000; 159:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/48\">",
"      Proesmans W, Van Dyck M. Enalapril in children with Alport syndrome. Pediatr Nephrol 2004; 19:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/49\">",
"      Webb NJ, Lam C, Shahinfar S, et al. Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant 2011; 26:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/50\">",
"      Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012; 81:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/51\">",
"      Gross O, Beirowski B, Koepke ML, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003; 63:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/52\">",
"      Grodecki KM, Gains MJ, Baumal R, et al. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 1997; 117:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/53\">",
"      Chen D, Jefferson B, Harvey SJ, et al. Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model. J Am Soc Nephrol 2003; 14:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/54\">",
"      Call&iacute;s L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 1999; 55:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/55\">",
"      Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 2007; 22:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/56\">",
"      Massella L, Muda AO, Legato A, et al. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol 2010; 25:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/57\">",
"      Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992; 42:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/58\">",
"      Qu&eacute;rin S, No&euml;l LH, Gr&uuml;nfeld JP, et al. Linear glomerular IgG fixation in renal allografts: incidence and significance in Alport's syndrome. Clin Nephrol 1986; 25:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/59\">",
"      Kashtan CE, Butkowski RJ, Kleppel MM, et al. Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome. J Lab Clin Med 1990; 116:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/60\">",
"      Kalluri R, Weber M, Netzer KO, et al. COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1994; 45:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/61\">",
"      Ding J, Zhou J, Tryggvason K, Kashtan CE. COL4A5 deletions in three patients with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol 1994; 5:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/62\">",
"      Shah B, First MR, Mendoza NC, et al. Alport's syndrome: risk of glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation. Nephron 1988; 50:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/63\">",
"      Hellmark T, Johansson C, Wieslander J. Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Kidney Int 1994; 46:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/64\">",
"      Heiskari N, Zhang X, Zhou J, et al. Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol 1996; 7:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/65\">",
"      Brainwood D, Kashtan C, Gubler MC, Turner AN. Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation. Kidney Int 1998; 53:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/66\">",
"      Kalluri R, van den Heuvel LP, Smeets HJ, et al. A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1995; 47:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/67\">",
"      Ding J, Stitzel J, Berry P, et al. Autosomal recessive Alport syndrome: mutation in the COL4A3 gene in a woman with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol 1995; 5:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/68\">",
"      Wang XP, Fogo AB, Colon S, et al. Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. J Am Soc Nephrol 2005; 16:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/69\">",
"      Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant 2006; 10:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/70\">",
"      Gross O, Weber M, Fries JW, M&uuml;ller GA. Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome. Nephrol Dial Transplant 2009; 24:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/71\">",
"      Kashtan CE. Women with Alport syndrome: risks and rewards of kidney donation. Nephrol Dial Transplant 2009; 24:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36377/abstract/72\">",
"      Kashtan CE, Ding J, Gregory M, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 2013; 28:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6093 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36377=[""].join("\n");
var outline_f35_33_36377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H198375925\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AND COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Phenotype-genotype correlation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ocular manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Carriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Leiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23922451\">",
"      Arterial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23922459\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal and skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Molecular genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Angiotensin blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anti-GBM antibody disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23922467\">",
"      - Living-related donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H595174595\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6093|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/17/39192\" title=\"figure 1\">",
"      Immunohistol kidney Alport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6093|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/46/34536\" title=\"picture 1A\">",
"      Hereditary nephritis EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/46/24303\" title=\"picture 1B\">",
"      Hereditary nephritis IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/37/3668\" title=\"picture 2\">",
"      Immunohistology skin Alport",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25591?source=related_link\">",
"      Causes of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/2/17445?source=related_link\">",
"      Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=related_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7432?source=related_link\">",
"      Treatment of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_33_36378="Mucocutaneous manifestations of systemic lupus erythematosus";
var content_f35_33_36378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mucocutaneous manifestations of systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Samuel L Moschella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/33/36378/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/33/36378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucous membranes are involved at some point in over 80 percent of patients with systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. There are tremendous variability and diversity in the type of involvement, ranging from the classic butterfly rash to fixed lesions that may be associated with scarring and atrophy (also referred to as discoid lupus erythematosus). In addition, cutaneous bullae, oral and nasopharyngeal ulcers, cicatrizing and noncicatrizing alopecia, and skin changes resulting from vasculitis may occur in patients with LE (",
"    <a class=\"graphic graphic_table graphicRef77275 \" href=\"mobipreview.htm?34/23/35197\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75563 \" href=\"mobipreview.htm?19/53/20316\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71774 \" href=\"mobipreview.htm?14/48/15116\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Photosensitivity is a common theme for lesions that are characterized by an interface dermatitis as well as for the tumid lesions characterized by dermal mucin and a lymphohistiocytic perivascular and peri-appendageal infiltrate. This includes discoid LE lesions and lesions of subacute cutaneous lupus erythematosus, acute cutaneous LE, and tumid LE. In some chronic forms, the rash can be disfiguring and can require aggressive therapy to minimize scarring and dyspigmentation.",
"   </p>",
"   <p>",
"    Inflammatory periorbital edema is uncommon in patients with SLE, which is useful as a distinguishing feature from dermatomyositis. Patients with localized discoid LE, hypertrophic LE, LE panniculitis, and lupus tumidus tend to have skin disease only; however, progression to systemic disease is possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical characteristics and treatment of the more common disorders of the integument and their treatment in patients with SLE will be reviewed here. An overview of the clinical manifestations of SLE, SLE in children, and neonatal lupus syndrome are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CUTANEOUS EXPRESSIONS OF LUPUS ERYTHEMATOSUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute cutaneous lupus erythematosus (butterfly rash)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic acute cutaneous lupus erythematosus rash (butterfly rash), characterized by erythema in a malar distribution over the cheeks and bridge of the nose (",
"    <a class=\"graphic graphic_picture graphicRef75781 graphicRef55875 \" href=\"mobipreview.htm?36/46/37608\">",
"     picture 1A-B",
"    </a>",
"    ), appears in approximately one-half of patients, usually after ultraviolet (UV) light exposure, and is frequently mistaken for a sunburn. The rash may precede other symptoms of lupus by months or even years or may be accompanied by other symptoms and signs of acute SLE. The involved skin feels warm and appears slightly edematous, creating at times a &ldquo;peau d&rsquo;orange&rdquo; appearance. Application of alcohol (found in many sunscreens) can enhance the redness, due to its irritating effect. The rash may last for hours or days and often recurs, particularly with inadvertent sun exposure.",
"   </p>",
"   <p>",
"    Some other skin lesions may be clinically quite similar to the classic acute butterfly rash of SLE. Rosacea, for example, may also present as malar &ldquo;flushing&rdquo; erythema, and patients may complain that the rash is photo-exacerbated (",
"    <a class=\"graphic graphic_picture graphicRef77020 \" href=\"mobipreview.htm?36/49/37649\">",
"     picture 2",
"    </a>",
"    ). A skin biopsy may be needed to distinguish between the two lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/8\">",
"     8",
"    </a>",
"    ]. Other facial dermatitides that may resemble this facial erythema include seborrheic dermatitis, atopic dermatitis, contact dermatitis, perioral dermatitis, tinea faciei, erysipelas, flushing (idiopathic or associated with carcinoid or mastocytosis), and dermatomyositis. Biopsy will aid in distinguishing most of these except for dermatomyositis. In dermatomyositis, the rash tends to involve the nasolabial folds whereas, in LE, this area is spared.",
"   </p>",
"   <p>",
"    Histologically, acute cutaneous LE (ACLE) may be initially quite subtle but may show damage to individual keratinocytes, basal layer vacuolation, follicular plugging, a perivascular and periappendageal infiltrate, and dermal mucin deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/9\">",
"     9",
"    </a>",
"    ]. Immunofluorescence may detect immunoglobulins and complement at the dermal-epidermal junction. This finding, which is said to be relatively pathognomonic of SLE, is present in 50 to 100 percent of lesional skin and may also be found in 73 to 90 percent of nonlesional, sun-exposed skin and in 26 to 92 percent of uninvolved, non-sun-exposed skin in patients with active SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/10\">",
"     10",
"    </a>",
"    ]. In one study, for example, a negative test had a 98 percent predictive value for diseases other than SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the specificity of this test is less when skin that has been exposed to UV light is biopsied, as illustrated by one study in which 20 percent of healthy young adults had a positive test when performed on sun-exposed skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/12\">",
"     12",
"    </a>",
"    ]. The cause of the high rate of false positive tests may have been the use of Michel&rsquo;s transport medium. However, because this transport medium is used in most clinical practices, direct immunofluorescence microscopy on non-sun-exposed skin (lupus band test) has limited utility as a diagnostic test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10330927\">",
"    <span class=\"h2\">",
"     Disseminated (generalized) ACLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated (generalized) ACLE presents as an erythematous maculo-urticarial to papular eruption involving primarily unexposed skin. Sometimes the inflammatory infiltrate can be severe enough to produce vesiculobullous skin lesions. Nonspecific LE skin changes, such as subungual erythema with cuticle changes, can be seen. Ulcers, pitting scars, and microinfarcts can be seen in the fingers and toes. Cheilitis, periorbital edema, diffuse telogen effluvium, and stubby hair (lupus hair) have also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Discoid lupus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic discoid lesions develop in up to 25 percent of patients with SLE but may also occur in the absence of any other clinical feature of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with only discoid lupus erythematosus (DLE) generally have a negative or low-titer antinuclear antibody (ANA) and rarely have anti-Ro antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with DLE have approximately a 5 to 10 percent risk of eventually developing SLE, which tends to be mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with more numerous and widespread lesions appear to be more likely to develop SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discoid lesions are characterized by discrete, erythematous, slightly infiltrated plaques covered by a well-formed adherent scale that extends into dilated hair follicles (follicular plugging). Lesions of DLE are most often present on the face, neck, and scalp but also occur on the ears and, infrequently, on the upper torso (",
"    <a class=\"graphic graphic_picture graphicRef75833 graphicRef64844 graphicRef53535 \" href=\"mobipreview.htm?35/19/36154\">",
"     picture 3A-C",
"    </a>",
"    ). They tend to slowly expand with active inflammation at the periphery and then to heal, leaving depressed central scars, atrophy, telangiectasias, and hyperpigmentation or hypopigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some chronic lesions of LE can become hyperkeratotic and may be confused with hypertrophic lichen planus, eczema, actinic keratosis, keratoacanthoma, squamous cell cancer, and prurigo nodularis. Some early lesions may be scaly and may be confused with psoriasis; such diagnostic confusion is more likely with the psoriasiform variant of subacute cutaneous lupus erythematosus. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Subacute cutaneous lupus erythematosus'",
"    </a>",
"    below.) This has therapeutic implications, since the psoriasis is treated with UV light, which should be avoided in patients with LE. Conversely, antimalarial drugs, which are effective in LE, may aggravate psoriasis and are generally avoided. Skin biopsy is helpful in distinguishing LE from psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Differential diagnosis of DLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous differential diagnosis of discoid lupus erythematosus includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tinea faciei",
"     </li>",
"     <li>",
"      Granuloma faciale (",
"      <a class=\"graphic graphic_picture graphicRef50769 \" href=\"mobipreview.htm?30/20/31046\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Lupus vulgaris (cutaneous tuberculosis)",
"     </li>",
"     <li>",
"      Lymphoproliferative disorders of skin (benign or malignant)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pathological examination of discoid skin lesions reveals hyperkeratosis, follicular plugging, basal layer vacuolar changes, and mononuclear cell infiltration (predominantly T cells) about the dermal-epidermal junction, dermal blood vessels, and appendages (",
"    <a class=\"graphic graphic_picture graphicRef81453 \" href=\"mobipreview.htm?18/54/19298\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/1\">",
"     1",
"    </a>",
"    ]. The basement membrane is usually thickened, a change that is best appreciated with a periodic acid-Schiff (PAS) stain, and there is dermal mucinosis. As noted above, although immunofluorescence microscopy may be positive in cutaneous LE, its use is limited by false positive results on sun-exposed skin and by negative results in long-standing chronic LE lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28543353\">",
"    <span class=\"h3\">",
"     Treatment of DLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of DLE is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/19/314?source=see_link\">",
"     \"Initial management of discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=see_link\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neonatal lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal lupus erythematosus (NLE) is a rare syndrome that is associated with maternal antibodies to",
"    <span class=\"nowrap\">",
"     Ro/SSA,",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     La/SSB,",
"    </span>",
"    and, much less frequently, to U1RNP. Infants develop eruptions characterized by erythematous arcuate macules, patches or plaques with raised active margins shortly after birth (",
"    <a class=\"graphic graphic_picture graphicRef51166 \" href=\"mobipreview.htm?17/34/17956\">",
"     picture 6",
"    </a>",
"    ). These skin lesions also seem to be photo-exacerbated. The lesions typically resolve without scarring. However, dyspigmentation may persist, and telangiectasia may occur. Some infants may also develop other transient complications including hemolytic anemia, thrombocytopenia, leucopenia, and hepatosplenomegaly. Congenital heart block (CHB) is another feature of NLE and may occur in conjunction with or in the absence of cutaneous NLE. CHB is permanent and may lead to congestive heart failure, to the need for pacemaker placement, and even to sudden death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the half-life of IgG antibodies is approximately 21 to 25 days, the rash is self-limiting and almost always resolves by six to eight months of age. Very few infants with neonatal lupus develop SLE later in life. About half of the mothers of affected infants have LE or another connective tissue at the time of delivery, but 80 percent will later develop SLE or another connective tissue disease. There is roughly a 25 percent risk for a subsequent pregnancy to be affected by NLE, and it may take the form of cutaneous lesions or heart lesions. Therefore, subsequent pregnancies should be considered high risk and should be monitored closely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Subacute cutaneous lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute cutaneous lupus erythematosus (SCLE) is a distinct entity and is frequently, but not uniformly, associated with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Approximately 50 percent of affected patients have SLE, and about 10 percent of patients with SLE have this type of skin lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/19\">",
"     19",
"    </a>",
"    ]. Cytopenia, serositis, and the presence of antinuclear antibodies are significantly less frequent among those with SCLE than among those with SLE, while photosensitivity is nearly twice as prevalent in those with SCLE than in those with SLE (86 versus 46 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/20\">",
"     20",
"    </a>",
"    ]. The prevalences of renal disease in those with SCLE and SLE were not significantly different, although the study included only 24 patients with SLE.",
"   </p>",
"   <p>",
"    In some patients with",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    antibodies, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , other antihypertensive medications, interferons, statins, sulfonylureas,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , calcium channel blockers, nonsteroidal antiinflammatory drugs (NSAIDs),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    , antihistamines, or the antifungal agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    may be responsible for initiating or exacerbating the skin disease (",
"    <a class=\"graphic graphic_table graphicRef86183 \" href=\"mobipreview.htm?22/22/22893\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Improvement in the rash and a decrease in the",
"    <span class=\"nowrap\">",
"     anti-Ro/SS-A",
"    </span>",
"    antibodies occurred within eight months following drug withdrawal in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/21\">",
"     21",
"    </a>",
"    ]. Skin lesions characteristic of SCLE have been associated with the use of antineoplastic drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ; in four cases, all had a photodistributed rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/24\">",
"     24",
"    </a>",
"    ] and adriamycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H14#H14\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Photosensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCLE skin lesions are seen in ANA-negative SLE lupus-like syndromes associated with homozygous deficiencies of the second or fourth components of complement and in patients with lupus erythematosus or Sj&ouml;gren&rsquo;s overlap syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCLE lesions begin as small, erythematous, slightly scaly papules that evolve into either a psoriasiform (papulosquamous) or annular form (",
"    <a class=\"graphic graphic_picture graphicRef55903 graphicRef66580 \" href=\"mobipreview.htm?39/32/40455\">",
"     picture 7A-B",
"    </a>",
"    ). The latter often coalesce to form polycyclic or figurative patterns. The lesions typically have erythematous and, sometimes, crusted margins. On the other hand, follicular plugging, hyperkeratosis, dermal atrophy, permanent pigmentary changes, and scarring usually do not occur, although telangiectasia may be seen. The most frequently affected areas in SCLE are the shoulders, forearms, neck, and upper torso. The face is usually spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike in discoid LE, the histopathology shows less follicular plugging and hyperkeratosis, and the perivascular and appendageal infiltrate is superficial. There are vacuolization of the basement membrane and mucin deposition in the dermis. Basement membrane thickening is generally absent or minimal (",
"    <a class=\"graphic graphic_picture graphicRef51438 graphicRef65220 \" href=\"mobipreview.htm?2/47/2810\">",
"     picture 8A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. There is a strong association with HLA-DR3, antibodies to",
"    <span class=\"nowrap\">",
"     Ro/SSA,",
"    </span>",
"    and polymorphisms in the tumor necrosis factor-alpha promoter gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Differential diagnosis of SCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of SCLE includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psoriasis vulgaris",
"     </li>",
"     <li>",
"      Tinea corporis",
"     </li>",
"     <li>",
"      Mycosis fungoides",
"     </li>",
"     <li>",
"      Gyrate erythemas (erythema multiforme, erythema annulare centrifugum, erythema gyratum repens)",
"     </li>",
"     <li>",
"      Seborrheic dermatitis",
"     </li>",
"     <li>",
"      Nummular eczema",
"     </li>",
"     <li>",
"      Pityriasis rubra pilaris",
"     </li>",
"     <li>",
"      Dermatomyositis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28543309\">",
"    <span class=\"h3\">",
"     Treatment of SCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of SCLE is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/19/314?source=see_link\">",
"     \"Initial management of discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=see_link\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other cutaneous lesions can be seen in patients with SLE, including bullous skin lesions; lesions which are characterized by dense dermal mucin deposition with absent epidermal changes, including lupus tumidus, lupus mucinosis, and reticular erythematosus mucinosis syndrome, and for which antimalarials are usually therapeutically effective; an overlap of lichen planus and lupus; lupus profundus (lupus panniculitis); and nail lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bullous skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subepidermal bullous lesions may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/28\">",
"     28",
"    </a>",
"    ]. These result from toxic necrolysis of the skin, mediated by deposition of immunoreactants at the basement membrane or by an underlying dermal vasculitis as described above (",
"    <a class=\"graphic graphic_picture graphicRef66048 \" href=\"mobipreview.htm?9/18/9504\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86216 \" href=\"mobipreview.htm?21/21/21845\">",
"     picture 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86217 \" href=\"mobipreview.htm?18/57/19351\">",
"     picture 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxic epidermal necrolysis (TEN)-like acute cutaneous lupus erythematosus is one of the diseases that have been described as an acute syndrome of apoptotic pan-epidermolysis (ASAP), which is characterized by massive cleavage of epidermis secondary to epidermal basal cell apoptotic injury. In addition to lupus erythematosus, so-called TEN-like skin eruptions may also be seen in association with various drugs, acute graft-versus-host disease, and pseudoporphyria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, SLE is rarely associated with bullous pemphigoid, dermatitis herpetiformis, or epidermolysis bullosa acquisita. These diseases can usually be differentiated from lupus by their characteristic pathologic changes (including immune deposits) at the basement membrane and circulating serum antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/33\">",
"     33",
"    </a>",
"    ]. Bullous pemphigoid is characterized by linear deposits of IgG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C3 at the epidermal basement membrane. In comparison, dermatitis herpetiformis is characterized by granular deposits of IgA at the epidermal basement membrane. However, both bullous LE and epidermolysis bullosa acquisita are characterized by continuous linear deposits of IgG within the dermal side of the epidermal basement membrane; both disorders are associated with the presence of antibodies to type VII collagen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/47/4858?source=see_link\">",
"     \"Epidermolysis bullosa acquisita\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bullous eruption of SLE is not limited to sun-exposed surfaces. Clinically, small vesicles alone or in groups may occur on erythematous or normal skin. They may heal with hyperpigmentation, milia, and scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lupus erythematosus tumidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lupus erythematosus tumidus (LE tumidus) is characterized by photo-distributed lesions consisting of chronic pink to violaceous urticarial nonscarring plaques",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nodules, some of which are ring-shaped (annular) (",
"    <a class=\"graphic graphic_picture graphicRef69725 graphicRef71792 \" href=\"mobipreview.htm?25/63/26613\">",
"     picture 12A-B",
"    </a>",
"    ). There is an absence of surface changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologically, there is moderate to dense, superficial and deep, perivascular, lymphocytic infiltrate consisting of predominately",
"    <span class=\"nowrap\">",
"     CD3+/CD4+",
"    </span>",
"    lymphocytes; in addition, there are focal to absent dermoepidermal junctional involvement and mucin deposition in the papillary and reticular dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/37\">",
"     37",
"    </a>",
"    ]. In a series of 40 cases, only 10 percent of affected patients were ANA positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/36\">",
"     36",
"    </a>",
"    ]. The differential diagnosis is benign lymphocytic infiltration of skin (Jessner&rsquo;s disease), polymorphous light eruption, pseudolymphoma B-cell lymphoma, plaque mucinosis, and solar urticaria. LE tumidus usually responds to antimalarials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10330994\">",
"    <span class=\"h3\">",
"     Cutaneous and reticular erythematosus mucinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous mucinosis presents as papules and plaques which favor the &ldquo;V&rdquo; of chest and upper arms. The lesions can antedate onset of LE. It is usually associated with discoid, subacute, and, most frequently, systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    Reticular erythematosus mucinosis is associated with the spectrum of photosensitive cutaneous lupus erythematosus. It is a persistent photo-aggravated papular plaque eruption, which involves the midline of chest and back. The papules present in a net-like (reticular) arrangement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Lichen planus-LE overlap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen planus-lupus erythematosus overlap syndrome is a rare skin disorder that has clinical, histopathologic, and immunofluorescent findings of both lupus erythematosus and lichen planus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The cutaneous lesions consist of atrophic livid red to violaceous plaques and patches. They are persistent and resistant to treatment. They are most often present on the acral portions of the extremities. The nails are commonly involved, and there may be anonychia (absence of the nail). Photosensitivity, pruritus, and follicular plugging (characteristics of discoid lupus) are generally absent. Some patients with this overlap develop SLE.",
"   </p>",
"   <p>",
"    Immunofluorescence microscopy in lichen planus-lupus erythematosus overlap syndrome reveals staining of the basement membrane with IgG, IgM, and C3. Linear granular deposits of IgM and C3 are also seen, as in lupus erythematosus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lupus profundus (lupus erythematosus panniculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lupus profundus represents a firm nodular lesion with or without an overlying cutaneous lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/41\">",
"     41",
"    </a>",
"    ]. The nodules, which are often painful, consist of perivascular infiltrates of mononuclear cells plus panniculitis, manifested as hyaline fat necrosis with mononuclear cell infiltration and lymphocytic vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef80683 graphicRef59536 \" href=\"mobipreview.htm?18/55/19319\">",
"     picture 13A-B",
"    </a>",
"    ). These nodules may appear on the scalp, face, arms, chest, back, thighs, and buttocks. They usually resolve but may leave a depressed area (",
"    <a class=\"graphic graphic_picture graphicRef83791 \" href=\"mobipreview.htm?1/15/1264\">",
"     picture 14",
"    </a>",
"    ). Ulcerations are uncommon. The presence of immune deposits in the dermal-epidermal junction in this setting is suggestive of lupus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/9\">",
"     9",
"    </a>",
"    ]. Coexistent DLE occurs in at least a third of the patients with lupus profundus, and SLE is present in 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This lesion has to be differentiated clinically and histologically from subcutaneous panniculitis-like T cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nail lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail lesions, particularly pitting, ridging, and onycholysis, have been noted in 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/45\">",
"     45",
"    </a>",
"    ]. Approximately 20 percent of patients have redness of the half-moon (lunula), a finding nearly always associated with periungual erythema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Photosensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photosensitivity refers to the development of a rash after exposure to UVB radiation found in sunlight or fluorescent lights [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/46\">",
"     46",
"    </a>",
"    ]. It occurs in 60 to 100 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Some patients are also sensitive to UVA, typically from sun exposure. UVA may also be emitted in small amounts from other sources (such as from a photocopier) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/49\">",
"     49",
"    </a>",
"    ] and may even be sensitive to the visible light spectrum. Glass protects individuals sensitive to UVB but only partially protects those sensitive to UVA. Blonde, blue-eyed, fair-skinned individuals are much more photosensitive than brunettes or individuals with pigmented skin; the incidence is also greater in those with anti-Ro antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all photosensitive patients have LE, nor are the two disorders causally linked in every patient with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/51\">",
"     51",
"    </a>",
"    ]. Some other diseases and causes to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic disorders with photosensitivity including polymorphous light eruption, reticular erythematous mucinosis (REM), light-induced prurigo, actinic dermatitis, and urticaria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/52\">",
"       52",
"      </a>",
"      ]. Polymorphous light eruption is the most common and has been estimated to account for approximately 90 percent of cases of photosensitive rash in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/53\">",
"       53",
"      </a>",
"      ]. The prevalence of polymorphous light eruption in otherwise healthy people has been reported to range from 5 to 21 percent.",
"     </li>",
"     <li>",
"      Approximately 50 percent of patients with dermatomyositis experience photosensitivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Drugs that cause photosensitization (",
"      <a class=\"graphic graphic_table graphicRef62152 \" href=\"mobipreview.htm?34/3/34878\">",
"       table 5",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      The pathophysiology of chemical- or drug-induced phototoxicity and photoallergy differ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/55\">",
"       55",
"      </a>",
"      ]. Phototoxic dermatitis results from direct cellular damage following UV radiation induced by activation of a light-sensitizing agent and depends upon an adequate amount of the chemical and radiation exposure in a susceptible individual. This contrasts with photoallergic dermatitis, which is a delayed type of hypersensitivity reaction and which consists of an initial sensitization phase followed by an incubation period and by the appearance of the dermatitis on a subsequent challenge.",
"     </li>",
"     <li>",
"      Foods that can cause phytophotodermatitis or phytophotoallergic dermatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      Phytophotodermatitis, which is characterized by streaky phototoxic erythema, occurs after exposure to plants such as yarrow, parsley, celery, parsnips, milfoil, lime, lemon, and fig followed by exposure to sunlight. When the resultant erythematous dermatitis subsides, a prolonged secondary hyperpigmentation usually occurs.",
"     </li>",
"     <li>",
"      Porphyria cutanea tarda, which typically causes blistering or superficial skin erosion on the sun-exposed dorsal surface of the hands (",
"      <a class=\"graphic graphic_picture graphicRef74528 \" href=\"mobipreview.htm?13/30/13794\">",
"       picture 15",
"      </a>",
"      ). It can be diagnosed by measurement of porphyrins in plasma, urine, and feces. Chronic cutaneous, subacute, and systemic lupus erythematosus have been described in patients with porphyria cutanea tarda. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=see_link&amp;anchor=H4527395#H4527395\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Susceptibility factors'",
"      </a>",
"      .) Pseudoporphyria refers to similarly appearing bullous lesions due to light exposure that occur in patients with normal plasma concentrations of porphyrins. This disorder is often due to medications. Those most relevant to rheumatology practice include the NSAIDs (particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/18/39208?source=see_link\">",
"       nabumetone",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , and tetracyclines. It can also occur in patients suffering from chronic renal insufficiency or in those undergoing hemolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photosensitivity due to SLE may vary in degree during a patient&rsquo;s illness. Acute, subacute, and discoid lupus lesions as well as some bullous and urticarial lesions are photosensitive. In addition to the rash, patients may also complain of vague feelings of being unwell while in the sun (although it is not clear if this represents photosensitivity).",
"   </p>",
"   <p>",
"    The severity of cutaneous reaction depends upon the intensity of the UV source and upon the duration of exposure. The mechanism whereby UV radiation causes skin lesions is not clear; UV radiation has a number of effects that may be involved in producing inflammation, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Damage to DNA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteins in the skin, which leads to antibody formation to these altered molecules. The subsequent antigen-antibody reaction causes a local inflammatory reaction.",
"     </li>",
"     <li>",
"      Enhanced binding of autoantibodies to UV irradiated keratinocytes from patients with LE as compared with normals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/58\">",
"       58",
"      </a>",
"      ]. This may be due, in part, to increased expression of",
"      <span class=\"nowrap\">",
"       Ro/SSA",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       La/SSB",
"      </span>",
"      autoantigens on the surface of keratinocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/59-61\">",
"       59-61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      UV light induced increased apoptosis in patients with lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/62\">",
"       62",
"      </a>",
"      ]. Because patients with LE have decreased ability to clear apoptotic cells, these cells may accumulate in UV exposed areas, contributing to inflammation.",
"     </li>",
"     <li>",
"      Alterations in cellular membrane phospholipid metabolism.",
"     </li>",
"     <li>",
"      Increased production and release of cytokines, such as interferon alpha, from cutaneous keratinocyte and Langerhans cells, especially after exposure to UV-B irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stimulation of the evolution of increased numbers of suppressor T cells.",
"     </li>",
"     <li>",
"      Increased local accumulation of reactive oxygen species [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the local effects in skin, UV radiation may also increase the degree of autoimmunity. UV radiation decreases T cell DNA methylation, which may lead to overexpression of lymphocyte function-associated antigen-1 (LFA-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/65\">",
"     65",
"    </a>",
"    ]. These T cells may then become autoreactive, resulting in autoantibody formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OF CUTANEOUS LUPUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment in the different forms of cutaneous lupus is to prevent long-term skin sequelae, such as telangiectasia, hyperpigmentation or hypopigmentation, alopecia, and scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/5\">",
"     5",
"    </a>",
"    ]. An overview of the treatment of cutaneous lupus is presented below. A more detailed discussion of the treatment of discoid lupus and subacute cutaneous lupus is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/19/314?source=see_link\">",
"     \"Initial management of discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=see_link\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures will prevent skin lesions in most patients. Those who are photosensitive should be taught to avoid high sun exposure (beaches, snow, lakes), especially between 10 AM and 3 PM, and, if possible, to avoid medications that may cause photosensitivity (",
"    <a class=\"graphic graphic_table graphicRef62152 \" href=\"mobipreview.htm?34/3/34878\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ordinary glass protects against UVB, but not UVA, so tinted glass may be useful in those very sensitive to UVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/67\">",
"     67",
"    </a>",
"    ]. Significant amounts of UVA are emitted from both incandescent and halogen lamps, and a considerable amount of UVB is emitted by unshielded fluorescent bulbs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, patients with great sensitivity to UVA and UVB need to take precautions against UV exposure indoors as well as outdoors.",
"   </p>",
"   <p>",
"    Photosensitive patients should use sunscreens daily, whether it is cloudy or rainy. The sunscreen should be applied 30 to 60 minutes prior to exposure and should be reapplied every four to six hours. Sunscreens of at least SPF 30 should be used; higher SPFs are available for more sensitive patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guides to clothing with SPF of 30 or greater are available at some internet sites, including sunprecautions.com, sunproof.com, and sungrubbies.com.",
"     </li>",
"     <li>",
"      Proper use of sunscreens and protective clothing may result in inadequate production of vitamin D. Testing for vitamin D deficiency and vitamin D supplementation in those with limited sun exposure are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of vitamin D deficiency in adults\", section on 'Optimal intake'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monitoring blood vitamin D levels can serve as a proxy for diligent sunscreen use. Those who are diligent have low vitamin D blood levels if they have not received adequate vitamin D supplementation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lupus rash should initially be treated with topical glucocorticoids. For early superficial involvement,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    may suffice, but more potent topical corticosteroids (particularly the fluorinated preparations) with or without occlusion or intralesional corticosteroids should be used for thicker lesions. There are several points that deserve emphasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluorinated topical corticosteroids may be used for facial lesions but should be used very cautiously and probably for no more than two weeks.",
"     </li>",
"     <li>",
"      Ointments are more effective than creams.",
"     </li>",
"     <li>",
"      Lotions, gels, and solutions are preferred for scalp lesions, though ointments may be used.",
"     </li>",
"     <li>",
"      Chronic use of topical corticosteroids may lead to skin atrophy, thinning, telangiectasia, hypertrichosis, striae, and depigmentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other topical agents are being investigated. Limited data suggest that the immunomodulatory agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ointment, may have some benefit for facial skin lesions due to lupus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/70\">",
"     70",
"    </a>",
"    ] including those resistant to other therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/71\">",
"     71",
"    </a>",
"    ]. Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    cream, another topical immunosuppressant available for use of atopic dermatitis, was associated with regression of skin lesions in 11 patients with cutaneous lupus in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/72\">",
"     72",
"    </a>",
"    ] and in 10 patients in another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/73\">",
"     73",
"    </a>",
"    ]. However, caution is required in the use of these agents as they may be linked to an increased risk of skin cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have recommended topical retinoids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional studies will be necessary to determine the efficacy and safety of these agents for patients with SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22992289\">",
"    <span class=\"h3\">",
"     Investigational topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The R enantiomer of salbutamol, R-salbutamol, selectively binds to and activates &beta;2-adrenoreceptors on the surface of many cells and has a primarily inhibitory effect on CD4 cells and other leukocytes that is therapeutically effective in some patients with DLE when used topically as a 0.5 percent cream [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antimalarial drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent rashes should be treated with an antimalarial. One of these drugs should be used only when the diagnosis is secure with the following precautions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They have been associated with flares of psoriasis.",
"     </li>",
"     <li>",
"      Antimalarial drugs should not be given to the rare individual with G6PD deficiency.",
"     </li>",
"     <li>",
"      They may cause serious eye changes, including macular degeneration; recommendations for monitoring for ocular toxicity are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H17#H17\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Ocular health'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They have been associated with flares or precipitation of porphyria cutanea tarda, a disorder that may be confused",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      that may coexist with lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=see_link&amp;anchor=H4527460#H4527460\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Hydroxychloroquine or chloroquine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most popular antimalarial in SLE is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/76\">",
"     76",
"    </a>",
"    ]. It is dosed based upon weight (less than 6.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day to a maximum of 400",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    less than 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for patients weighing less than 61 kg) (",
"    <a class=\"graphic graphic_table graphicRef52656 \" href=\"mobipreview.htm?5/42/5804\">",
"     table 6",
"    </a>",
"    ). In one study, for example, overall improvement of erythema, infiltration, scaling, and hyperkeratosis occurred in 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/77\">",
"     77",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    (250 to 500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is somewhat more potent but has a higher risk of eye damage. It produces an antiinflammatory effect by binding to dermal keratinocytes and, thereby, presumably decreasing cellular infiltration after UV exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/78\">",
"     78",
"    </a>",
"    ]. Quinacrine (50 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is even more effective and has a much lower risk of eye damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. However, the skin turns somewhat yellow in most patients, and bone marrow depression is a rare complication. Improvement with antimalarials may not be seen until 6 to 12 weeks of use. The combination of quinacrine (50 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and hydroxychloroquine has also been effective in our (unpublished) and others&rsquo; experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H12#H12\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Ocular effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCLE and lupus panniculitis respond best to antimalarial drugs, but higher doses may be needed. Combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    and quinacrine was found to be effective among most patients with chronic cutaneous lupus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    SCLE resistant to antimalarial monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/82\">",
"     82",
"    </a>",
"    ]. Smokers appear to be less responsive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimalarial agents provide benefit via a number of mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/79\">",
"     79",
"    </a>",
"    ]. These include photoprotection, lysosomal stabilization, influence on apoptosis, immunosuppression, and inhibition of antigen presentation, prostaglandin synthesis, lipid peroxidation, and proinflammatory cytokine synthesis.",
"   </p>",
"   <p>",
"    Tobacco smoking is associated with decreased effectiveness of antimalarial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/84\">",
"     84",
"    </a>",
"    ]. For patients who smoke, this information, along with the premature aging effect of smoking, may provide additional incentives to stop.",
"   </p>",
"   <p>",
"    Long-term use of antimalarials may result in yellow skin (quinacrine) or hyperpigmentation (HCQ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids and immunosuppressive agents are rarely needed to clear skin lesions except for bullous lesions. Some dermatologists favor local injections of resistant lesions with glucocorticoids. Systemic glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    can be effective when local therapy is inadequate; other agents that have been used when local therapy fails include oral retinoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , anti-CD4 antibodies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/5,28,50,85-89\">",
"     5,28,50,85-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efalizumab, which had been used in the treatment of discoid lupus, has been voluntarily withdrawn from the United States, Canadian, European Union, and Australian markets by its manufacturer because of a potential risk to patients of developing progressive multifocal leukoencephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other systemic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other systemic agents and approaches to treatment have also been used. While some of these may have immunomodulatory activities, the mechanism of others are unknown (eg, gold compounds). Among the agents and systemic approaches in this class are the following:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , gold, retinoids, intravenous immune globulin, diphenylhydantoin, clofazimine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , interferon alpha,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , and extracorporeal photophoresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/28,77,86,88,89,92-96\">",
"     28,77,86,88,89,92-96",
"    </a>",
"    ]. Dapsone may be particularly useful for bullous disease of the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cosmetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythematous lesions can be disguised with the use of cosmetics such as Cover Mark&trade;, Dermablend&trade;, or a green foundation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Assessing response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An index of cutaneous lupus disease and severity (CLASI) has been proposed as an aid to assessing response of lesions in clinical trials of treatment of skin disease in SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ALOPECIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair loss occurs in a majority of patients with SLE at some time during their illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/98\">",
"     98",
"    </a>",
"    ]. In some cases, it can precede other manifestations of lupus. Lupus alopecia may involve the scalp, eyebrows, eyelashes, beard,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    body hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Scarring alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scarring alopecia of the scalp is a complication of cutaneous discoid LE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/100\">",
"     100",
"    </a>",
"    ]. Early lesions are characterized by well-circumscribed, erythematosus, infiltrative patches with adherent follicular hyperkeratosis. Later, the lesion progresses toward an atrophic, smooth, depressed, white-ivory colored plaque. Histopathology demonstrates follicular hyperkeratosis, epidermal atrophy, basal vacuolar degeneration, thickened basement membrane, and immune deposits of IgM, C3, and IgG in many patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nonscarring alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonscarring alopecia has two major causes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature hair loss (telogen effluvium), characterized by a diffuse thinning of the scalp three months after a stressful event, emotional upset, pregnancy, or the use of glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/99\">",
"       99",
"      </a>",
"      ]. In this condition, the scalp hair has presumably been put into a resting (telogen) phase, and normal hair usually grows back when the initial insult resolves.",
"     </li>",
"     <li>",
"      &ldquo;Lupus hair,&rdquo; which is generally seen during exacerbations of SLE. It is characterized by thin, unruly hair that easily fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/101\">",
"       101",
"      </a>",
"      ]. It usually occurs along the frontal hairline and grows back normally when the disease activity subsides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hair loss in active SLE usually responds well to treatment of the lupus. Because of the scarring, the hair loss is usually permanent in discoid lesions of the scalp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Scarring alopecia'",
"    </a>",
"    above.) Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    may be beneficial in a limited number of patients with acute, nonscarring alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MUCOUS MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucous membrane involvement occurs in 12 to 45 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. Several different manifestations can be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characteristic discoid lesions with erythema, atrophy, and depigmentation can occur on the lips.",
"     </li>",
"     <li>",
"      Irregularly shaped raised white plaques, silvery white scarred lesions, areas of erythema, and punched out erosions or ulcers with surrounding erythema may appear on the soft or hard palate or buccal mucosa (",
"      <a class=\"graphic graphic_picture graphicRef63605 \" href=\"mobipreview.htm?24/32/25103\">",
"       picture 16",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gingivitis may occur, particularly in individuals with xerostomia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The oral ulcers are usually painless. There is no apparent association between the presence of such ulcers and systemic activity. Oral lesions may be the first sign of lupus.",
"   </p>",
"   <p>",
"    The oral lesions of lupus demonstrate the typical histopathology of skin lesions, including hyperkeratosis, atrophy of rete processes, and superficial and deep inflammatory infiltrates; edema in the lamina propria, PAS-positive deposits in the basement membrane zone, deposition of intercellular mucin, and deposits of immunoglobulin and complement at the dermal-epidermal junction are also seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. These lesions should be distinguished clinically from those of lichen planus, candidiasis, aphthous stomatitis, intraoral herpes, Beh&ccedil;et&rsquo;s disease, bite marks, leukoplakia, and malignancy.",
"   </p>",
"   <p>",
"    Nasal ulcers have been noted in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/107\">",
"     107",
"    </a>",
"    ]. They are usually in the lower nasal septum and tend to be bilateral. The appearance of nasal ulcers tends to parallel other features of active SLE. Nasal perforation, possibly secondary to vasculitis, is infrequent, occurring in 4.6 percent of 885 patients with SLE who were prospectively followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/108\">",
"     108",
"    </a>",
"    ]. Involvement of the mucosa of the upper airway may also occur and may cause hoarseness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucous membrane lesions respond well to topical glucocorticoids, 0.1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ointment, intralesional glucocorticoids, and systemic antimalarial drugs. The response to topical corticosteroids (usually Orabase mixed with either 0.1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    or 0.05 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    ) takes a few days to weeks, while the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    takes weeks to months.",
"   </p>",
"   <p>",
"    If the oral lesions are refractory to the above therapy and are creating significant symptomatic problems, more aggressive therapy such as immunosuppressive or other systemic therapies as used for cutaneous lesions may be tried.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     VASCULAR LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions from vascular involvement in lupus include periungual erythema, livedo reticularis, telangiectasia, Raynaud phenomenon, and various forms of vasculitis; they occur in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Periungual erythema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periungual erythema is due to dilated tortuous loops of capillaries and a prominent subcapillary venous plexus along the base of the nail. Similar lesions have been noted along the edges of the upper eyelid. A strong association has been reported between nailfold capillary changes and anticardiolipin antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Livedo reticularis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Livedo reticularis refers to a reddish-cyanotic, reticular pattern of the skin seen on the arms, legs, and torso, particularly in cold environments (",
"    <a class=\"graphic graphic_picture graphicRef79545 \" href=\"mobipreview.htm?13/33/13841\">",
"     picture 17",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61842 \" href=\"mobipreview.htm?34/30/35311\">",
"     picture 18",
"    </a>",
"    ). In lupus, it is induced by vasospasm of the dermal ascending arterioles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/99\">",
"     99",
"    </a>",
"    ]. Vasospasm in these cutaneous vessels results in decreased blood supply to the superficial horizontal vascular plexus, with a secondary increase in circulation to the remaining patent vessels. Pathologic examination of involved blood vessels reveals thickening of the walls of the dermal vessels with subsequent narrowing of the lumens and, in some cases, intravascular thrombi. The most informative pathogenic biopsy site is a purpuric nonulcerative macular or papular lesion in the erythematous reticular cutaneous background.",
"   </p>",
"   <p>",
"    These lesions can progress to vascular occlusion, leading to ischemia and to tissue infarction. This is manifested clinically by purpuric macules, cutaneous nodules,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    painful ulcerations; this constellation is often called livedoid vasculopathy or atrophie blanche. It usually occurs on the lower legs, about the ankles,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    on the dorsum of the feet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/61/6103?source=see_link\">",
"     \"Livedoid vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Livedo reticularis may be associated with antiphospholipid antibodies and with cerebrovascular disease (Sneddon&rsquo;s syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. A related skin disorder, &ldquo;livedo racemosa,&rdquo; has also been associated with antiphospholipid antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias are common in patients with lupus, typically appearing on the face. They consist of discrete, dilated blood vessels and do",
"    <strong>",
"     not",
"    </strong>",
"    represent active, inflammatory lupus. The blood vessels appear more prominent whenever there is increased blood supply to the area as with blushing, heat, or a vasodilator such as alcohol. Histopathologic examination reveals dilated blood vessels without inflammation.",
"   </p>",
"   <p>",
"    Telangiectasias are not specific for lupus. They can be seen in association with solar damage, aging, hypertension, alcoholism, local pressure (such as eyeglasses), diabetes, rosacea, amyloid, other rheumatic diseases (especially systemic sclerosis and dermatomyositis), and familial hereditary telangiectasia.",
"   </p>",
"   <p>",
"    Telangiectasias require no specific therapy, other than makeup for the concerned individual. A green foundation (to neutralize the red) followed by the makeup color of choice usually suffices. Cutaneous lasers, such as the tunable dye, are very effective in removing telangiectasias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raynaud phenomenon (RP) in SLE is a vasospastic process that occurs in approximately 15 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/114\">",
"     114",
"    </a>",
"    ]. It is characterized by blanching of the nail beds, fingers, and toes (and occasionally ears, nose, and tongue), with accompanying pain.",
"   </p>",
"   <p>",
"    The vasospasm usually reverses spontaneously with return of normal skin color. In some cases, however, the ischemia progresses, leading to a bluish mottled cyanosis. When ischemia persists, local anoxia develops with the local accumulation of carbon dioxide. The hypercarbia induces reactive hyperemia and vasodilation, producing pain and erythema. There may also be loss of digital pulp, as well as ulceration and scarring. A rare outcome of persistent vasoconstriction is gangrene (",
"    <a class=\"graphic graphic_picture graphicRef67307 graphicRef82451 \" href=\"mobipreview.htm?12/32/12803\">",
"     picture 19A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The RP can often be prevented by educating the patient about trigger factors such as avoiding of smoking, caffeine, vasopressors, and vasoconstrictors and, for cold-induced RP, wearing warm clothing (such as thermal underwear, mittens, and hats). More severe or resistant disease can be treated with vasodilators such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    , topical nitroglycerine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    . Intravascular treatment with prostacyclin may be required in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/115\">",
"     115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Urticarial or purpuric vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis develops in approximately 11 to 20 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/99,110,116\">",
"     99,110,116",
"    </a>",
"    ]. The most common form, occurring in 10 to 15 percent of cases, is urticarial vasculitis. Urticaria is usually a manifestation of an IgE-mediated allergic reaction, typically lasting four to six hours and resolving without residue. In urticarial vasculitis, however, the lesions may persist for more than 24 hours and frequently evolve into painful petechiae or purpura that may heal with hyperpigmentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/60/32714?source=see_link\">",
"     \"Urticarial vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urticaria or purpura in lupus vasculitis reflects fibrinoid necrosis of postcapillary venules due to immune complex deposition. The lesions are infiltrated with either neutrophils or mononuclear cells. Neutrophilic infiltration is often accompanied by circulating cryoglobulins, elevated serum levels of immune complexes, and low levels of CH50, C1q, and C4, but it is often accompanied by normal levels of C3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/114\">",
"     114",
"    </a>",
"    ]. The complexes are typically cleared within one to two days.",
"   </p>",
"   <p>",
"    Purpuric lupus vasculitis may also be associated with hypergammaglobulinemia. As an example, among 12 patients with purpuric lupus vasculitis, all had polyclonal hypergammaglobulinemia and antibodies to",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/117\">",
"     117",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    resulted in complete or partial remissions in eight patients with mild lesions;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at doses of 25 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was recommended for more severe disease.",
"   </p>",
"   <p>",
"    Vasculitis may also affect small arteries, possibly resulting in small microinfarcts of the tips of the fingers, the toes, the cuticles of the nail folds (splinter hemorrhages), and the extensor surface of the forearm and shin (",
"    <a class=\"graphic graphic_picture graphicRef67922 \" href=\"mobipreview.htm?10/49/11024\">",
"     picture 20",
"    </a>",
"    ). The palms of the hand, soles of the feet, and area around the ankle are less commonly involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/109\">",
"     109",
"    </a>",
"    ]. The ankle lesions may develop into painful punched out ulcers and may heal slowly. Periarteritis nodosa-like lesions may occur.",
"   </p>",
"   <p>",
"    These forms of vasculitis parallel lupus activity and are usually associated with circulating immune complexes, low levels of serum complement, and elevated levels of anti-DNA antibodies. Pathologic examination reveals fibrinoid necrosis and thrombosis but reveals only a sparse cellular infiltrate in contrast to the vasculitis noted above. This lesion may be mediated by antiphospholipid antibodies (a lupus anticoagulant, anticardiolipin antibodies, or others) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/118\">",
"     118",
"    </a>",
"    ], antibodies to endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/119\">",
"     119",
"    </a>",
"    ], and platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/120\">",
"     120",
"    </a>",
"    ]. Antineutrophil cytoplasmic antibodies also may be seen in some patients with SLE but do not correlate with disease activity or with the presence or severity of vasculitis, and they are rarely, if ever, directed against either the proteinase-3 or myeloperoxidase antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other manifestations of vasculitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Painful, tender, erythematous indurated lesions on the palms, especially on thenar eminences (&ldquo;Janeway lesions&rdquo;) and the tips of the fingers (&ldquo;Osler&rsquo;s nodes&rdquo;) are uncommon. Sepsis (eg, infective endocarditis) should always be excluded in this setting.",
"     </li>",
"     <li>",
"      Atrophie blanche lesions have been noted in SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/99\">",
"       99",
"      </a>",
"      ]. They are ivory white scars with telangiectasia and surrounding hyperpigmentation that represent small healed ulcerations from various forms of vasculitis (",
"      <a class=\"graphic graphic_picture graphicRef54537 \" href=\"mobipreview.htm?4/38/4719\">",
"       picture 21",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef68647 \" href=\"mobipreview.htm?17/36/17988\">",
"       picture 22",
"      </a>",
"      ). They begin as either erythematous papules or infiltrated plaques.",
"     </li>",
"     <li>",
"      Chilblains, or chilblain lupus erythematosus (CHLE), presents with tender, bright red to reddish-blue nodules on the toes, fingers, nose, or ears that occur in cold weather (",
"      <a class=\"graphic graphic_picture graphicRef56419 \" href=\"mobipreview.htm?41/7/42111\">",
"       picture 23",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/122\">",
"       122",
"      </a>",
"      ]. Those on cold acral areas may ulcerate. Approximately 25 percent of patients who present with this lesion meet classification criteria for SLE, and others (5 to 6 percent in one study) may fulfill criteria subsequently [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/123\">",
"       123",
"      </a>",
"      ]. The differential diagnosis of CHLE includes vasculitis. Patients with sarcoidosis may have lesions on the face, nose, or ears with a similar appearance; these are referred to as lupus pernio. Some patients with chilblains have no evidence of systemic rheumatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/33/36378/abstract/123\">",
"       123",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=see_link&amp;anchor=H18191808#H18191808\">",
"       \"Cutaneous manifestations of sarcoidosis\", section on 'Lupus pernio'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37671?source=see_link&amp;anchor=H2#H2\">",
"       \"Frostbite\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/5/16466?source=see_link\">",
"       \"Patient information: Discoid lupus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14812788\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucous membranes are involved at some point in over 80 percent of patients with systemic lupus erythematosus (SLE), and there is tremendous variability and diversity in the type of involvement (",
"    <a class=\"graphic graphic_table graphicRef77275 \" href=\"mobipreview.htm?34/23/35197\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75563 \" href=\"mobipreview.htm?19/53/20316\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71774 \" href=\"mobipreview.htm?14/48/15116\">",
"     table 3",
"    </a>",
"    ). Patients with localized discoid LE, hypertrophic LE, LE panniculitis, and lupus tumidus tend to have skin disease only; however, progression to systemic disease is possible. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <strong>",
"      </strong>",
"      acute cutaneous lupus erythematosus rash (the classical acute butterfly rash), characterized by erythema in a malar distribution over the cheeks and bridge of the nose (",
"      <a class=\"graphic graphic_picture graphicRef75781 graphicRef55875 \" href=\"mobipreview.htm?36/46/37608\">",
"       picture 1A-B",
"      </a>",
"      ), appears in approximately one-half of patients, usually after ultraviolet (UV) light exposure, and is frequently mistaken for a sunburn. The involved skin feels warm and appears slightly edematous, creating at times a &ldquo;peau d&rsquo;orange&rdquo; appearance. The rash may last for hours or days and often recurs, particularly with inadvertent sun exposure. The rash may precede other symptoms of lupus by months or even years or may be accompanied by other symptoms and signs of acute SLE. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute cutaneous lupus erythematosus (butterfly rash)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic discoid lesions of discoid lupus erythematosus (DLE) develop in up to 25 percent of patients with SLE but may also occur in the absence of any other clinical feature of SLE (",
"      <a class=\"graphic graphic_picture graphicRef75833 \" href=\"mobipreview.htm?8/11/8372\">",
"       picture 3A",
"      </a>",
"      ). Patients with DLE have an approximately 5 to 10 percent risk of eventually developing other clinical features of SLE, which tend to be mild. Discoid lesions are characterized by discrete, erythematous, slightly infiltrated plaques covered by a well-formed adherent scale that extends into dilated hair follicles (follicular plugging). Lesions of DLE are most often present on the face, neck, and scalp but also occur on the ears and, infrequently, on the upper torso. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Discoid lupus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal lupus erythematosus (NLE) is a rare syndrome that is usually associated with maternal antibodies to",
"      <span class=\"nowrap\">",
"       Ro/SSA,",
"      </span>",
"      <span class=\"nowrap\">",
"       La/SSB,",
"      </span>",
"      and, less frequently, U1RNP. Infants develop eruptions characterized by erythematous arcuate macules, patches or plaques with raised active margins shortly after birth (",
"      <a class=\"graphic graphic_picture graphicRef51166 \" href=\"mobipreview.htm?17/34/17956\">",
"       picture 6",
"      </a>",
"      ). These skin lesions also seem to be exacerbated by ultraviolet (UV) light exposure. The lesions typically resolve without scarring, and the rash is self-limiting, almost always resolving by six to eight months of age. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Neonatal lupus erythematosus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subacute cutaneous lupus erythematosus (SCLE) is a distinct entity. Approximately 50 percent of affected patients have other clinical features of SLE, and about 10 percent of patients with SLE have SCLE. In some patients with",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibodies, the use of certain medications may initiate or exacerbate the SCLE skin lesions. The SCLE lesions begin as small, erythematous, slightly scaly papules that evolve into either a psoriasiform (papulosquamous) or annular form (",
"      <a class=\"graphic graphic_picture graphicRef55903 graphicRef66580 \" href=\"mobipreview.htm?39/32/40455\">",
"       picture 7A-B",
"      </a>",
"      ). The latter often coalesces to form polycyclic or figurative patterns. The lesions typically have erythematous, and sometimes crusted, margins. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Subacute cutaneous lupus erythematosus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of other cutaneous lesions can be seen in patients with SLE, including bullous skin lesions, lupus erythematosus tumidus, a lichen planus-LE overlap, lupus profundus, and nail lesions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bullous skin lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Lupus erythematosus tumidus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Lichen planus-LE overlap'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Lupus profundus (lupus erythematosus panniculitis)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Nail lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photosensitivity refers to the development of a rash after exposure to UVB radiation found in sunlight or fluorescent lights. It occurs in 60 to 100 percent of patients with SLE. Some patients are also sensitive to UVA and may even be sensitive to the visible light spectrum. Not all photosensitive patients have LE, nor are the two disorders causally linked in every patient with SLE. Photosensitivity due to SLE may vary in degree during a patient&rsquo;s illness. Acute, subacute, tumid, and discoid lupus lesions, as well as some bullous and urticarial lesions, are photosensitive. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Photosensitivity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of treatment in the different forms of cutaneous lupus is to prevent long-term skin sequelae, such as telangiectasia, hyperpigmentation or hypopigmentation, alopecia, and scarring. Preventive measures will prevent skin lesions in most patients. Photosensitive patients should use sunscreens daily. A lupus rash should initially be treated with topical glucocorticoids. Patients with persistent rashes should be treated with an antimalarial. Tobacco smoking is associated with decreased effectiveness of antimalarial agents. Systemic glucocorticoids and immunosuppressive agents are infrequently needed to clear skin lesions except for bullous lesions. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of cutaneous lupus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Topical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Antimalarial drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Immunosuppressive agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Other systemic therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Cosmetic'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Assessing response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hair loss occurs in a majority of patients with SLE at some time during their illness. In some cases, it can precede other manifestations of lupus. Lupus alopecia may involve the scalp, eyebrows, eyelashes, beard,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      body hair. Both scarring and nonscarring alopecia may occur. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Alopecia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mucous membrane involvement occurs in 12 to 45 percent of patients with SLE. Several different manifestations can be seen, including oral ulcers, discoid lesions on the lips, gingivitis, and nasal ulcers. Various topical therapies are effective, but, if not, systemic treatments may be tried. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Mucous membranes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin lesions from vascular involvement in lupus include periungual erythema, livedo reticularis, telangiectasia, Raynaud phenomenon, and various forms of vasculitis; they occur in approximately 50 percent of patients. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Periungual erythema'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Livedo reticularis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Telangiectasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Raynaud phenomenon'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Urticarial or purpuric vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/1\">",
"      Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/2\">",
"      Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/3\">",
"      Pistiner M, Wallace DJ, Nessim S, et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991; 21:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/4\">",
"      Petri M. Dermatologic lupus: Hopkins Lupus Cohort. Semin Cutan Med Surg 1998; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/5\">",
"      Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol 2006; 47:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/6\">",
"      Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol 2007; 33:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/7\">",
"      Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 2009; 145:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/8\">",
"      Black AA, McCauliffe DP, Sontheimer RD. Prevalence of acne rosacea in a rheumatic skin disease subspecialty clinic. Lupus 1992; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/9\">",
"      Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/10\">",
"      Mutasim DF, Adams BB. Immunofluorescence in dermatology. J Am Acad Dermatol 2001; 45:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/11\">",
"      George R, Kurian S, Jacob M, Thomas K. Diagnostic evaluation of the lupus band test in discoid and systemic lupus erythematosus. Int J Dermatol 1995; 34:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/12\">",
"      Fabr&eacute; VC, Lear S, Reichlin M, et al. Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol 1991; 127:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/13\">",
"      Provost TT. The relationship between discoid and systemic lupus erythematosus. Arch Dermatol 1994; 130:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/14\">",
"      Healy E, Kieran E, Rogers S. Cutaneous lupus erythematosus--a study of clinical and laboratory prognostic factors in 65 patients. Ir J Med Sci 1995; 164:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/15\">",
"      Rowell NR. Laboratory abnormalities in the diagnosis and management of lupus erythematosus. Br J Dermatol 1971; 84:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/16\">",
"      Callen JP. Systemic lupus erythematosus in patients with chronic cutaneous (discoid) lupus erythematosus. Clinical and laboratory findings in seventeen patients. J Am Acad Dermatol 1985; 12:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/17\">",
"      Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/18\">",
"      Stavropoulos PG, Goules AV, Avgerinou G, Katsambas AD. Pathogenesis of subacute cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 2008; 22:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/19\">",
"      Wollina U, Barta U, Uhlemann C, Oelzner P. Lupus erythematosus-associated red lunula. J Am Acad Dermatol 1999; 41:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/20\">",
"      Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol 2002; 138:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/21\">",
"      Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/22\">",
"      Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol 2001; 137:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/23\">",
"      Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/24\">",
"      Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/25\">",
"      Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol 2010; 146:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/26\">",
"      Callen JP, Hodge SJ, Kulick KB, et al. Subacute cutaneous lupus erythematosus in multiple members of a family with C2 deficiency. Arch Dermatol 1987; 123:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/27\">",
"      Watanabe T, Tsuchida T, Ito Y, et al. Annular erythema associated with lupus erythematosus/Sj&ouml;gren's syndrome. J Am Acad Dermatol 1997; 36:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/28\">",
"      Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003; 4:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/29\">",
"      Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 2000; 115:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/30\">",
"      Bullous eruption in lupus erythematosus. Ann Intern Med 1983; 98:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/31\">",
"      Paradela S, Mart&iacute;nez-G&oacute;mez W, Fern&aacute;ndez-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus 2007; 16:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/32\">",
"      Ting W, Stone MS, Racila D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 2004; 13:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/33\">",
"      Tuffanelli DL. Cutaneous immunopathology: recent observations. J Invest Dermatol 1975; 65:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/34\">",
"      Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993; 100:28S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/35\">",
"      Gandhi K, Chen M, Aasi S, et al. Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype. J Clin Immunol 2000; 20:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/36\">",
"      Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/37\">",
"      Alexiades-Armenakas MR, Baldassano M, Bince B, et al. Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis. Arthritis Rheum 2003; 49:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/38\">",
"      Schmitt V, Meuth AM, Amler S, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 162:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/39\">",
"      Romero RW, Nesbitt LT Jr, Reed RJ. Unusual variant of lupus erythematosus or lichen planus. Clinical, histopathologic, and immunofluorescent studies. Arch Dermatol 1977; 113:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/40\">",
"      Ahmed AR, Schreiber P, Abramovits W, et al. Coexistence of lichen planus and systemic lupus erythematosus. J Am Acad Dermatol 1982; 7:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/41\">",
"      Peters MS, Su WP. Lupus erythematosus panniculitis. Med Clin North Am 1989; 73:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/42\">",
"      Watanabe T, Tsuchida T. Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 1996; 134:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/43\">",
"      Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 1999; 26:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/44\">",
"      Parveen Z, Thompson K. Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas. Arch Pathol Lab Med 2009; 133:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/45\">",
"      Urowitz MB, Gladman DD, Chalmers A, Ogryzlo MA. Nail lesions in systemic lupus erythematosus. J Rheumatol 1978; 5:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/46\">",
"      Rihner M, McGrath H Jr. Fluorescent light photosensitivity in patients with systemic lupus erythematosus. Arthritis Rheum 1992; 35:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/47\">",
"      Wysenbeek AJ, Block DA, Fries JF. Prevalence and expression of photosensitivity in systemic lupus erythematosus. Ann Rheum Dis 1989; 48:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/48\">",
"      Callen JP, Kulick KB, Stelzer G, Fowler JF. Subacute cutaneous lupus erythematosus. Clinical, serologic, and immunogenetic studies of forty-nine patients seen in a nonreferral setting. J Am Acad Dermatol 1986; 15:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/49\">",
"      Klein LR, Elmets CA, Callen JP. Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthritis Rheum 1995; 38:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/50\">",
"      Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994; 20:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/51\">",
"      Roelandts R. The diagnosis of photosensitivity. Arch Dermatol 2000; 136:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/52\">",
"      Ferguson J. Diagnosis and treatment of the common idiopathic photodermatoses. Australas J Dermatol 2003; 44:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/53\">",
"      Morison WL. Clinical practice. Photosensitivity. N Engl J Med 2004; 350:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/54\">",
"      Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol 1994; 131:205.",
"     </a>",
"    </li>",
"    <li>",
"     Hawk JL, Lin HW. Photodermatoses. In: Dermatology, Bologna J, Jorrizo JL, Rapini RP, et al (Eds), Mosby, London 2003. p.1365.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/56\">",
"      Weber IC, Davis CP, Greeson DM. Phytophotodermatitis: the other \"lime\" disease. J Emerg Med 1999; 17:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/57\">",
"      Egan CL, Sterling G. Phytophotodermatitis: a visit to Margaritaville. Cutis 1993; 51:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/58\">",
"      Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 1992; 90:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/59\">",
"      Niimi Y, Ioannides D, Buyon J, Bystryn JC. Heterogeneity in the expression of Ro and La antigens in human skin. Arthritis Rheum 1995; 38:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/60\">",
"      Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/61\">",
"      Saegusa J, Kawano S, Koshiba M, et al. Oxidative stress mediates cell surface expression of SS-A/Ro antigen on keratinocytes. Free Radic Biol Med 2002; 32:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/62\">",
"      Bijl M, Kallenberg CG. Ultraviolet light and cutaneous lupus. Lupus 2006; 15:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/63\">",
"      Reefman E, Kuiper H, Limburg PC, et al. Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients. Ann Rheum Dis 2008; 67:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/64\">",
"      Golan TD, Dan S, Haim H, et al. Solar ultraviolet radiation induces enhanced accumulation of oxygen radicals in murine SLE-derived splenocytes in vitro. Lupus 1994; 3:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/65\">",
"      Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/66\">",
"      Drugs that cause photosensitivity. Med Lett Drugs Ther 1995; 37:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/67\">",
"      Ilchyshyn L, Hawk JL, Millard TP. Photoprotection: does it work? Lupus 2008; 17:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/68\">",
"      Nuzum-Keim AD, Sontheimer RD. Ultraviolet light output of compact fluorescent lamps: comparison to conventional incandescent and halogen residential lighting sources. Lupus 2009; 18:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/69\">",
"      Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999; 107:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/70\">",
"      Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/71\">",
"      Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/72\">",
"      Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/73\">",
"      Tlacuilo-Parra A, Guevara-Guti&eacute;rrez E, Guti&eacute;rrez-Murillo F, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005; 44:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/74\">",
"      Ring J, M&ouml;hrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008; 31:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/75\">",
"      Jemec GB, Ullman S, Goodfield M, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol 2009; 161:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/76\">",
"      Wozniacka A, McCauliffe DP. Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol 2005; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/77\">",
"      Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/78\">",
"      Sj&ouml;lin-Forsberg G, Berne B, Eggelte TA, Karlsson-Parra A. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 1995; 75:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/79\">",
"      Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/80\">",
"      Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int J Dermatol 1981; 20:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/81\">",
"      Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 2009; 18:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/82\">",
"      Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/83\">",
"      Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/84\">",
"      Turchin I, Bernatsky S, Clarke AE, et al. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol 2009; 36:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/85\">",
"      Bottomley WW, Goodfield M. Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 1995; 133:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/86\">",
"      Duna GF, Cash JM. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 1995; 21:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/87\">",
"      Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/88\">",
"      Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011; 65:e179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/89\">",
"      Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011; 65:e195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/90\">",
"      Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007; 143:873.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market. file://www.fda.gov/bbs/topics/NEWS/2009/NEW01992.html (Accessed on April 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/92\">",
"      Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997; 36:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/93\">",
"      Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003; 139:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/94\">",
"      Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005; 118:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/95\">",
"      Duparc A, Staumont-Sall&eacute; D, Broly F, et al. [Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal]. Presse Med 2006; 35:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/96\">",
"      Cort&eacute;s-Hern&aacute;ndez J, Avila G, Vilardell-Tarr&eacute;s M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012; 14:R265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/97\">",
"      Albrecht J, Werth VP. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 2007; 20:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/98\">",
"      Wysenbeek AJ, Leibovici L, Amit M, Weinberger A. Alopecia in systemic lupus erythematosus. Relation to disease manifestations. J Rheumatol 1991; 18:1185.",
"     </a>",
"    </li>",
"    <li>",
"     McCauliffe DP, Sontheimer RD. Cutaneous Lupus Erythematosus. In: The Clinical Management of Systemic Lupus Erythematosus, Second Edition, Schur PH (Ed), Lippincott, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/100\">",
"      Fabbri P, Amato L, Chiarini C, et al. Scarring alopecia in discoid lupus erythematosus: a clinical, histopathologic and immunopathologic study. Lupus 2004; 13:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/101\">",
"      Alarcon-Segovia D, Cetina JA. Lupus hair. Am J Med Sci 1974; 267:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/102\">",
"      Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/103\">",
"      Urman JD, Lowenstein MB, Abeles M, Weinstein A. Oral mucosal ulceration in systemic lupus erythematosus. Arthritis Rheum 1978; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/104\">",
"      Jonsson R, Heyden G, Westberg NG, Nyberg G. Oral mucosal lesions in systemic lupus erythematosus--a clinical, histopathological and immunopathological study. J Rheumatol 1984; 11:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/105\">",
"      Louren&ccedil;o SV, Nacagami Sotto M, Constantino Vilela MA, et al. Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of epithelial maturation. J Cutan Pathol 2006; 33:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/106\">",
"      Pennebaker JB, Gilliam JN, Ziff M. Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus. J Clin Invest 1977; 60:1331.",
"     </a>",
"    </li>",
"    <li>",
"     Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/108\">",
"      Rahman P, Gladman DD, Urowitz MB. Nasal-septal perforation in systemic lupus erythematosus--time for a closer look. J Rheumatol 1999; 26:1854.",
"     </a>",
"    </li>",
"    <li>",
"     Ropes MW. Systemic Lupus Erythematosus, Harvard University Press, Cambridge, MA 1976.",
"    </li>",
"    <li>",
"     Sontheimer RD, Gilliam JN. Systemic lupus erythematosus and the skin. In: Systemic Lupus Erythematosus, Lahita RG (Ed), Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/111\">",
"      Bongard O, Bounameaux H, Miescher PA, De Moerloose P. Association of anticardiolipin antibodies and abnormal nailfold capillaroscopy in patients with systemic lupus erythematosus. Lupus 1995; 4:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/112\">",
"      Englert HJ, Loizou S, Derue GG, et al. Clinical and immunologic features of livedo reticularis in lupus: a case-control study. Am J Med 1989; 87:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/113\">",
"      Levine SR, Langer SL, Albers JW, Welch KM. Sneddon's syndrome: an antiphospholipid antibody syndrome? Neurology 1988; 38:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/114\">",
"      Kammer GM, Soter NA, Schur PH. Circulating immune complexes in patients with necrotizing vasculitis. Clin Immunol Immunopathol 1980; 15:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/115\">",
"      Clifford PC, Martin MF, Sheddon EJ, et al. Treatment of vasospastic disease with prostaglandin E1. Br Med J 1980; 281:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/116\">",
"      Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006; 85:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/117\">",
"      Sen&eacute;cal JL, Chartier S, Rothfield N. Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine. J Rheumatol 1995; 22:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/118\">",
"      Greisman SG, Thayaparan RS, Godwin TA, Lockshin MD. Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardiolipin antibody. Arch Intern Med 1991; 151:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/119\">",
"      D'Cruz DP, Wisnieski JJ, Asherson RA, et al. Autoantibodies in systemic lupus erythematosus and urticarial vasculitis. J Rheumatol 1995; 22:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/120\">",
"      Slater D. \"Lupus\" and prostacyclin formation. Lancet 1981; 1:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/121\">",
"      Pauzner R, Urowitz M, Gladman D, Gough J. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. J Rheumatol 1994; 21:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/122\">",
"      Doutre MS, Beylot C, Beylot J, et al. Chilblain lupus erythematosus: report of 15 cases. Dermatology 1992; 184:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/33/36378/abstract/123\">",
"      Viguier M, Pinquier L, Cavelier-Balloy B, et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore) 2001; 80:180.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4666 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36378=[""].join("\n");
var outline_f35_33_36378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14812788\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CUTANEOUS EXPRESSIONS OF LUPUS ERYTHEMATOSUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute cutaneous lupus erythematosus (butterfly rash)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10330927\">",
"      Disseminated (generalized) ACLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Discoid lupus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Differential diagnosis of DLE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28543353\">",
"      - Treatment of DLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neonatal lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Subacute cutaneous lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Differential diagnosis of SCLE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28543309\">",
"      - Treatment of SCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bullous skin lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lupus erythematosus tumidus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10330994\">",
"      - Cutaneous and reticular erythematosus mucinosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Lichen planus-LE overlap",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lupus profundus (lupus erythematosus panniculitis)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nail lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Photosensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OF CUTANEOUS LUPUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22992289\">",
"      - Investigational topical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antimalarial drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other systemic therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cosmetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Assessing response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ALOPECIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Scarring alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nonscarring alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MUCOUS MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      VASCULAR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Periungual erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Livedo reticularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Urticarial or purpuric vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14812788\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4666|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/39/32371\" title=\"picture 1A\">",
"      Acute cutaneous lupus erythematosus - malar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/47/3828\" title=\"picture 1B\">",
"      Acute cutaneous lupus erythematosus - malar eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/49/37649\" title=\"picture 2\">",
"      Rosacea erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/11/8372\" title=\"picture 3A\">",
"      Discoid lupus - left ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/56/16261\" title=\"picture 3B\">",
"      Discoid lupus - right cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/14/40166\" title=\"picture 3C\">",
"      Discoid LE of the scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/20/31046\" title=\"picture 4\">",
"      Granuloma faciale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/54/19298\" title=\"picture 5\">",
"      Skin biopsy discoid SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/34/17956\" title=\"picture 6\">",
"      Neonatal lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/11/12467\" title=\"picture 7A\">",
"      Subacute cutaneous lupus - annular plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/61/7122\" title=\"picture 7B\">",
"      Subacute cutaneous lupus - papular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/28/4550\" title=\"picture 8A\">",
"      Skin biopsy subacute SLE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/63/41973\" title=\"picture 8B\">",
"      Skin biopsy subacute SLE II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/18/9504\" title=\"picture 9\">",
"      Bullous lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/21/21845\" title=\"picture 10\">",
"      Bullous lupus erythematosus chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/57/19351\" title=\"picture 11\">",
"      Bullous lupus erythematosus pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/28/26062\" title=\"picture 12A\">",
"      Lupus erythematosus tumidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/8/13443\" title=\"picture 12B\">",
"      Lupus erythematosus tumidus on face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/17/4372\" title=\"picture 13A\">",
"      Skin biopsy lupus profundus I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/17/11536\" title=\"picture 13B\">",
"      Skin biopsy lupus profundus II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/15/1264\" title=\"picture 14\">",
"      Lupus panniculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/30/13794\" title=\"picture 15\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/32/25103\" title=\"picture 16\">",
"      Mucous membrane lesions in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/33/13841\" title=\"picture 17\">",
"      Livedo reticularis - lower extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/30/35311\" title=\"picture 18\">",
"      Livedo reticularis - lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/27/8639\" title=\"picture 19A\">",
"      Digital gangrene Raynauds I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/39/43647\" title=\"picture 19B\">",
"      Digital gangrene Raynauds II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/49/11024\" title=\"picture 20\">",
"      Skin vasculitis in lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/38/4719\" title=\"picture 21\">",
"      Atrophie blanche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/36/17988\" title=\"picture 22\">",
"      Skin biopsy atrophie blanche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/7/42111\" title=\"picture 23\">",
"      Chilblain lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4666|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/23/35197\" title=\"table 1\">",
"      Gilliam classification skin LE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/53/20316\" title=\"table 2\">",
"      Skin lesions SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/48/15116\" title=\"table 3\">",
"      Cutaneous nonspec lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/22/22893\" title=\"table 4\">",
"      Drugs associated with DIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/3/34878\" title=\"table 5\">",
"      Drugs and photosensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/42/5804\" title=\"table 6\">",
"      Hydroxychloroquine dosing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37671?source=related_link\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/19/314?source=related_link\">",
"      Initial management of discoid lupus and subacute cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/61/6103?source=related_link\">",
"      Livedoid vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=related_link\">",
"      Management of refractory discoid lupus and subacute cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/5/16466?source=related_link\">",
"      Patient information: Discoid lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_33_36379="Organisms in transfusion-associated infections";
var content_f35_33_36379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Organisms implicated in transfusion-associated infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Organism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gram-positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacillus cereus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coagulase-negative staphylococci",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterococcus faecalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propionibacterium acnes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gram-negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serratia spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escherichia coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acinetobacter spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proteus mirabilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Providencia rettgeri",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pseudomonas spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yersinia enterocolitica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pasteurella multocida",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36379=[""].join("\n");
var outline_f35_33_36379=null;
var title_f35_33_36380="Preconception control in IDDM";
var content_f35_33_36380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preconception evalaution and management of women with type 1 or type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"       History and physical examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"1\" rowspan=\"1\">",
"       Hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       goal blood pressure less than 140/90 mmHg except goal blood pressure less than 130/80 mmHg in patients with diabetic nephropathy and proteinuria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       stop antihypertensive drugs, if possible, or switch to agents with fewest risks to fetus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"1\" rowspan=\"1\">",
"       Retinopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       ophthalmology consult",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       treat active proliferative retinopathy before pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Cardiac",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       screen for coronary heart disease as per guidelines for nonpregnant women with diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Renal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       measure serum creatinine concentration and total protein-to-creatinine ratio",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       women with an elevated serum creatinine concentration are at risk for deterioration of renal status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Thyroid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       obtain serum thyrotropin and free thyroxine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Achieve good glucose control before conception.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       If A1c is above the normal range for women without diabetes, intensive insulin therapy is warranted.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       3-4 injections/day of short and long acting insulin subcutaneously are usually required to achieve good glycemic control. Either subcutaneous insulin injections or an insulin infusion pump is acceptable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Self-blood glucose monitoring is performed before and after each meal and at bedtime",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Repeat A1c one month after initiation of this program.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Retest every month until target A1c value is achieved. Once in the target range, the patient can try to conceive.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       A pregnancy test is done 1 week after a missed period to confirm pregnancy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Psychosocial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Assess \"readiness\" of patient for pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Advise patient to stop smoking and stop use of illicit drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       Review medications. Discontinue those that are associated with potential fetal risks or change to medications with fewer fetal effects, if possible.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36380=[""].join("\n");
var outline_f35_33_36380=null;
var title_f35_33_36381="Pulse volume recordings";
var content_f35_33_36381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulse volume recordings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 261px; background-image: url(data:image/gif;base64,R0lGODlhsQEFAdUAAP///wAAAP+ZM4iIiFVVVREREczMzHd3d6qqqiIiIjMzM+7u7kRERP/mzd3d3f+zZv/MmWZmZv/585mZmf+fQP/s2f+mTf/Zs/+/gP/z5v+sWbu7u//fwP/Tpv/Gjf+5czAwMPDw8NDQ0BAQEKCgoEBAQODg4CAgIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACxAQUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsYABtLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3OuFUBstPUgdJU19Xa23bZUt7c4eJr4FDl4+jpYOdO7Orv8NHy8fT1U+5M+Pb7/AD6Sv/6CXwXEEnBgQjDHTSyMKHDaQ2J4Iv4sKIoikImWtwIC6M/gBxDsvKoUaTJUyRBnlw5KmUSjyxjLnJpUKZNTjSPwLzJU1BO/4Y9g1L6WWSn0KN5iEpEypSR0iFGm0qF8zTj1KuEqn7EyvWP1qhdw475KrYsHrJm085Bq7atG7Zu46aBK7cuGbp2837Bq7evFr5+A8+7p1KwYSuAuzTQIIAChMNcE2+5IKByZQyQr0rOQtmy5QuZpW6+UsGyhgwfKlsI3XR0FQkWKmuQACCD5QqskbqmAuH2kNQCPOQ+ultKBgqVHw/prGG40OJRMKimPUSCZedBoT+RgFwA6CKxBTTAzlO7kw6qjwDvQP6m+SbhlRfpHby9zfdLSlemXoRD5QeioFbZB7jZR9VgOnnhwYBINCBbKBV095mBb+CnRHjfGWFdZaBw5/+ZZeNRyIaFSNi2XxLXfbJgZRxEOJ2I5CAIFBedAYjiiZ1sKAB7AOgngHwwnkHiEfQBacQDlYXIiX8CrDYEfRTwF2QZQx5ZWYZHICmeJysKR0R8UwopY1FdMLZlEloquYmZHBTRWZRhUjnmUlykiGaSOVompRDh8RinGFUSYaIAS6SpRgkhxMFkc0ag1yQhiKYV6BAOCmDjnQK0ORcIib7R5RE6qukVp2ZNKkRnHyxRpBq0kOqGlpoaIZ0AmPkUgKthmQrAqkrwikYtuK5hWQYNVganNa122pWusxpphK9C1nKCCGzoR8GFV9pKy7S5zgkVF4b2WpmXv9oyArVq1Kj/xIqpIlvLuct6a9UWZopqBJOXXoEMvGms6CwRPu454jH8aibvVlrouUSl+SK2L7pnwLpEePaS8zBWutqZRKWMYrEMCWh0R6wSElOlDMhTmTpoExo7fLIZKy/hbxzMoNzawWABwDDLHGbRjM1i7KzqZTTXLBrOWwg9MZ4e/0yGo+0qwXHRRjNlqrpMlKxvMyOYMAa0SOg48ltce60b0lqAjcTMTS9TcBhaK2EmlgO7DTFxaGeh9hGO1rq1Mm+HUW8TjnbcBjOBP5c3FnsbMXXbF5fRchKDVlxuMokrjk1hWGhJd9gK/03w3WLo+MSshlsc+dGbv7RFuEyEF2s0q5Oh/zQTg/qpujGZ4916TVrAvsSs5NJuDAikj4EvFCueuTsxyEe2+BXCK9GZk2bcEmwZ9BXPhARmUlCgHtora/DvCWohshMeehdtsmo0noSL2ZIPrPnnE+Z6wj07Mav42YOfGtYjBfrRSmBrEWC80DejLExOCcexzAc6ML513Ap/EWNaFCoQniZZzmTbw9j0rPBA632oSbPrwgXbUL3taGlAY1tLCEXIQDLxj1BRaEAHLeO3LszwDMOygqOMpbs4/DB/3+CcFfSDvQ12ADjjekQJoZCBFwpAAxX8UztGSIXbTSEDZsqUI6YYhQtIaEdaNAcXp+DFKYDPWAgshImupQUJNP/PUnFMow31BzwstNGN3YlaIv5oBR1axgJZ1GMDk7g/P/5HC0xyHiIIaQUJzKoxeVTkpJYXvPQogpJX6MwVFdlIRvbxCt3bQu4UgbUviLKIpJwXH9PHuORwYUXHOgSqxIDLTGpxUvIDpC0n+cgwtO9zpATmMLcApRgSApR6e1As6TTLRVohmG4MTw+fWcwwDMqZyVyjFGYFSyyIMpGBgGYWzFROPU6qhevsJjctRQb6CDKW79QgFyolxkKo05GNmea3akhN6umTC8CxgC/18E8s+Eag+ZQkFyL4I3/KE271m+akuoPOtIFong0DA322qUlxRoGM8WxMR/eQStt5UqP/JoUCSrFAP4UKgm1keCg+Y/qEmWIhkrMJRNzEABzvuZOnTZhjGUQZ0j3odAzX04QEGkDVqjZgpa0IVEOxMESS5oFJdCyDjpDpiApAwIon/A8GKNgRpDJhq1i4pFfvAJy5ggF1kpBAB3aY1r5SAAMpREWgOGmGS35goW/g5we/4KN2IoIDfJXNAyZL2cgeEgLgJEWgsOmFS2IxD7C5aBkuiVVCXPIyF8jsEDLQAAh84IyXUS0oAoXTM5wWAohNQwXCWNovhLYxgS2EJS3jmNwSgQMYgC0GZNuJQA3VDHe0FGYVdVqyksGAy0XEG//D3O9dgK+41axbl/BUNBjSM4ut/2darVsGAwpggr3Fw3ZpNZkdFvci400CWN/w3Y+2gT6HTG8ZqphWCkw2vnEAIw+90F/iTvcTVZqVXdGQAQ5AAMEiVQ1g6cCBMH5IwHHAbhg6AFsNsBUn+T1CJEFsie7CwaxoZXHQNowEALuvdBCAbWMeAIELNMC4iCCRGUUblKlSFch3NRZg+XOBMFKAvVyQQJP7SlzKegACWM5yjxOBHwEZy8VB0nGTPoRINWTgiWKmsmWa6pMU6+y0ABRoA5KrZg8g2QsVuMBZPaxmNltjvHrl6wPA/CcOeMDDFvAAodVQgapqWcuOncV40foAGStSAhiuR3FEiQFLC5QjxYFNB/8W/WmR6KrUMTk1qlei6lWbpNWuDgmsY72Rrzzj1rjOta53zete+/rXwBZGKaNQElqXys3GLg+yk32fZTM71c5+NqujLe1XU7vasr42tmut7W1XZNbe3ge4w63pbpMbIeM+NzzSrW51sLvd6Hg3vMUh73lzo9721ga+802NffNbFv7+d1sJOlCBQ5vgsjT4tBGOMIWfJOAOXwXEI56KiVMcJea+uEIyrvFtWLzjLeE4yPst8pEDvOQmH3g1U25thrP82wd7+UO0InOH0Lzm6I45zgdy8533o+c+F7fOgy50bAT76EhPutKXzvSmOz0YRI+61KdO9apb/epYz7rWt87/9a57/etgD7vYx072sstiAAEgACUQEAAFXP0AtCjAAoqggAAgIA9oV/sk2O52q8OdFgegu93xnva1t70MBQiAAbwNdwYEQO5EqPvd8ZB3w/d9DIlf/LbhfgACBCDwQ5A84fUuCb4jXvGM/7wBHj93IYh+CA6IQC0YMHkhVP7vbs87Ahz/+AEAYAF/T3vrhTCBBNiC9kSo/Bo8P4AB1L3tdzeA52nh+yI4P+6gt37iA8AA2V9eCLuvRQSGD4DMh9/uC5g+9oewelxoHgDnD8D42xD7WhTgAO+HP+/lP/zEb6AIbJcAyfd8BVB9QrB6BQAAA2B8AdB69UcLDJB/qcB5/wDgedn3egBgANtnCwaIdgrAgIeHdhtYC+o3e0RQgrUwAUOgfFqQACrYBJ43grSAggFggBWICwpAfvtnC98XfLWQAP3HfbaAAO13C31XhLageT5IC0C4BROQg03gADJYeEKwhAHQhAAgexFQBBY4BDsIgez3eDs4d2yHC/+3ChSIgK2HgcbHAA4gBNOneWgHfckHgZPHewVIfLRwhkfgeQJoe1SoBRMQAC+4BNNHAG/oAAyoAC8oewkIiHkIf8ZHenBXAC+YfoenhzV4gHVHetu3hUmAAMZngJlXBIO4iRnYiVyQAFC4BI5HegbQeZpYfQagigCwAY9XBKWYhVc4ef8TkHi0GHc2KIVUuACO94eqQIE3CHqvN4jICIfyB4jfB4gMQAS4GABvOATGV4hHkHjZyIJawHxMII4reIVE4AC0kI2jSATt94YLkHi1B3+ZCADbyI65KATwyARoB4rlh3pEUI9h+IhasHoKkI1J4H9IAJAHeI/0SIhDMIh9h44FYJAKyH0LCXlEoIVFYHx8iArKqIYA8Hqyl316+IfgCIik93u0QH7kKAQOcABLKIeBqAUL0IYUaQQtKY/TWIro2IAb6ZABCICZKJFGYHyat4vWdwA76In+6JIMqY1NmQVzyI1G4HjIVwRE+ZMyWY1C4HjVN4hcCXv3iIBFGQAdyYv/NngKyriMITl4N5iWZFmRKYmSRLAAK3mCqAgAVkgLMjmXRYEMAtmHeamTuoh6cYmXvneSpneLvDB5SOmSIGgLTJl/16gL8ViHyJCW7LiBCYB/QlCZuTB5Ejl3WVmRuzB3hzkEU1gLJKmWnxeQC/B6OZmB93iSclmXdzkE5FiGBECK/mibV6CBgymYNriYqmmYTwmNiTmThMmYu+CYUdmWndmXx0mZjckF3ieBR6CUHOiclqmbm7iP5XiatBmY+LgLrWkKa7mMIhmNROCMdGl9M2mXPgme1deFRLCLwGkFCVAAZ0mcRGCc57l4PXmT9QiWQhmRyWkEjwmS5TiZ57ig/14wiH65BJiYgKUZiodXd3xIoUqQmkJglNOwnghofL5ojngJirYJjvTJkqg4m/rJnFcwAAWgnQA6BALaj5q3jmGIjQAwmgE6jyaqBA2anCyIkP/olmDwjvwYBaU4pEuwjSjqlBh5BCDKi+nZCut5g7RQezYJjb8poyyam8pZhW33jc9HnTRZo06Qkzkao6goioFYd274e7g3ntkHfAzQeo/5jqj4gKRnlfL5mkKgp+RnBQNQoUegAJ5ppiYJeENgqERQicPphwYYi3p3pe2HiCtIAJepnoTao0oqnLfQgWI6n2T6loUamW0Xo4pKBm46jwMKnkY4fKT6g7K6l/X5mP+myYOBOIe1oIS6cKinhwu1p6vk135V6oW5cIQSWobGioahSqvx+IDcF48riqr1WaYuyXsJ4HuuygaxupNReX2Pl54GwHsKMAA5igAleAC1x6sKuH0EYADgSKNMOHzuagvwugYI4IP1CoDv+qm2aAQDsH+dmY1X6pIAq5lm97AQG7ESO7EUW7EWe7EYm7GHsJ/2wbFWgADP14DyahYe2wd1l6WtcLJP4LFlSKxKAK0rObJlUbJKQLNbwKsqOwY2KwY72wQ52wQsm6pM4HhNKrNi0bMGK6NhYLQ6q7RogLRdALVN4I35GZ1pIbUPegZMy7NOewZYqwVfmwR2aZ5b2xP/8RcBFJl30ieMALh/jDp3NKh2ZLmAK5mj+DkEB7B99+cASBisqgp7smeH9piA+Cp8ShC3OLp/aKuPt7C4WYt7iOuSgct9+cd8DjB9gdeSxXd82Nq15fmgCzC5plqqOhqgimuQ8DkEsmeAGboPwGp/7yeCuJB9p0i6iIuAY2i3oaqIuFCvubB4LXmrtXCpjxeytDCNXNi7gHgLbEqkuDCR5fiBtaAAkQuztcCHnreDmZuXNOiQ8YkEh+mBMqiiuACuTfm6cad5GdqGD2mR/dB+oOgAxzieEWim/giMD9mb37uQvRek03i3dKp5mDqriAmVdcqlAsyEX9mlNcuc8Nut/1Maha84ngrQuXNJjHpnjFM6fQfMrYKJjB4bvhDYiKxXqKm6iw/8o/Mbomb5mXHXenDnsPEge3MJkCfplZ+LBCfpoDgqq2wJAM7osqVbwEAcwTcIiiCKw0lwkjT8k1S5BLgIwj58mxnpnlB5hndrn877jZ4rwmF5nmfYolWreU2cpCRcffvovY73n/QAparrniepfInHqUk7l1equ6CnkUjAq+Q4kqaIoiDqx0vMnG4sBHocip1nCwKZrTXcwlV8n8P5twwbk/trBCLcyJMnxtXJwpepxwhKjwmAjnpXAOZpD7yqfIqZia/LAAcwfDu8oHjswQwaneQ4m3EJolsqn/9zecqe+4Vxl7W6XJi6AHqzKcm6qqbgy5An+XqaTMC8rHdEiY6+158/6r798MyV/Mk/egAh27yvXMqxLMmzLIG1PJy3nJy5XIe7HJ0c+3cH8IKXXMfCnAvEHMm7OYO+icxWqszMycwnfL/sHIjG5wBo939ohwCDKMPxoJCGDMfMKZ6WLKhUHJBGEJR4mcdWPM7JW32HXJIXWQTpDMxQSZUdXZjxGM/BnKQ2qsUbDY2tGa5JgNKh55bNPMQMzYv8KHsTwAB/iIsRAHdsTA9lPNKVXHdP7MKPiHZfnMPWmJyOB3pBvMeOzNKpC55IjM7TmrRLPdQsfNQE/NGVXJFbndX/LV3WMBqmr8rUy0zT/0zGhOy9RUy02pgADFDK9rCpECzFFZzXB8jKrafBeneNJy2hiQeK55d9bSjAsggAEs3SDXnAcQjWeEvWTa2ktEmF8mvEgheWecvPfinY9ph2Bpmok1fM5Ah3BWl7aRrWgyvSrsfW2zrEeK3CEdyTU/13S80P6Pt4sZsLzdu3TGiQkSm3ErqEBfCzwjuDy+u3wTuFxGueIQ2VJLjcsKsEoHm8nn0Eww1+3ynO3FqTRgjTybzI/Qzb5IeUu928UPmM16jQ9XC2act9k0vHtveu5JfZ1MfUg8p/WQx8P9jKK7h9TZiT1nqVkm2mKAt7+2eA8M0EVCA7wjJ9jgsOew3r2I6N3986xCGc3ZFn3mNsuuJ3kzj9k0GtsSZ+4iie4iq+4ize4i7+4jAe4zI+4zRe4zZ+4zie4zq+4zze4z7+40Ae5EI+5CYXBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulse volume recordings are most useful in detecting obstruction in calcified arteries in which falsely elevated pressure measurements are frequent.",
"    <br>",
"     - A normal PVR waveform is composed of a systolic upstroke with a sharp systolic peak followed by a downstroke that contains a prominent dicrotic notch.",
"     <br>",
"      - Mild to moderate disease is characterized by loss of the dicrotic notch and an outward \"bowing\" of the downstroke of the waveform.",
"      <br>",
"       - With severe disease, the amplitude of the waveform is blunted.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Courtesy of the Division of Vascular Surgery at OHSU.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36381=[""].join("\n");
var outline_f35_33_36381=null;
var title_f35_33_36382="Tuberculosis verrucosa cutis on knee";
var content_f35_33_36382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculosis verrucosa cutis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 287px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEfARUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDycLux61IEHIB+tNAP3h1pwJznjNZFIlUYwMce9P3A5K8gU2PH8ZNSYwpGAF9KBiCQdx+ApR8/JXHpTgAyjChT3J71IIs9c49KAGnCkbVHvSllbptGPSnbAFy3QdhQvlg/LH16ZoAYZMcBf/r09cMAQo+melDY2/PxjoBQsatyPl9OaQx4VtuM/KfUVIIgOML9SeKhRXY4+Z8c47VIFIPKYX0Jp3Cw5kkKgblxSle278hToiu3CpuHf1FIeh64poQ5SN3UkYxnHNPKSMw2LlsZyB1qEKd+SzEHtipow/I3kkdicVWwNDfLaVSu5lYH7p4qMRKRtkkKnsQanlZSB8rmQHg5qTaWXIx5g6cUAVTvVwHlYoB95aljhV4izLJJj+LOKed4jJK/kKrOgfrKy+oU8UPQNyeO2JUyIpKjnDN1pkcCum5Y3HPc8UxxEAnlFhjqc0qx3EqsY2LKvOCcflQhWJTAgXjBPvTwQkYHk7hn86gjZmwsy4IPBJxVhgZEG2TGP4RzQAzKEfcKHtio2LA5VQRnrjBqUpIOWAI9acrtgeYgb6UgIFiLEktsHvVeaJg2UYEZ4Iq+5i6q5Uehquy7WDIVx7d6AKRiJJ24Dd/eoHQBvnGwjoR0NaUowvzpg9Miq80RYAY3CgCiwON3amF1Zdp4PY1LJC8Y3JkjupqI7MZ28HqPSkBGeAQTnNRqQDtcZ96kICkBuQentTHTnryOhoAkGzHJ5opi/MMk0UXFcm2naB0FOVeRx+dNGSwqdFI68k0hihV6HOamVCPurke9LGoYe9ThSON+B2FAEQVQehZv5U9iDjeenYVKqNjOFpAAQSQPekMjbthQue9Ltx1ZcHvUnyMeBx6elSrHvOFVSR29aYyntJBG9fcVHGyrIU3ZHpWrDbNKwHlIo9afNFBC2yQIHHelpuFymittymRj0pBHI7g8Ae5qeN4wMIxY+q0ScjESlT1yaaAYiurdB9afhlO7cqqfSiEO6bZWXI6e9NlUqxXYBntmgLDt4PBkA/DFLsQjMjq6nvnkVEoZY/8AVqQD1p0SByysFp3CxMpjUYQ5I7VDIu5/lOGz1J5oRArZMmPYVNIFbB2L7E9TTuK1hFGQcSgDvmmsixkAMmD3FO3RFRuUAg0+OZVcFk3gdgO1FwIPMIKlAjY9RSLkNu3bG9Oxq2GhfLRoy7u2OtNkzjhXUjgcU9wKboJDkuA3uKcQq5zKFcjggcGpTtwQdufUimG3XYMbHHp3qQEjWVeQfMU9cdqXdgEDOaZgpjyiVPfJqXypHx86lu2aEA0sjDk4b0IpMfLlSrAdSO1DQyA/MAQOMikaJohlozt9QaNQF43ZYMKY7IegwfTtSEjcpDHPYGlMm2TkDb3OKAsQTAsAWGR7dRVOVQBkjn+dae1CpKPzVd4t33evdfX6UxGWw+U+n8qiCiM4bJHrV2aNUJZc/T0quQSAp5XqDSArhSCfm47UUsw+b5QRiiiwFsjHK/jViP7o7CoVOB0yanQE8jpQDJ4gOv3RUwAxgnmokzx8pA96sD5eTigBGTjp9Kb+7T727JqbceABuz04ph37sFOO9IaHHawyUyvTI60xwhKqodW6gg0gKKcFxmpcZHMfGMg5pDEERU5M75+vSnfZonG6TLnuSelN85VOSm49Mk0qzRhiJDgGpVh6jPKjjX5W2jPT1pPtAVwu9mHtQFhTlWB5+uKSSaIECNFz3yKoCVCZDgZJ7e9APl5zGSAec8kVGjcHa6gdhT9z53IxGeG4607gSBt2dkfPfHao1GDkqM9s0N+65BLEd80pVWXJbaD3zmhiHFnwV2pnrjHIqRVkEeWKZHY1XliTcCJP1pJGCqFcttPfNAW7FgyOUKtAhGc7qTc4AJXB7EHio4mhU7SThu+akVRGrAE49xT3ARi7MCCoI75xTxOVXAXc/f5qgLkHBVXQ9O2KQEt86x42980ILA9wGfDbsH1FOCrtLtk47rTjKTyYFIPHWomB3ABSp/2RQABSecF4z69aGRl6KwHbmkJZnwNygdQRShVY/LMRjsaLAEWfMxvJ/wBlqbMZN2Odp7A1LNFiEbJU3k1WMcyj5l5H8S0WsIRdrNhSyn3pzeZkZwB6jpTTMUIVgXB68c0iuu44JweOaAJJI3RsgAD2PFN2Mz5Jxj0oCMp3Rkle+aAw8zCnn0oAbcQlgXJznrWdIDGxXHynkH0Na33iSeDVS5TcDkUEmW5w2c8miib79FAF5IjjdmrESg9sf1qFAc8HirKDn60IZIoz948elSxJySO3Wmcpgbeexod0deHKv3oYIlLnkoQCOAaiiJZ/3suH7LVFjM0uDG5X1qQQyAFhE5PXJqS7WLbDY+GVcH1FPG1fuuSD+QqtHJKylJSAmeCRyKl8zAAD5TuMUgB9rYCnnuDSBA3XHFP8yDgnLMPakLxbSY4z9QaYEeHTA28dsU5y3G4KAKASEyqYJ96YSD97r9aQD87R8pRWxkUqO7/eUMe4FRLJD90oRnv6U4kKvyO35c0DJkK5Pytj0NPDJtZQG34znFVVLBgZMsp9T0qUtIqgqACDwc00IlMoccnB+lIJAxAd1JHTIqDMkxJyNw9BShJNxyAp/PNMLEkm+QkLsC+46VIpkACPIPMI/i70yJZzkucj6USPEigFMsT0PWgV+g8SGKQCRkz6AVITITxswe2KbviY7DbyAn2qWPfCMQoST/e5NNCGKzAk4jBHpU8VwyMCFDewFOhaQkiaFYyenFX0hkCA+Yqnt8tUk2JszmudzHCNj3WmokMkqu0LsPZa1YmaPJOHJ7Yqy1zPGP8AR7PcD7Vahfcm/Y5q+W3lnBCNFj0qrIrow8qYnPY966tLSadt0tpjPbFSPoasVBgwT0zT9i5A5pHJySMiZniy3+zVVpYypDbgvbcOa6nU9BWOYbxJG3t0rKuNOKsVb94MYAIwal02hqSaMre2P3D5A7N3pftAACSoQf72OlOnjFtwR8p7HqKYs/GHUN6e1ZtWGSkMVzuJ9DUbOCMEZ9qQSbTlT+FMaTuB9aQFC6TEnHeipLllDjmiqFcuKMcjiplzxhqrox4Bq1H7c0AKckYyTSNDGQo+bk/eodgRgjj2pgkVOjsc9jSZSuW97BQAPMxwTjtSSTeVwCxJ/QVXFw5+ZTjtUPmPnLnJHQGpY7Fl3DHKqTx3Peowzf3FBH8VMDls8KPxoMrCLCKM/wB6kPYeJfm+ZUyPSlLoXz90nsKrqXcDeqhv7wpwYnguD6ZFA7EwaMcgEnuD3oLKGyiEH2phb5QCwqIMN3yMRj1oAezqzklWV/51MuQMtHwOvNVvNcnru/ClkWTIIYk9x2xQBIS2SVwfSjMydHTaeopV2sMNLjjjikj2gHKKadgJQGfDJKM9wKk+ddolIGOeDVYvEMnYQpHUUqzICFET/wC8eaYiwZVzw7Ee9PaSPaRJC2e2KSK6hZtrRsvbIHNSq7Bz5ZZiOgK0CBZZCeGZY++4dKsQSJnKy9e+KfHM+wGVQwPapVaID5IkGecGnYByY5Am/MZqWIDPzM8ij+6KFAIUbwv4U4IAwH2t0z1wOK1hAhsV2mjcPEpQD/npVqG4nfJiV5D6IvBNMt7e2dyTcPOw5+ZsCtWFpWjxBhVH9yuiEb9SJNLoFnHqcis8iiBAM8mphdzpg5SVh2qhdz3ETYklYoO1ZmpXbSw5hR/MB5C8AittI6IlR5jqriZ5UEjKsqf3e61mzbXYlocD3FYen3d206pG232Y9KuJfyLL5d6u05+Xn9aLprUfs+UtzaVZzoCTweDkdK5jX/D62Y8+xkLJjkVs3U7shaN+Ceari68uIRtlw3BJ7VlNRejQRi1qmckJRIAsi7SP4qGYDpy3Q1bu4ESd2i5T0qmwQHKnPqK4mrOxqUboqrgEGio74HzRjmigk1I+KsIcdKhU4AwKkBzQUDHI6cmo8bRjI9804jOcVC20nD5BqWUh7bSckhfTBppIbgoSB3zTHbao+RW96rXEhLLglcc0mMn4kPyBuOoJpolK52HC+lRrP5oALBT61Ou9xgSJ05NIZGGPORu+lOLqRkDHt1pu0oSPMB9xShkPKPyPUUAOJIAPlksKcHDrgoQfamb2Y/MWI9QKCMfdD59aAH4Ckbhg49etMSQeYBh8d80b1GPlYt6mpd0jKMrwOmOtMBrRI5ykmSOi0sf7v5lZlJ9R1pFlbI25HPXbUyynP7xs9wcUACTMGBDZB7EVZS7deOGU9gKiVkc7XkAB9BUqwxkFTLg9qfoLQk+0nPzRnHbNTJfopBJZcVVmjCKPn3EU1b8RYH2YFv8Ad609h2uXVvwOQny56kVdhk8z5hAx91Wsxtf+TyzbhWHqKSPVpY5VYSYB6qD0rVNIXLJ9DcWVlwXs5GH06VfSXSprbHlP5ndQcYrGi155RtR/mHXnmoJmMkwmSTZKOo/vV0RklqjJwb30Okh07T3hEmWib+6x6/jTJpo7JSbYkdsg9azLnUmmtI4FBUrz071l+fKCwcjHvVuatohRg3q2aP8AaXns5cHeO56GrdlcW3n4uEIB4+U8VzkN0A+WXj09a1rRDcr56tGNvBGahSZVRJGzHdWxdhDEv93B6irE0UE1pjAWcDgsa46S6MNxLkFGJyD2NW7O/a6MsUuBhfllHY1ftOjMnTe6Y9LifzHhZOQDz2NUZ7l42MbjCNzk9jTIbmW0uTGW8xSc76h1ecltp+fccg1jKSexr1Ez8m7nd61VkOJNxwQ3XFWQGEa4bHtUE+CpCD65rmeoGTdgmY80U5xuc5opXGaqr83tT+QeaXFIcgc0wGMecZpjFD2Oaeyd8VEwPUcVLKRGyhmOG6djUcgQH94rAe1SEFjjkmmSAL8pLA+lIZJvswm3a+71xVaR4Q3BJB71IAHXaXAIpwVVA2FHz1yKW4EGDklVyvrTlZc9dv4VYQAHII2n+EGgfZ/M2hCfqaY7kSPsJxIQfp1oRyzna5/GrXlQlOFOOx3U57e18lXRsEfwE9aLBdEAaQsMsrVInnNyCoPTimlbYHGHx9amWKKPDurBD0BNADQs5OVZcCpYo5ec4P1oj8hxjawPr61NFEHOBE+0dDmmIRNPnk5Vo8f3c1Mlr5YO6Lcw9amidFxmFlx3qV2z93lT0PXFVZBqRM1wqY+zgejAVD5UpIPkhn+taCBzjEpGexHFJc2V2AJUCyIOuzrWsYN7E8yTEtkklIE9mr49q0f7GspYiX011Y9xUel3EJbypZDG56BuDmtHUL9reKJIZi3Hr3963jJLRmMnJvQzl8M6dJk7JImAznPIrB1Gxmst8ttIbiBT0PDCu2t7kXWmMjBRKPv+pFY18m+2McX5VUoxlsEJyT1ZytvqSMTksJO+e1aUg+0WAZcGUHrnqKwL+HE535jkFQQXM0b+W+dvrXMpOLszoavqjdigmVeGQ98GrdrLs2llVeexrHiMsnRzjrRlI13PIdxPG6tLmb1OrMtu+I7gLKG6FRnFSpZW4jYQsFJ4wa5L7VMgJSLAH8Qq9Y6pIIirAEN19qtVF1MnTfRk2oWy292vlE5Iye4qF7RpVV0rbgNrcWyeY+1V+9xzVgyWszJBax/uwpPPUUnBS1Dna0OYkEi4DlTjgiqlxhQSvOa0r1V3kKwOO/es24/2TXLKNnY0TuUQhJJoqyqcUVBRo446UMrHinohFSLHk8nmqApuhBzmo2BYZYCr7RckdT71XkgIHOPwqWMg2DHyHFQOhLZ3gkVYZJM4XHPpUaQSlySuT70hkRWQn7oI7GnrGdpOEY+lTm1bbk4+gNNjiRnJZipoGQDyY+ZVYHsBTY0ti5aTzAhqwbDzGAhmVj1APapY7K4y0bhGI/hz1p2C5TeK1LnyJG2nnk09be3GCZeP7venNbRFgk1rJG4OQR0q1HFZhgGtZBJ+lFgI/It5eI43DDt60+OF0U7kyB/CTVlrYMU2xurjjhutSG0laQb90bDuearlC5BHIZCD5JOP4egq3bh5mIRGx6ZoeCSLnDSZ/ujpVmzfbgxbQ3cOcYq4x11BvTQuwWLAAzI+32NXEitwuEly391lrPW/ukBZzwD90+lNa8huGDq4SQdR3rZSitEYuMnubj2Mi26SvHHLEOu3qtVZb62RTEECuD1A5FVJdWWHY8TMH6MD0YVSFyJJnzGASeK1VRW0F7J/aN21aPUCI7uOEqf41X5l/Gse80yESS/ZJnbBO0N3rRstsUJeORI36EE1Bd7jcJMCFi/2TVtRktSE3GWhzcWo3NlcYmDqwPfrWzZTpcjzCx5pl/bpeTBmOSeN3pWdI32TMSurbf7prHlcHfoatqa8y/f2FtfZV+H7MO1YM1pJZlhJEs0QPDd6s3F4+AVJD98U1tR2sFly0bDn2NTKz1ElJD7drUsreUynHSmasbQQ7kQluwNXc232ZZIcMw/MVm3/AJcy9Pm7mm9EKLuxsMcbWYlE5XnDKR2qAqpcqhI2nj3qW2hxFkkbc4x606eEICwYYHGB1FTyjb1FZnZclwhPGM9ak0W8kivHEhy20gc1k3Jwg25z3qFJyCAM7+9JuxaV1Y22PmM7JwQc9agnU4zuBz2FRQM+0ZYe9SIN0gGcmsZO+oiSNBt5FFT7MDpRUpAaAQd+9SBBQowc0+PGeMGqAidCvORiq5jy24DFXCMljgGo94B/un6VJRUZecfdzV21tY3cKx35puHc8KM0gSZWHkrhhzj1q4rUFqaf9n2gBGzB9zQNLjkX5QoUeoptuk9wwMsZDD1PFW/sl8qEB02H+EVvyt62Fp3KD6PgEpHG3PBpU098j5TuHpWnamSFioi3N/tVWk1UecyPhCD83ajkh1Bc0nZFeS2wwEhf3DCqr2IVmNvJiTGdjHg/St6w1GB5QLkAoeM1burOKWMtbNG46jPUVp7BNXiQ5uLs0cUFYfM0TY7kHpU9oWc7RMw9jzxWpcIEkKuhjfHbvUDWkdwP3QaKYd1rD2WpfOrE9pbbchnO8dGB61JLZQvJ5nG/+IHjNU4dO1FASzb2XnaOpFEN2twfIlULtPJJwRWq93dEWb2Z0Lafo8dgJLnzJ5sZ2I/865DWNOM7mW0Vkwchf7o+tXpXW2kIRty9qI7hp+FV8d60dprUUbw1TMC9gu7aCKSTMi9gRyKii1aNyUUkSng5rrpPKv8ATzFckoI+FJGDXK6h4fQgyR5yDww4NYOm1rE0jVUtJE1vf43rJ857A1WfV8goz7eeOayZI7yzYh0Mi/3hVaWdJgdyEP71HMXyrc6JbxzCQHz9DVV5NkgdAce9YEEskUn7tirf3TyDWjHfmc7ZflYcY7VSn3JasWZrlnPPOO4pI8OpD8Z9agSZEcZBxmpNRKRlAjZ3DNOxDfQuS2zwwpLFLkd9p6VAspz+8YZ96qC4CRbd2MjBqABw3zfMO2KG7Al3NjzxH8o+4fXrVSVv3+55Tj61A3mSkZGAOgpTaE9eaiU+g1EWR1lfCAt71es9PiI8yY/L1J9KhiVIE5AqOWaRyAxKx+grNu+5XkiWR0adjAMIKsWXJLdapgALxWjYp8gPrUskt8YGaKGHSigRfbkccU5VAI71E7lenIpyEZ4JB9KplJEpJP3QCvtUXlFjxk0OWUgoc04OTz6e9SMCpHBPI7GrMEgjUts+btiokZZMYOcetWpLi0tAocZZxheehroprqRJ9CrNcXBmUmQfN2rTt5n8qLLYkY9CetY80YJ85H5Xn2NTveB4WSRAJDgKwHStE2inZpFubXobecLMG3ZwNozWddTwXk5naDEbcNtP61DNayJJtccDnJpvmQOfJZWRh3U8UneW5cXGGsSrdkoWSGRigPB9quaHq7wS+VKG8s1BKu9gsoHyngigFQWI+8Ome1XFNao0nKM42Z1ayQT3AKSCSTHI9qsKLbPzZRq5zQ5Psskk2FMjjbnParl7M4MYGHUDkjrWvMcTp62N2G8Uhv3kfmqMAOcZFU7/AEe31KN5IJYbe8POCeGNY73KTr5dwuQowr9CtFukkTIyktH1VwaHNS0YKny6p6lS9tbiwOy9JTH3WAyKbaavKAiARjDdcdq3prpZ1WN1SRf9rtWDetFHcP5UcRxxkdRWMo8usWUp82kkaL3aXDnDqze4xTHVZjtikUH+6TWDuy24P8ue3Y1QuLqT7QU5AH8VCq6agqfY6P7PEMiSZM+nWs+9sbKYNkKPRwKyGkYkEsTnqM0pvWWJo+Cp6ZqXLuilFrqQXWm7W3K4PoRVZbfzCUkGGq5ZXIIIc5welWpVWU74xhhXNLujXyZlCCeLIDBl9xT386R1EwHAwDXQ2Jgb5pUy6j7vvVOa0eRyVHU0c+mhPXUyjbR7snkmpEhYcAYzWtBppxlqvxW0MC+ZLg+1Ju4Nox7e3OMkU6VlT5V+Zq1ncSrgKEXsBUKWsSNubFAr9zEmgkbnB3GmlvKPluMtXRXl1bQIpJUuB92ucdhJI7njJzQ0F7iH261sWvyxr16VlJ8zqB0rVjbgCkJj5G5oqtcShSKKqwjVMmBnA4p0MolyVIGOoqEZbgVXP7uXOMUmy0jQc5ye3qKa/TOfoaiWQlNwKjNNLFMHr6j1qRktjJ+/IJyCOKh1GGWW9jkZjhRgKO9VJbjbLvj+Ug5xVsziZBMj/MOq+hraLVrC2dzR0+SJIjFMu2VuVFV4vtMomZsAKcljVPzzLgzMysvIYCp4JYLlRE08q5+8D3rW9yNi9BNBNE4uZHcgZBB6H2qkuXmzgHPSoL+eKNvKtRgLxubvVSO5kTjOAafMNR0ubF1FcSWj3MdvtSLhsnrVKGRJIldclyenYUyS+mltzHIxkjIxjNUrSV/MZFA3DqoHaqU3fUpL3S4zG1mCk/K/K+xqxNqDQ3SzRsofbgk8ge9WoLeE2xa6YSgDgL1rIvFhkP7kt16GiZMZJvUtLfxzbfMYk7iSy9DU39prbI0afNGxzyayGkeNUyuF9QKp3MiyNhF2Ee/BqLsqyZvR3sMkm0EqG9TVK7EaM0aSZz1bvWStwQdr4IHX2+lWJJIgyyhy0QHUdaL3JasW7GJI4Hj3blb+InkGqN00yzsGG5McMB1pk2puFKwphPpUQv7h0YYGPQihtAr7jt7kE4AFQPJnIHWmCSSXLOABQJFXI2iobKuQmN43Dhyu49quQX9xBw21x6mojMXXDoCvqajZVIxgVm0NPuaaauE+Z0UEelXoPEVtgeZGR9BXPuiiMFlz9Kj2lsfJgVOwaM6abxHbMuIgfyqq+twtglXYjtWKEx0wKTvxzRuKyRpz65I3McP4mqjX93Nz5m0HsKqjdn5ulWIwvrQBJGPmy2WPqTU2ccA1Aikk98U/OBzSAtWfzSEkVo78Vn2nAyOtWXf5STTJMzV7wxzKo9KKwdbud14cHpRXbCj7qMJT1PQ4ZNnQciiYq+ckAGocnBycUiMBgGuFnSh0bhco4GD0NS7tqEMu7uD3qq8TSE7GDAdAahPmRn7xFTcdiScCUblIyOoNZ+54X3RnBHarjysoBkjDD+8tVZmRm4GQe9O9thomhvlk+Vzsb0PQ09XCb1BZSedwrMdCAe4pkdzJCdv3l9DWqqdxWN9ZUdYyY/NYDDFTTmhgyskcgjH8StzWNbzkyEwvsP8AdNXzKiR/MgZ2HQcgVonczeglxeRhisAAHc0zzmcGRCC+MH1qnMyNncpVu/FV43EcpOevY96otWsW11Ca3JD5K9iDUsWoQunJIbOeelVryRHkJSPYpH3aiSPdGVAGTSu0GjNMSpNkRy7u5BqvcmNRlcZHp0NUE5cLnYR6cVK8LbNyt07ZouJqxC5wcdVz0qPziuQvCntSmPB+Zs0zABwKhyDcQS8cU4yPjgr9KQgHjb0pCOf4anmYWF3ErnANJ8v90mhRls4x9KDjcctSuMQd+DilBB5AzQSo+vtS5wOnWpAd24xn0NAY56U3LHoKeDx0JNADSWLcnH0oJOMZ/KnhvROD70bQDwMGkA1Tj3HvUqn0Ipu4Y45NOXOBxQMXGc9RSDkgZob0zT7dMn1piZbi4UE8CmXtwEgYg9qkZCwC9AKxtcn8uPYDWlGDnNJESdlc528cyTs1FROfmor1+S2hybnp7uQeelRkkkMCcVLMgJzTInVWw/3TXhvU7izFJE6jeQsg6Ed6jk2TNjPzj9aZPblOSu5TyGFQiJgd6HOKn1GiePaikK2QeCp7VVukKnoDn07VLM+RkAFu+arMVUZyQT+NMEQyKCCAxB9KgdRjBGfpUzkHsfwqJ+cDIpFFZuW+UkfWmF5UPykj6GrRAUdCTULJlsjA/GqTsTYBfyrgOA2PUUyS8Eh+aNc+xoKsD90NTGRG6oRVc7FYd9s2jG3g+9M+1nsMUwxLnjikaPHHX8KfO2Fh4uM+tL5xx1bmowqjsc1IEGMg0rhYQSd8H8RSiUZ+7j6U8KemRSnI5G0n0pXCxGXJOSTSZbGeeKfjcfuEU4ADOckfSi4yMFye+DTsbTwpPuakX0GMUEPj0pXATCtgDilIHA4p64Tqu7NI7KeNnH8qAG49cUgbnpz9acRkdOKBjAyuPegLCnBIA4NByeuAabgE0vTvTAcVHYimn2oyfXNMZ+cZoBjlG5gBmtG2UKKpWyEn3rTjXbgmkSErbUJPQCuO1WbzZ29K6LWLnZCRmuRmYsxNengaW82c1eX2SButFI3Wiut7mNj1Rhjg1Wl2jitCePiqcybRnbXgnoDLa7eFh/Eo7Grctzbt88I2MeorNcYOe1QEbhkUBoS3Mm98DgU1XOMbQ31po3EHOCB603GBnkfSkMGxjOME1E2M9iakzx1z9aZIVyMjFA7jGOB7U0j0wac3sTUZHtQMCQB905pAVPc/jSbj3pAcdRQIcygjtTCMdjRuHdSKQAE5BwaAHAY6gUmFycUpB7GlGR2FADAi56GnDHalGT/CKdj2pgGTjggU0k4HApGznG00o4HIJFAMZjByvU1KTx1H400AHpmmsqnuQaAHbsGlPXIPNRg+2feg88cimA4lj3AFAJJ+Y5FJgAc80E56cCgAOB0pN3qKM85PNMZhnIoExzEdqSMb2qMHccVdtY+M0MW5ato8DpVl/lTmkhUBetQ302yMntiiKuxNnPa3Pul2g8CsV6t3j+ZKxqm/1r6GlT9nTSPOlLmlcibrRSNjPNFYN6lnsjjIFVZlLHHSrP8ADwKhkOecc14Z3IzposHk1XKhSccVoyAtz2qoV5zj8KBlZmx1FIccdamdMnI4qI5X7w4oAjYrjI5pD055FK2AeBtz3FIVO3rQMY3txUWSD60NuBIYAijjHX86BoQkKOQaaMGlP6Uwt7ZoAe2egpgOMZFICM9DSnB6Ej60AOIU+o+lKNo6k0innqKcevIzQAZUj5TilHHU8UgXngc0fUc0wDGDndTsccNTRjvSq68gAgUBcXHHNNIHTOaczAfdJOaYSc9aYrgQB3NNPvigsc8nNRu4JxQFx+cd800tTA1N3Fic0CuOLZNNJzwKQcVJGvc0C3JIEJPvV+IYFV4hVuMdKQyYfKtY+s3GI9o61pyvhT6VzOpTeZKR2rtwVH2lRdkYV58sSg1V3qd6rvXt1NjigQv1oobrRXmvc3R7MWIIFRMTzkVKcEZqOTDCvIZ2FVxhjnoagdRVuUYXpmq5AxkUDKsmf4cjFRsNwParEgBPWoX4GBzTAgb5RkVFkEelSNzx0qNyMdOfagY12O0E4xUW4d1NPIBHIz9KaQFHXj3oC5GWGPlH503PrxSknPy9KY55welADy3pmkLkDpTM4oJBHGaAuO3D0ApQw9aiHWnYOeDTsFyUkn7pAppBz980zDY6ig5yOaBEikjoaHPPUZpoNGc0AGT6AU056k04DrRQAnHYmk6HpSj8vekY4FAhpP50mO+aXn8KUAdBQAg5NWIlyfemxqOlWEGOtJlIlRcCpR0qJeDQ5wKEJkN/NshPNc1K24k981panNubaDWY/SvoMvo8lPmfU87ET5pWInNQSHipmNV5K1rPQmCIm60Uh60V5z3Nz2RZMHBppYAn0qur+YQDwRQzFMnrXlnWiVgcEjBFQsuP8KWORWBK8j0psjZGetIZE5AP1qJ1Ugk5FSvg03aSvXpQBUb8CKgkAz0Iq4wXbhlH1qB0BJwRTArMuec1EWcHHB+tSumCR0qNoz1HNMZE3U/KRSHHrSkHODkUhU9MikAmAOSKMflQVbHSlBHoQaYCH6UmOR2pec9TTjxQIb7cUEc8UfNnNGT70AG0il570g5pSMCgQ0k55NGR65o7c0HH1oAQ/SjJI6UgGacuc0AIAT1p6rjinBc81InpSGCKB7VKOO9IBS0AOz0NQ3Mm1Sc0rN6Vn38uBtrehSdSaiRUlyxbM+dy7k1A1SE1E9fU8qhFRR5V7u7I3qB+lTPUDmuKs9DaBFRQaK4GzY9UJ6NjmnkkjIqNWOMH86TPBryjrH5XOV+V/T1pGcqR6H9KjfpyOR0pmdw5poCXr3GaYXycHIqPPvSbuKBitycHpUMi5PBzipAQTkE0jEA5xQBXc4FRs3sMVYkAbioXUdCKYETDPemMnHOMe1SlPQ4pu3PXFAyEge9Jt98/WpSoB5H5UmDngjFAiJh+FGM96mznjAppHoBQAwjjjrSKpHvTwDnqBSKpZjzTEIw59KYTz61MY/mwaQoqg4pDIgPWl29aeBkZxS4GaBDFWpAmBSDmpOO9IYirxTwoB5oH6UH1oAU+3SmlsdaaSTTHOBTExJWwCRWRcSbpDk1duZCENZROSa9fK6d25s48VLTlFOKjbFKc0x69ibORIY2KhfH41KelQv3riqm0CI0UGiuGxsf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A violaceous plaque with a verrucous surface is present on the knee. Scars are evident at the periphery of the plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Research Institute for Tropical Medicine, Philippines.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36382=[""].join("\n");
var outline_f35_33_36382=null;
var title_f35_33_36383="Slit lamp keratitis";
var content_f35_33_36383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slit lamp keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows the characteristic dendritic appearance of corneal lesions caused by a herpes simplex infection. Note how little fluorescein is needed to highlight the lesion; scant fluorescein is visible on the remainder of the cornea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_33_36383=[""].join("\n");
var outline_f35_33_36383=null;
